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ABSTRACT 
 
Dengue fever (DF) and dengue hemorrhagic fever (DHF) are emerging 
infectious diseases which are endemic in many regions of the globe, many of 
which are resource-poor areas. DHF and DF impose a severe economic health 
burden in tropical and subtropical areas. Dengue virus causes an acute febrile 
illness that can be a self-limited febrile illness, as seen in most cases of DF, or a 
life-threatening illness with plasma leakage and shock, as seen in cases of DHF. 
A systematic review of the literature revealed gaps in the knowledge base of 
clinical laboratory findings of dengue illness with regards to longitudinal dynamics 
and classification and predictive modeling of disease severity. The objective of 
this thesis was to investigate the utility of clinical laboratory variables for 
classification and prediction of disease outcomes. 
 The data used in this investigation was derived from a prospective study 
of Thai children presenting to either of two study hospitals within 72 hours of 
onset of an acute febrile illness. Systematic data collection, including clinical 
laboratory parameters, and routine clinical management continued each day until 
24 hours after the fever had subsided. A final diagnosis of DHF, DF, or other 
febrile illness (OFI) was assigned by an expert physician after chart review. 
 The first research objective of this study was to describe the temporal 
dynamics of clinical laboratory parameters among subjects with DHF, DF, or OFI. 
Data were analyzed using lowess curves and population-average models. 
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Quadratic functions of clinical variables over time were established and 
demonstrated significantly divergent patterns between the various diagnostic 
groups.  
 The second research objective was to establish and validate tools for 
classification of illness severity using easily obtained clinical laboratory 
measures. Bivariate logistic regression models were established using data from 
one hospital in an urban area of Thailand as a training data set and validated 
with a second data set from a hospital in a rural area of Thailand. The validated 
models maintained a high sensitivity and specificity in distinguishing severe 
dengue illnesses without using the hallmark indicators of plasma leakage. 
 The third research objective used classification and regression tree 
(CART) analysis to established diagnostic decisions trees using data obtained on 
the day of study enrollment, within the first 3 days of acute illness. Decision trees 
with high sensitivity were established for severe dengue defined either as: 1) 
DHF with evidence of shock (dengue shock syndrome, DSS); or 2) DSS or 
dengue with significant pleural effusion. 
  This study expands existing knowledge of the potential utility of clinical 
laboratory variables during different phases of dengue illness. The application of 
the results of these studies should lead to promising opportunities in the fields of 
epidemiological research and disease surveillance to reduce the health burden, 
and improve the clinical management, of dengue illness. Future directions 
vi 
 
involve application of these algorithms to different study populations and age 
groups. Additionally, other analytical techniques, such as those involving CART 
analysis, can be explored with these data. 
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Chapter I Introduction 
IA. Overview of dengue illness 
“The pains which accompanied this fever were exquisitely severe in the 
head, back, and limbs. The pains in the head were sometimes in the back parts 
of it, and at other times they occupied only the eyeballs. In some people, the 
pains were so acute in their backs and hips that they could not lie in bed…. A few 
complained of their flesh being sore to the touch, in every part of the body. From 
these circumstances, the disease was sometimes believed to be a rheumatism. 
But its more general name among all classes of people was Break-bone fever”. 
(Benjamin Rush’s description of dengue epidemic in Philadelphia in 1780 taken 
from Nelson and Williams1) . 
IA. 1 Dengue virus  
 The etiologic agent of “break-bone fever” was found to be dengue virus 
(DENV). DENV is a flavivirus of the family Flaviviridae. Other flaviviruses in the 
same genus include Japanese encephalitis, yellow fever, West Nile, and tick-
borne encephalitis viruses. Dengue viruses are single-stranded positive-sense 
RNA viruses 2. The DENV genome is 11kb in length and encodes three structural 
and seven nonstructural proteins 2. DENV has four different serotypes: DENV1, 
DENV2, DENV3, and DENV4. Infection with one serotype provides lifelong 
immunity to the infecting serotype only but has been associated with increased 
risk of severe dengue illness upon secondary infection with a different serotype 3. 
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It is debatable if one serotype is more infectious or causes a more severe 
infection compared to another. Some studies have suggested there are 
differences in the pathophysiology of the different dengue serotypes, but 
currently no one serotype is considered more dangerous than another 4, 5, 6. 
IA. 2 Dengue illness 
 Dengue viruses are transmitted through the bite of an infected mosquito, 
usually Aedes aegypti or Aedes albopictus 7. Once a susceptible host is infected, 
symptoms of dengue infection may occur and usually appear after an incubation 
period typically between 4 and 7 days, with a range from 3 to 14 days 8. Dengue 
illness can range from an uncomplicated febrile illness, as seen in most dengue 
fever (DF) cases, to a more severe illness with bleeding tendency, 
thrombocytopenia, and plasma leakage as seen in dengue hemorrhagic fever 
(DHF). DF and DHF are emerging infectious diseases that are endemic in 
tropical and subtropical areas 9, 10, 11. 
Patients with confirmed dengue are classified as having DF if fever and 
any two of the following are present: headache, myalgia, arthralgia, rash, 
hemorrhagic manifestations, and leukopenia 12. Patients are classified as having 
DHF according to World Health Organization (WHO) guidelines based on the 
presence of all  four of the following four signs: fever, thrombocytopenia (platelet 
count <100,000/µL), bleeding tendency (positive tourniquet test or spontaneous 
bleeding), and evidence of plasma leakage (evidence of pleural effusion, ascites 
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or ≥20% hemoconcentration) 11; however, these findings may not appear until 
patients are already critically ill.  
DHF is categorized by severity into four grades 11. A diagnosis of DHF 
grades 3 and 4, termed dengue shock syndrome (DSS), includes all DHF criteria 
with the addition of circulatory failure. There is not a reliable definition of what 
constitutes a severe dengue illness and much controversy surrounds the WHO 
definition of DHF. This classification system is often impractical in the clinical 
setting, which leads to inconsistency of scientific data, such as under- or over-
reporting of severe dengue cases. Studies have shown that the WHO 
classification of DHF doesn’t account for all severe dengue illnesses 13, 14, 15, 16, 17. 
Setiati et al found that a modified classification system using only 
hemoconcentration with either thrombocytopenia or hemorrhagic tendency was 
in better agreement with the treating physician’s diagnosis of DHF than the WHO 
criteria 16. Harris et al found that strict adherence to the WHO classification of 
DHF excluded severe dengue patients that had shock, defined as hypotension 
for age or narrow pulse pressure with clinical signs of shock, but lacked 
thrombocytopenia or hemoconcentration, so they set up another category in their 
study “dengue with signs associated with shock”, which included 3% of 1,027 
patients 16.  
The term ‘hemorrhagic’ in DHF can lead to the false assumption that 
suspected dengue cases must have hemorrhage before being classified as 
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severe; however, 1) dengue can be severe even without significant hemorrhage, 
2) hemorrhage is not the sole criterion for DHF, and 3) dengue can be severe 
without meeting all the criteria for DHF. For example, Murgue et al found that 
when dengue cases were classified according to severity score (developed after 
close examination of clinical and laboratory data), the 50 most-severe cases 
were characterized by hemorrhage, decreased platelet count, and associated 
hepatic disorders, of which 17 were DF cases as classified by WHO criteria 14. 
Specifically, the most severe DF cases were characterized by severe 
hemorrhage, miscellaneous (cardiac, renal, pulmonary) manifestations, and 
elevated serum transaminase levels 14. These studies demonstrate the failure of 
the WHO classification system to account for disease severity in all dengue 
cases. Recently, Srikiatkhachorn et al studied a cohort of Thai children (the same 
cohort of patients presented in this study) and used the need for clinical 
intervention (fluid intervention or blood transfusion) as an indicator of disease 
severity; 15% of DF cases met the criteria for a severe dengue illness and 42% 
of physician-diagnosed DHF cases did not meet the criteria for a severe dengue 
illness 17 
IA. 3 Dengue vector 
The female Aedes aegypti mosquito, the most important vector for 
transmission of DENV, is known to be a nervous feeder and will disrupt a feeding 
at the slightest movement and return later to continue feeding on the same 
individual or a different individual 8. Due to this type of feeding, the female Aedes 
5 
 
aegypti can infect numerous individuals in a single blood meal spreading the 
virus to each person it feeds on 8. Furthermore, Aedes aegypti are indoor 
mosquitoes, in that they prefer to feed inside a residence, making control efforts 
more cumbersome due to the inability to effectively reach breeding sites with 
spraying of insecticides. 
Despite major efforts from the Pan American Health Organization and the 
CDC to prevent and control dengue, such strategies have proven to be poorly 
implemented and mostly ineffective 18. Community-wide participation and active 
involvement in prevention is needed to sustain any mosquito control effort. In a 
survey of knowledge, attitudes, and practices in rural Thailand, a negative 
association was observed  between respondent’s knowledge of mosquito 
development sites and the number of unprotected containers; however, 
preventative practices were only carried out after already having mosquito 
infestation 19. 
IA. 4 History of dengue and current magnitude  
The first known report of symptoms similar to dengue-like illness was in 
China between AD 265 to 420; however, the first dengue virus was not isolated 
until the 1940s during World War II 20. There has been an increased occurrence 
of dengue illness in the 20th century which has been attributed to poor vector 
control, rapid urbanization, and increased globalization 20, 21. DHF first appeared 
in Asia in the 1950s and the first major epidemic of DHF/DSS in the Americas 
6 
 
was caused by the introduction of DENV2 shortly after a large DENV1 outbreak 
in Cuba in 198122. The first cases of DHF in the Americas were due to secondary 
DENV2 infections that followed a DENV1 outbreak in 1977 22, 23. Dengue 
infection continues into the 21st century; recent estimates are that 3.6 billion 
people (55% of the global population) are at risk for dengue infection and that 70-
500 million dengue virus (DENV) infections occur annually, 2.1 million of which 
are severe dengue illnesses with ~21,000 deaths 24. Moreover, industrialized 
nations, such as the United States and European countries, are not 
unsusceptible to dengue outbreaks, as it is the most common systemic febrile 
illness among American and European travelers returning from Southeast Asia, 
the Caribbean, and South America 25. Additionally, recent outbreaks of dengue 
fever have occurred in south Texas and Hawaii 26, 27.   
IA. 5 Economic impact of dengue 
The economic impact of dengue in developing countries is substantial and 
has been associated with higher costs and longer disease duration when 
compared to non-dengue febrile illnesses 28, 29, 30, 31. As with most severe 
illnesses, individuals and families are impacted by lost wages from missed work, 
costs of seeking care, costs of treatment, missed school, and extended effects of 
recovery. For families who are already in the low socioeconomic bracket, a 
severe infectious illness could be detrimental both physically and economically. 
Clark et al estimated that an amount equal to approximately 82% of the average 
Thai family’s monthly household income is lost for each household member with 
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dengue infection 29. Although healthcare treatment for children in Thailand is paid 
for by the government under the "30-baht to cure every disease project" (Dr. Pra-
on Supradish, personal communication), Clark et al also found that most families 
first sought care at a private clinic that was not government funded 29. 
Transportation  costs for seeking care have also been shown to substantially 
impact the economic burden of disease in Thailand 28. Meltzer et al found that the 
average disability-adjusted-life years lost due to dengue illness in Puerto Rico is 
658 per year per million population 32. These studies may under-estimate the 
actual impact of dengue given the difficulties in diagnosis of dengue and under-
reporting of cases (See section IB). 
IA. 6 Treatment of dengue illness 
 Currently, there is no vaccine to prevent dengue infection. For a dengue 
vaccine to be effective, it must provide long-lasting protection against all four 
dengue serotypes. The standard treatment for patients with suspected dengue is 
supportive care consisting of oral rehydration therapy, bed rest, paracetamol (to 
reduce fever), and avoidance of aspirin 11. In practice, patients suspected to have 
DF or DHF are usually treated the same up to defervescence (initial febrile phase 
is subsiding); they are sometimes hospitalized and their condition is closely 
monitored with routine laboratory tests and maintenance of fluid intake. Around 
the time of defervescence, usually within 24 hours after defervescence, patients 
with DHF will develop severe symptoms and may become severely ill often with 
decreases in platelet count, hemorrhage, and signs of plasma leakage.  
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However, many DF cases are considered mild and may not require 
hospitalization but are often hospitalized until 24 hours after defervescence to 
ensure that the characteristics of DHF do not manifest. Currently, there are no 
early diagnostic/prognostic tools available to distinguish dengue from OFI or DF 
from DHF or severe dengue from non-severe dengue. If such tools were 
developed, they could potentially impact clinical practice in many ways, including: 
1) decreasing the number of un-necessary hospitalizations, 2) improving 
utilization of limited hospital resources to treat more severely ill patients, 3) 
improving outcomes of severely ill patients by getting them the care they need 
earlier, and 4) improving the capability of physicians in developing or rural areas 
to make a more accurate early diagnosis with limited resources.  
IB. Importance of early dengue diagnosis 
Most developing countries have epidemics of febrile illnesses that can be 
confused with DF, including measles, typhoid fever, and leptospirosis 33, 34, 35, 36, 
37. At initial presentation, DF and other febrile illnesses may have similar clinical 
features, including fever, headache, myalgia, and rash. The distinguishing clinical 
features of DHF, such as bleeding and signs of plasma leakage, are seen around 
the time of defervescence, typically the third or fourth day after the onset of fever. 
Suspected dengue patients, who include patients with other febrile illnesses, are 
sometimes hospitalized unnecessarily for observation until at least 24 hours after 
defervescence to ensure that the characteristics of DHF do not occur. 
9 
 
Hospitalization of patients with suspected dengue has been shown to be a 
significant financial burden in developing countries 29, 30. Ideally, only severe DF 
and DHF cases should be hospitalized.  
Confirming a dengue diagnosis by serologic tests may take days due to 
the time required for development of an antibody response, and plasma leakage 
may be difficult to detect and measure 38. Polymerase chain reaction (PCR) 
testing for DENV RNA is rapid but is presently only available as a research tool. 
Furthermore, expensive laboratory tests may not be available in many 
developing countries and remote areas. Areas that do not have access to 
sophisticated laboratory tools need early clinical and/or simple laboratory 
indicators that can provide an accurate and reliable diagnosis of dengue prior to 
the burden of an unnecessary hospitalization.  
The most common clinical measurements of plasma leakage include a 
chest x-ray or ultrasound (to measure the amount of pleural effusion) or serial 
hematocrits for the detection of hemoconcentration. These measurements add 
additional economic burden and may be unavailable in resource-poor areas. 
Furthermore, detection of hemoconcentration requires baseline and convalescent 
blood samples which are often not available. Classification tools that do not 
require these expensive and burdensome clinical measures are needed by 
researchers and epidemiologists to maintain active and reliable dengue disease 
surveillance in endemic, resource-poor areas.  
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IC. Distinguishing dengue from other febrile illnesses 
Differences in clinical and laboratory features between dengue and other 
febrile illnesses have been reported; however, published studies differ in terms of 
duration of symptoms, age of patients, and quality of the study, which could 
impact the clinical applicability of their findings 39. 
IC. 1. Systematic review 
I conducted a systematic review to evaluate studies that analyzed 
differences in clinical and laboratory variables between patients with dengue and 
patients with OFI to determine which factors, or combination of factors, best 
distinguished between the two. 
IC. 1.1 Search strategy 
An electronic search of Pubmed and Global Health databases using 
combinations of Medical Subject Headings (MeSH) and text words was 
conducted. Search terms were grouped as follows: (indicators OR 
"Dengue/diagnosis" OR clinical aspects OR clinical features OR clinical 
manifestations OR clinical characteristics OR clinical presentations OR physical 
signs OR physical symptoms) AND (dengue OR dengue fever OR dengue 
hemorrhagic fever OR dengue haemorrhagic fever). Articles were obtained 
electronically or in paper form.  
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IC. 1.2 Selection criteria 
Studies were included if they met the following criteria: published between 
1990 and October 2007, in English, and included comparisons between patients 
with DF and/or DHF and OFI patients in the abstract. The exclusion of studies 
prior to 1990 was to improve the reliability and global distribution of clinical 
experience with and the laboratory diagnosis of dengue. Studies were excluded if 
they used “travel” or “travelers” as MeSH terms in order to assess only 
populations in dengue-endemic areas. An assessment of titles and abstracts was 
done to exclude non-human studies, studies that assessed only molecular 
detection methods, and studies that did not compare patients with dengue and 
those with OFI. 
IC. 1.3 Study assessment and data extraction 
The quality of selected studies was assessed using a modified version of 
the Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) statement 40. The STROBE is a quality assessment checklist for 
observational studies that consists of 22 items. The STROBE was modified by 
adding questions about the serologic method used to confirm dengue diagnosis, 
use of viral isolation, and whether the study was based on a single dengue 
outbreak or transmission season. Use of viral isolation increased the score 
whereas single outbreak studies received no additional points. The quality score 
was the number of items from the STROBE checklist addressed as a percentage 
of the total number of items applicable (minimum of 23 and maximum of 25). 
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Studies with a quality assessment below 50% were excluded. Each selected 
article was characterized for study design, study location, type of patients 
(outpatients or inpatients), age of patients, type of dengue illness (primary or 
secondary; DF or DHF), method to confirm dengue (viral isolation, ELISA), 
duration of illness, and clinical and laboratory features.  
 
IC. 1.4 Results 
IC. 1.4.1 Search  
The initial search retrieved 1575 articles/abstracts (Figure 1-1). We 
excluded 182 studies because they included "travel" or "travelers", 293 published 
prior to 1990, 112 non-English studies, 147 duplicates (in both databases), and 
790 based on title/abstract assessment. A total of 51 articles were selected for 
data abstraction. Among these, two were unavailable for review 41, 42. Forty-nine 
articles were reviewed and an additional 34 (Suppl. 1.1) were excluded for the 
following reasons: 18 lacked statistical comparison between dengue and OFI, 9 
lacked an OFI comparison group, 4 had a quality assessment <50%, one had a 
limited number of dengue cases (nine), one compared environmental factors 
only, and one was a short report lacking necessary abstraction data (Table 1-1). 
A total of 15 published articles were included in this review. 
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IC. 1.4.2 Characteristics of included studies  
The characteristics of the included studies are listed in Table 1-2. There 
was substantial heterogeneity in study design and inclusion criteria. Among 
these, 10 were prospective cohort studies and five were case-control studies; 
9/15 (60%) were single outbreak studies or concluded within one year (study was 
concluded within one rainy season). The majority of studies were carried out in 
dengue-endemic regions of Southeast Asia/Pacific except for three studies from 
the Americas (Brazil, Nicaragua, and Puerto Rico) and one study from Australia. 
The included studies had quality assessment ratings ranging from 63% to 88%. 
One study assessed outpatients only and one study failed to give information on 
the type of patients included. Four studies assessed adults only (defined as >14 
years old), four studies assessed children only (defined as >11 months and <14 
years old), and seven studies assessed all age groups (including infants).  
 The sample sizes of laboratory-confirmed dengue patients ranged from 13 
to 2108 and the sample sizes of OFI patients ranged from 37 to 1065. All studies 
used hemagglutination inhibition and/or enzyme-linked immunosorbent antibody 
(ELISA) assays for serological confirmation of DENV infection; seven studies 
also used viral isolation for laboratory confirmation of infection. Six studies relied 
on a single blood sample for serology. For studies with convalescent serum 
samples, the shortest time between acute and convalescent samples was three 
days; however, this study obtained an additional sample at 3-4 weeks 43. Five 
studies used duration of fever prior to enrollment as part of their selection criteria 
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15, 43, 44, 45, 46, four studies mentioned duration of fever prior to enrollment but did 
not use it as an enrollment criteria 37, 47, 48, 49 and six studies failed to  mention the 
duration of fever prior to enrollment 35, 50, 51, 52, 53, 54. The mean duration of illness 
during the study period, noted in nine of the 15 studies, ranged from 3.3 to 10.5 
days. Only two studies analyzed clinical and laboratory symptoms according to 
day of illness 44, 48. The percentage of DHF cases was determined in eight 
studies and ranged from 0% 54 to 47% 44. The percentage of secondary 
infections was determined in seven studies and ranged from 43% 43 to 93% 44. 
No study statistically compared clinical or laboratory variables of patients with 
DHF and patients with OFI; however, Kalayanarooj et al listed the frequencies of 
symptoms separately for DHF and OFI 44. Only two studies separated primary 
and secondary infections in the analysis; neither found any significant differences 
in signs or symptoms between patients with primary and secondary infections 43, 
45. Two studies used a serologically identified comparison group- either SARS or 
leptospirosis 37, 50; three additional studies provided information about the specific 
diagnoses in the OFI group 15, 35, 47. Seven of the 15 studies used data collected 
at presentation to make comparisons 15, 37, 43, 44, 45, 47, 50; the other eight studies 
did not clearly define which data were used for statistical comparisons. 
Table 1-2 indicates the direction of association (increasing ↑ or decreasing 
↓ likelihood/frequency of dengue compared to OFI) for clinical and laboratory 
features that were reported in at least two studies where one (or more) found a 
significant difference between dengue and OFI patients. Bruce et al (2005), 
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Deparis et al (1998), Hammond et al (2005), Karande et al (2005), Low et al 
(2006), Nunes-Araujo et al (2003), and Phuong et al (2006) showed significant 
increases/decreases in mean likelihood of dengue versus OFI as relative risks or 
odds ratios. All other studies reported independent associations as differences in 
proportions (for categorical variables) or means (for continuous variables) 
between patients with dengue and OFI. For clinical and laboratory features 
reported in at least two prospective and two retrospective studies, the directions 
of association were similar except for gender and headache/retro-orbital pain. 
The consistency score is an evaluation of the direction of association for each 
variable across all the studies that measured that variable, weighted by the 
quality assessment percentage of each study. 
IC. 1.4.2.1 Demographic indicators 
No consistent associations were observed between age and occurrence of 
dengue across all studies or within age-grouped studies. Two retrospective 
studies showed a significantly higher frequency of dengue among males 37, 50.  
IC. 1.4.2.2 Clinical indicators 
Studies that assessed adults only reported consistently higher frequencies 
of rash and hemorrhagic signs in patients with dengue when compared to 
patients with OFI 37, 47, 53; however, the frequency of hemorrhagic signs showed 
no differences between dengue and OFI in the four studies that assessed 
children only 45, 48, 52, 54. Hammond et al reported hemorrhagic signs in specific 
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categories; the frequencies of melena and hematemesis were higher in children 
with dengue but not in adults 52. In four of seven studies assessing all age 
groups, the frequency of rash was also higher in patients with dengue 48, 52, 54; 
however, two studies assessing children only found no significant association 
with rash 35, 49. Three studies that assessed children only found a higher 
frequency of petechiae among patients with dengue and one study that 
measured petechiae in adults only also found a positive association among those 
with dengue compared to OFI 15, 44, 47, 49. A greater percentage of patients with 
dengue reported lethargy/prostration and arthralgia/joint pain in two studies 
assessing adults only 53; however, lethargy/prostration was not reported in 
studies assessing children only and the patterns of arthralgia/joint pain were 
inconsistent in all other studies (children or all ages). In two studies that only 
included children, the frequency of anorexia was higher among patients with 
dengue 15, 44. Taste alteration and skin sensitivity were more frequently reported 
in patients with dengue in two studies assessing adults only. Nonspecific 
symptoms, such as headache/retro-orbital pain, abdominal pain, diarrhea, 
vomiting, itching/pruritis, and nausea showed inconsistent or non-significant 
associations when comparing patients with dengue and patients with OFI. 
Duration of fever prior to or during the study period showed inconsistent or non-
significant associations with the occurrence of dengue versus OFI.  
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IC. 1.4.2.3 Laboratory indicators 
Neutrophil and lymphocyte counts were significantly lower in patients with 
dengue in comparison to patients with OFI among studies that measured these 
variables 15, 35, 37, 43, 44, 47, 48, 52. All studies measuring WBC found a lower WBC 
count among patients with dengue, except for one retrospective study by 
Sawasdivorn et al 49, which showed no association. Nine of 11 studies found 
lower platelet counts among patients with dengue compared to OFI patients. Two 
of three studies that measured prothrombin time found significantly lower values 
among patients with dengue 37, 47. Bruce et al and Chadwick et al found lower 
creatinine levels and a lower percentage of jaundice among patients with dengue 
47, 50. Higher levels of hepatic transaminases (AST/ALT) were found in patients 
with dengue in three of four studies 37, 44, 47. Increased hematocrit and 
hemoglobin levels were observed among patients with dengue in two adult-only 
studies 37, 47; however, hematocrit showed inconsistent associations in three 
children-only studies. Other laboratory measures, such as total protein, APTT, 
and urea, also showed inconsistent patterns with the occurrence of dengue 37, 47.  
Kalayanarooj et al and Hammond et al were the only studies to measure pleural 
effusion or ascites 44, 52. Kalayanarooj et al reported a higher frequency of pleural 
effusion in patients with DHF compared to DF or OFI 44. Hammond et al found an 
increased odds of having pleural effusion and ascites among children and adults 
with dengue 52.   
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IC. 1.4.2.4 Other indicators 
Table 1-3 lists additional symptoms that showed associations between 
dengue and OFI but were reported in only one of the 15 studies reviewed. Table 
1-4 lists symptoms that were measured in only one study and showed no 
association with dengue or OFI. Other common laboratory tests- sodium, 
potassium, glucose, alkaline phosphotase, and lactate dehydrogenase- 
measured in Chadwick et al and Wilder-Smith et al showed no differences 
between dengue and OFI 37, 47.  
IC. 1.4.2.5 Combined indicators 
Seven studies 15, 35, 37, 47, 48, 49, 53 carried out multivariable regression 
analysis in an attempt to distinguish patients with dengue from those with OFI 
(Tables 1-5 and 1-6). Among these seven studies, all studies that measured 
WBC included this variable in their final model and showed a reduced WBC 
count in patients with dengue compared to patients with OFI. Three of these 
seven studies included some measure of liver function in the final model. Wilder-
Smith et al found that increased AST resulted in an increased odds of dengue. 
Phuong et al found that hepatomegaly resulted in an increased adjusted odds of 
dengue. On the other hand, Chadwick et al found that lower bilirubin values 
resulted in increased adjusted odds of dengue 47. Chadwick et al was the only 
one of these studies that reported platelet count and did not include this variable 
in the final regression model 47. Three studies included signs of bleeding such as 
petechiae, hematocrit, and positive tourniquet test in their final model and 
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showed that positive signs of bleeding increased the odds of having dengue 15, 49, 
53. Three studies also showed a higher frequency of rash among dengue patients 
in their final model 47, 48, 53. The final model in Karande et al had a negative 
predictive value (NPV) of 45% and was the only study to report a NPV along with 
the final model's positive predictive value (PPV) 35. 
IC. 1.5 Summary of findings 
This review of the literature suggests that several clinical and laboratory 
measures distinguish patients with dengue from those with OFI. Low platelet 
count/thrombocytopenia and decreases in WBC and neutrophils were 
independently associated with the presence of dengue, when compared to 
patients with OFI in both adults and children. These variables, as well as signs of 
rash and liver damage, were also used in multivariable models to distinguish 
patients with dengue from those with OFI.  
Low platelet count is used as a criterion for the diagnosis of DHF 11. The 
cause(s) of thrombocytopenia in dengue are  unknown; but decreased production 
of platelets in DF and increased destruction of platelets in DHF have been 
described 55.  Kalayanarooj et al attributed the reduction in WBC to bone marrow 
suppression by the dengue virus; however, it has been suggested that these 
laboratory measures are not dengue-specific in the early stages of the disease 44, 
48, 56.  
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Alterations in the microvascular endothelium in patients with dengue are 
thought to lead to a higher likelihood of hemorrhage 55, 57. In this review, an 
increased frequency of hemorrhage was observed in adults with dengue but was 
not associated with the occurrence of dengue in studies that only included 
children; however, Hammond et al demonstrated that some types of hemorrhage 
(e.g., hematemesis and melena) were associated with dengue in children, 
suggesting that the types of hemorrhagic manifestations seen in patients with 
dengue may depend on the age of the patient 52.  
It is unlikely that any one indicator will be useful in clinical practice 
because these signs and symptoms are present in other diseases, such as viral 
hepatitis and leptospirosis, which are also endemic in areas with a high 
prevalence of dengue. However, a combination of rash and indicators of liver 
damage in combination with other variables, such as age, myalgia, WBC count, 
and platelet counts, may help to establish a diagnostic algorithm that can be 
used to distinguish dengue from OFI patients. Several studies used multivariable 
regression models to discriminate patients with dengue from patients with OFI; 
however, most published models had lingering statistical questions or did not 
describe some statistical issues such as over-fitting, co-linearity, and how 
variables were categorized. Wilder-Smith et al presented a model with very large 
odds ratios; however, the confidence intervals for their model were also 
extremely large and questions of over-fitting and co-linearity were not discussed 
37. Deparis et al presented a model with an unusually small odds ratio for a 
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categorical variable (low platelet count), which may not be applicable in a clinical 
setting 48. None of the regression models were validated using a training and 
testing dataset approach. Furthermore, the generalizability of these models is 
questionable since most were derived from single outbreak studies. For example, 
Karande et al was a single outbreak study and presented a model with 100% 
PPV but they only had 13 patients with dengue in the model 35.  
Any algorithm to identify patients at risk of dengue would need to be 
applied early after the onset of illness in order to be useful in preventing 
unneeded hospitalizations. This review highlights a weakness in the literature as 
few studies indicated which day of illness clinical and laboratory measures were 
assessed. Only Kalayanarooj et al and Deparis et al separately analyzed clinical 
and laboratory measures according to day of illness 44, 48. Kalayanarooj et al 
showed that positive and negative predictive values for individual variables 
differed depending on the stage of illness 44. Deparis et al showed that the 
frequency of clinical and laboratory symptoms varied according to day of illness 
48.  
Five of the included studies were case-control studies that relied on the 
review of medical records or patient recall, which could potentially bias the 
findings of these studies. Furthermore, two of the case-control studies did not 
use a standardized data collection form. Six studies relied on serologic testing of 
a single blood sample, which could increase the risk of misclassification of 
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patients with dengue. Only two studies serologically confirmed all patients in the 
non-dengue comparison group and differences found between patients with 
dengue and patients with OFI depended on the specific comparison febrile 
illness. Bruce et al used a leptospirosis comparison group and was the only study 
that showed no differences in platelet count or AST/ALT 50. Illnesses with similar 
characteristics, such as dengue and leptospirosis, will clearly be more difficult to 
discriminate on the basis of any clinical algorithm.    
Duration of illness prior to study enrollment did not distinguish patients 
with dengue from those with OFI in four out of five studies. This finding indicates 
that patients with dengue do not have an initial febrile period that is different in 
length from patients with OFI. Duration of illness prior to presentation may be 
more applicable in distinguishing patients with DHF from patients with DF. On 
average, patients with DHF have a more severe form of illness and may require 
hospitalization for a more extended period of time after defervescence in 
comparison to patients with DF. However, no study in this review statistically 
compared clinical signs and symptoms in patients with DHF to patients with DF 
or OFI. We are, therefore, unable to make any conclusions from this review 
regarding which readily available signs and symptoms, if any, are able to 
prospectively distinguish patients with DHF from patients with DF or OFI. 
This review has several limitations. There was no assessment of inter-
rater or intra-rater reliability of quality assessment ratings and the STROBE is 
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mainly a score of reporting and may reflect the ability to extract information rather 
than quality of the study itself. There is a lack of established quality assessment 
rating scales for evaluating observational studies. The STROBE contains items 
that give merit to a study for addressing its limitations, which may explain why 
retrospective case-control studies had the highest quality assessment rating. Not 
all studies had robust statistical methods due to poor study quality and 
retrospective design. Some studies failed to include duration of fever or duration 
of illness in their analysis which limits the conclusions that can be made about 
the impact of this variable as well as other variables that may be time-dependent. 
Finally, many studies did not include what day of illness the clinical and 
laboratory data presented were measured, which makes it impossible to 
determine whether this data can be used to distinguish patients with dengue from 
those with OFI early in the course of illness. Additional prospective studies are 
needed to establish a diagnostic algorithm that can be validated and generalized 
to distinguish dengue from OFI and DF from DHF in the early stages of illness. 
Furthermore, longitudinal studies that routinely document clinical and laboratory 
signs and symptoms throughout each patients' course of illness would provide 
much needed data to develop  a predictive model that can distinguish patients 
with dengue who will require hospitalization from patients with OFI.  An easily 
applicable clinical algorithm could have a favorable impact on the healthcare 
economies of developing countries that have endemic levels of dengue. 
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ID. Correlates of clinical laboratory measures and physician’s diagnosis of 
DHF or DF  
Using the data source from Thailand covering study years 1994-97, we 
conducted a preliminary analysis to assess the feasibility of the application of our 
data to establish disease classification models. Using only data from these study 
years, we used readily available clinical and laboratory variables from 318 
subjects with confirmed dengue to determine which variable(s) distinguished an 
expert physician's final diagnosis of DHF or DF. Data included in the analysis 
consisted of each patient’s maximum aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), percent change in hemoconcentration, and receiving 
any intravenous fluid received throughout their hospitalization, and their minimum 
albumin and platelet count. There were 301 patients with sufficient data to be 
used in the modeling. Kappa statistics were used to assess the percent 
agreement between the expert physician’s final diagnosis of DHF and WHO 
criteria for the diagnosis of DHF, using two different indicators of plasma leakage: 
percent change in hematocrit and pleural effusion index (PEI). Kappa statistics 
showed 86% agreement between physician’s final diagnosis of DHF and WHO 
criteria when PEI was used as the indicator of plasma leakage (K=.71); 75% 
agreement was observed between physician’s final diagnosis of DHF and WHO 
criteria when percent change in hematocrit was used (K=.47). Univariable and 
stepwise multivariable logistic regression analysis was done on clinical and 
laboratory variables thought to correlate with a final diagnosis of DF or DHF.  
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Two different final models adjusting for age and gender were produced using the 
different indicators of plasma leakage. Area under the curve (AUC), sensitivity 
and specificity were generated for the best models using each of the indicators. 
The multivariable model using PEI as the indicator for plasma leakage that 
included other indicators such as maximum AST, gender, and minimum platelet 
count had an AUC of 98%, sensitivity of 91% and specificity of 98%. The 
multivariable model using percent change in hematocrit as the indicator for 
plasma leakage had an AUC of 86%, sensitivity of 75% and specificity of 83%, 
and included other indicators of minimum serum albumin levels, gender, and 
minimum platelet count. Based on these results, plasma leakage as measured by 
PEI is the best indicator of a diagnosis of DHF and best mimics real clinical 
experience. However, PEI may be difficult to measure and resource-poor areas 
may not have access to equipment to measure it. Percent change in hematocrit 
also mimicked real clinical experience but to a lesser degree and also required 
baseline and convalescent hematocrits that are not typically available outside of 
a research setting. 
These results suggest that physicians did not rely on a single measure to 
distinguish DHF from DF and did not strictly adhere to WHO criteria to make a 
diagnosis of DHF. However, strong correlations were established with measures 
of plasma leakage (PEI or hemoconcentration), which may not be measured in 
resource-poor areas. The multivariable modeling demonstrates that a 
combination of variables, both WHO criteria and other variables, such as liver 
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enzymes, albumin, and need for intravenous fluid, may better mimic the clinical 
experience and better distinguish DHF from DF. Furthermore, this preliminary 
study suggests that a classification model using a combination of clinical 
laboratory measurements, but which lacks indicators of plasma leakage, may 
also have a strong correlation with a physician’s diagnosis and may be useful in 
classifying dengue disease when indicators of plasma leakage are not available.     
 Additionally, a classification scheme for individuals diagnosed with dengue 
illness who were not in need of hospitalization was done using the same patients 
from the Thai 1994-1997 data.  Patients who had DHF grade 3 and/or received 
IVF, and/or had evidence of significant pleural effusion measured by chest x-ray 
(PEI >5), were classified as patients in need of hospitalization. Using data from 
246 patients with dengue who had information available on all classification 
variables, 142 patients with DF or DHF grade 1 or 2 did not require 
hospitalization. Of patients with DHF grade 1 or grade 2, one-third did not require 
hospitalization. In contrast, 16.2% of patients with DF required hospitalization. In 
conclusion, a diagnosis of DF is not always indicative of mild illness and a 
diagnosis of DHF isn’t always indicative of a severe illness. By using a different 
categorization that can distinguish between severe and non-severe dengue, 
physicians will be able to better utilize limited resources by reserving treatment 
for more severe illnesses.  
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IE. Summary and significance 
Dengue is a significant health burden and consists of a wide range of 
disease severity from a self-limited febrile illness to severe hemorrhagic fever 
with shock. Controversy surrounds the practicality of the WHO guidelines 
regarding DHF classification versus classification of severe dengue disease. 
After a systematic review of the literature, research gaps exist with regards to 
prospective longitudinal studies that can describe dengue illnesses in terms of 
routine clinical laboratory measures and that could potentially establish predictive 
algorithms that can benefit dengue endemic regions. Preliminary research 
suggests that more useful classification tools can be developed.    
IF. Research objectives 
The research objectives of these analyses were to describe the dynamics 
of dengue diseases over the disease course, establish validated correlation 
models that can be used to classify dengue illnesses without the need for 
indicators of plasma leakage (chest x-ray, ultrasound, and hemoconcentration) 
and investigate the potential utility of clinical laboratory variables as early 
indicators of dengue illness among children in a hospital setting. Our approach 
was to apply robust statistical techniques to a well defined clinical dataset. Our 
dataset was designed to capture early symptomatic dengue illnesses and to 
systematically record routine clinical data throughout each subject’s illness 
episode.  
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Research objective 1 
To describe the temporal dynamics of clinical laboratory variables over the 
course of illness among hospitalized children with DHF, DF, and OFI to 
determine whether the temporal patterns of these variables differ among these 
diagnostic groups. Additionally, we identified trends in clinical laboratory 
variables that could be used to distinguish patients with impending plasma 
leakage. The analytical techniques used for this analysis were lowess curves and 
population average models. 
Research objective 2 
To establish and validate binary logistic regression models using 
maximum and minimum clinical laboratory variables throughout each patient’s 
hospitalization, without relying on direct measures of plasma leakage (chest x-
ray, ultrasound, and hemoconcentration), that are able to distinguish between: 
DHF vs. DF, DHF vs. DF + OFI, severe dengue vs. non-severe dengue+OFI, and 
subjects with dengue vs. subjects with OFI.  
Research objective 3 
To establish and validate predictive diagnostic trees, using clinical 
laboratory data obtained on the day of presentation, that can distinguish subjects 
with impending severe dengue from subjects with non-severe dengue and OFI. 
The analytical technique used for this analysis was classification and regression 
tree (CART) analysis. 
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Figure 1-1 Flow-chart of review process 
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Table 1-1 Characteristics of included studies 
First Author Study design Study 
Year(s) 
Location Patients Age Sample Size Viral 
isolation 
Duration of 
fever prior 
to 
enrollment 
(days) 
Duration 
of illness 
during 
study 
period 
(days) 
Modified 
STROBE 
QA (%) 
Dengue OFI 
Low Prospective 
cohort 
2005 Singapore Mixed Adults 133 321 Yes <3 Mean 
10.5 
84% 
Phuong 
(2004) 
Prospective 
cohort 
1996-1998 Vietnam Inpatients Children 712 85 No <7  N/A 84% 
Chadwick Prospective 
cohort 
1998-2000 Singapore Inpatients Adults 148 233 No Mean  
5.2  
N/A 80% 
Kalayanarooj Prospective 
cohort 
1994 Thailand Inpatients Children 60 112 Yes <3  Mean 4.0 80% 
Phuong 
(2006) 
Prospective 
cohort 
2001- 
2002 
Vietnam Mixed All ages 234 463 No <14  Median 
5 
79% 
Deparis  Prospective 
cohort 
1996-1997 French 
Polynesia 
Outpatients All ages 196 102 Yes Median 2.5  N/A 76% 
Hammond  Prospective 
cohort 
1999-2001 Nicaragua Inpatients All ages 2108 1065 Yes N/A Infants 
6.4   
Children 
6.0 
Adults 
5.2  
76% 
Karande Prospective 
cohort 
2002 India Mixed Children 13 37 No N/A Mean 5.5  68% 
Buchy Prospective 
cohort 
2001-2002 Vietnam Inpatients All ages 108 17 Yes N/A Median 
3.9 
64% 
Suwandono Prospective 
cohort 
2004 Indonesia Inpatients All ages 180 92 Yes <7 N/A 63% 
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Wilder-
Smith 
Retrospective 
case-control 
2003; 
1997- 
2000 
Singapore Inpatients Adults 147 55 No Median 4 Median 4  88% 
Bruce Retrospective 
case-control 
1996-1997 Puerto 
Rico 
Mixed All ages 84 42 No N/A Median 
10 
83% 
Nunes-
Araujo 
Retrospective 
case-control 
1993-1998 Brazil N/A All ages 495 650 No N/A N/A 78% 
Sawasdivorn Retrospective 
case-control 
1998-1999 Thailand Inpatients Children 45 38 Yes Mean 3.71  
 
Mean 
3.37  
76% 
McBride Retrospective 
case-control 
1995 Australia Mixed Adults 399 600 No N/A N/A 67% 
 
List of included studies indicating: first author, study design, year the study was performed, location of the study (country), type of patients ("inpatients", "outpatients", 
or "mixed" which includes both inpatients and outpatients), sample size ("dengue" is the number of confirmed dengue patients, and "OFI" is the number of other febrile 
illness patients), viral isolation, duration of fever prior to enrollment (among the dengue patients enrolled), duration of fever during study period, and modified STROBE 
quality assessment rating (shown as a percentage)
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Table 1-2 Symptoms and laboratory measures assessed in at least two 
studies where one study showed an association with dengue 
Symptoms Consistency
Score 
All ages 
PhuongA 
(2006) 
DeparisA  HammondA Nunes-
AraujoA 
Buchy BruceA Suwandono 
DEMOGRAPHICS         
  Age  ↑ 25% ↓ 0 0 ↑ 0 - - 
  Males  Males 9% 0 0 0 0 0 ↑ - 
CLINICAL INDICATORS         
  Taste alteration ↑ 100% - - - - - - - 
  Skin sensitivity ↑ 100% - - - - - - - 
  Petechiae (scattered, spontaneous     
  bleeding)/positive tourniquet test  
↑ 75% 0 - - ↑ 0  ↑ 
  Liver size >1cm/hepatomegaly  ↑ 74% 0 - ↑ - -  - 
  Anorexia  ↑ 74% 0 - - - -  - 
  Lethary/Prostration ↑ 74% - ↑ - 0 -  - 
  Rash (including macular rash)   ↑ 65% 0 ↑ ↑ ↑ 0 ↑ - 
  Arthralgia/joint pain ↑ 50% ↑ 0 - 0 -  - 
  ***Hemorrhagic signs  ↑ 49% 0 ↑ ↑ 0 0  - 
  Itching/Pruritis ↑ 46% - - - - -  - 
 Cough/rhinitis/breathlessness/ 
  coryza/runny nose 
↓ 44% ↓ 0 - - 0  - 
  Vomiting  ↑ 42% 0 0 - - 0  0 
  Abdominal pain/abdominal  
    tenderness/stomach ache  
↑ 32% ↑ 0 ↑ - 0  0 
  Nausea  ↑ 31% 0 - - 0 0  0 
  Myalgia/muscle pain/backache  ↑ 30% ↑ - - 0 0 0 0 
  Sore throat/red pharynx  ↑ 21% 0 - - - -  0 
  Duration of feverB ↑ 20% 0 - - - -  - 
  Headache/retro-orbital pain  ↑ 16% ↓ 0 - ↑ 0 0 0 
  Diarrhea  ↓ 16% ↓ 0 - - -  - 
  Splenomegaly 0 0 0 - - -  - 
LABORATORY INDICATORS         
  Neutrophils/neutropenia   ↓ 100% - ↓ - - -  - 
  Hemoglobin  ↑ 100% - - - - -  - 
  Lymphocytes/lymphopenia  ↓ 100% - ↓ - - -  - 
  WBC/Leukocytosis/Leukopenia  ↓ 89% - ↓ ↓ - - ↓ ↓ 
  Platelets/Thrombocytopenia  ↓ 83% - ↓ ↓ - 0 0 ↓ 
  AST/ALT  ↑ 75% - - - - - 0 - 
  PT  ↓ 67% - - - - - 0 - 
  Creatinine ↓ 65% - - - - - ↓ - 
  Hematocrit  ↑ 55% - 0 - - 0  ↑ 
  Total Protein ↓ 52% - - - - -  - 
  Albumin ↑ 50% - - - - -  - 
  Jaundice/Icterus/Bilirubin§  ↓ 43% 0 - - - - ↓ - 
  APTT ↑ 32% - - - - - 0 - 
  Urea 0 - - - - - 0 - 
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Table 1-2 (Continued) 
Symptoms Children Adults 
Phuong 
(2004) 
*Kalayanarooj KarandeA Sawasdivorn Chadwick Wilder-
Smith 
McBride LowA 
DEMOGRAPHICS         
  Age  ↑ ↑ 0 0 0 0 - ↑ 
  Males  0 0 0 0 0 ↑ - 0 
CLINICAL INDICATORS         
  Taste alteration - - - - - - ↑ ↑ 
  Skin sensitivity - - - - - - ↑ ↑ 
  Petechiae (scattered, 
spontaneous     
  bleeding)/positive tourniquet 
test  
↑ ↑ - ↑ ↑ - -  
  Liver size >1cm/hepatomegaly  ↑ - - - ↑ - -  
  Anorexia  ↑ ↑ - - - - - ↑ 
  Lethary/Prostration - - - - - - ↑ ↑ 
  Rash (including macular rash)   - - 0 0 ↑ - ↑ ↑ 
  Arthralgia/joint pain 0 - ↑ 0 - - ↑    ↑ 
  ***Hemorrhagic signs  0 0 0 0 ↑ - ↑ ↑ 
  Itching/Pruritis - - - - 0 - ↑  
 Cough/rhinitis/breathlessness/ 
  coryza/runny nose 
↓ - 0 - 0 - ↓  
  Vomiting  ↑ ↑ 0 - 0 - ↑ ↑ 
  Abdominal pain/abdominal  
    tenderness/stomach ache  
↑ 0 0 - 0 - 0 - 
  Nausea  - ↑ - - 0 - - ↑ 
  Myalgia/muscle pain/backache  0 - - 0 ↑ - ↑ 0 
  Sore throat/red pharynx  ↑ - - - 0 - 0  
  Duration of feverB ↑ 0 0 0 - - - ↑ 
  Headache/retro-orbital pain  0 0 0 - 0 - ↑ ↑ 
  Diarrhea  0 - 0 - 0 - 0 0 
  Splenomegaly ↓ - - - ↑ - -  
LABORATORY INDICATORS         
  Neutrophils/neutropenia   - ↓ - - ↓ ↓ - ↓ 
  Hemoglobin  - - - - ↑ ↑ -  
  Lymphocytes/lymphopenia  - - - - ↓ ↓ - ↓ 
  
WBC/Leukocytosis/Leukopenia  
- ↓ - 0 ↓ ↓ - ↓ 
  Platelets/Thrombocytopenia  ↓ ↓ ↓ - ↓ ↓ - ↓ 
  AST/ALT  - ↑ - - ↑ ↑ -  
  PT  - - - - ↓ ↓ -  
  Creatinine - - - - ↓ 0 -  
  Hematocrit  ↑ 0 ↑ - ↑ ↑ - 0 
  Total Protein - - - - 0 ↓ -  
  Albumin - 0 - - ↑ - -  
  Jaundice/Icterus/Bilirubin§  - - 0 - ↓ 0 -  
  APTT - - - - ↑ 0 -  
  Urea - - - - ↓ ↑ -  
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Footnotes to Table 1-2 
*Only analysis performed on day of presentation is shown 
**Consistency score= |[∑(quality assessment %)(+1/-1/0)]/[∑(quality assessment % of studies measuring this 
variable)]|, 
 for example, anorexia: |[(.84)(0) + (.79)(1) + (.80)(1) + (.84)(1)]/[(.84) + (.79) + (.80) + (.84)]|= ↑74% 
***Hemorrhagic signs: other than petechiae (bleeding gums, gingival bleeding, mucosal bleeding, vaginal bleeding, hematemesis, 
reported bleeding, bleeding manifestations, melena) 
§=bilirubin is a laboratory measure that correlates with clinical measures of jaundice/icterus 
↑= indicates positive association with dengue positive patients compared to patients with OFI 
↓= indicates negative association with dengue positive patients compared to patients with OFI 
0= indicates no significant association 
-= not measured 
A=Reported associations as relative risks or odds ratios 
B=prior to enrollment except for Karande and Low which is during illness 
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Table 1-3 Signs, symptoms, and additional indicators reported in only one 
study but which showed a significant association between dengue and OFI 
Study Symptoms Direction of association 
McBride 
(1998) 
Days of work lost 
Visited the doctor 
Hospitalized 
↑ 
Chadwick 
(2006) 
Pulse 
Temperature 
↓ 
Chadwick 
(2006) 
Skin flushing 
Islands of sparing 
↑ 
Hammond 
(2005) 
Chills ↑ 
Karande 
(2005) 
Edema ↓ 
Phuong  
(2006) 
Pallor ↑ 
Kalayanarooj 
(1997) 
Absolute monocyte counts ↓ 
Bruce 
(2005) 
Skin abrasions ↓ 
Low 
(2006) 
Red eyes ↑ 
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Table 1-4 Non-significant signs, symptoms, and additional indicators 
reported in one or more studies 
  Study Symptoms 
Phuong  
(2006) 
Tender muscles on palpation, arthrites, dehydration, tender liver, 
constipation, altered consciousness, bruises, lymphadenitis, eschar, 
and vesicles 
Bruce 
(2005) 
Red eyes, eye irritation, eye pain, nuchal rigidity 
Karande 
(2005) 
Polyserositis, altered sensorium, convulsions, oliguria, respiratory 
rate, and hepatosplenomegaly 
Deparis 
(1998) 
Acute respiratory distress 
Chadwick 
(2006) 
Respiratory rate 
Buchy 
(2005) 
Conjunctival injection 
Low 
(2006) 
Swollen glands 
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Table 1-5 Studies with multivariable predictor models presented as odds 
ratios 
Study Predictors OR (95% CI) 
Wilder-Smith 
 
Platelet count (10^9 platelets/L)   <140 
AST (IU/L)   >34 
WBC (10^9 cells/L)   <5 
456 (37, 5917) 
68 (6, 719) 
47 (4, 518) 
Phuong  
(2004) 
Petechiae 
Hepatomegaly   >1 cm 
Admission after >3 days of illness 
Hematocrit 
Coryza 
Sore throat    
4.82 (2.71, 8.58) 
2.93 (1.14, 7.53) 
2.47 (1.38, 4.42) 
1.13 (1.05, 1.22) 
0.36 (0.16, 0.81) 
0.33 (0.14, 0.76) 
Deparis 
 
Macular rash 
Pruritis 
Low Platelet Count 
Leukopenia 
2.07 (1.53, 2.62) 
2.55 (2.31, 2.79) 
1.002 (1.001, 1.005) 
1.2 (1.06, 1.37) 
Chadwick 
 
Rash (patient reported)  
Hemoglobin 
WBC 
Creatinine 
Bilirubin 
Prothrombin Time 
9.13 (2.14, 38.94) 
1.52 (1.11, 2.06) 
0.43 (0.31, 0.59) 
0.73 (0.57, 0.93) 
0.74 (0.59, 0.94) 
0.44 (0.30, 0.65) 
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Table 1-6 Studies with multivariable models presented as positive 
predictive values 
Study Predictors Positive Predictive 
Value 
Sawasdivorn Fever + Positive Tourniquet Test + Leukopenia 73% 
McBride Rash + Bleeding (gums, nose, vagina) + bone pain + Taste Alteration 73% 
Karande Arthralgia + Thrombocytopenia 100% 
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Supplemental Table 1-1 
 Characteristics of Excluded Studies 
Authors Year Title Reason for exclusion 
Ali 
41 
2006 Dengue fever in malaria endemic areas Unavailable through UMass library 
Zahur 
42 
2001 Clinical spectrum of thrombocytopenia in 
adult population of Karachi 
Unavailable through UMass library 
Flannery 
34 
2001 Referral pattern of leptospirosis cases during 
a large urban epidemic of dengue 
No statistical comparison of dengue and 
non-dengue patients 
Ageep 
58 
2006 Clinical presentations and laboratory findings 
in suspected cases of dengue virus 
No statistical comparison of dengue and 
non-dengue patients 
Akram 
59 
1998 Dengue virus infection among children with 
undifferentiated fever in Karachi 
No statistical comparison of dengue and 
non-dengue patients 
Baruah 
60 
2006 Incidence of dengue in a tertiary care centre- 
Kasturba Hospital, Manipal 
No statistical comparison of dengue and 
non-dengue patients 
Barauh 
61 
1996 Haemorrhagic manifestations associated with 
dengue virus infection in Nagaland 
No statistical comparison of dengue and 
non-dengue patients 
CDC-
MMWR 
27 
2007 Dengue hemorrhagic fever---U.S.-Mexico 
border, 2005 
No statistical comparison of dengue and 
non-dengue patients 
Cheng 
62 
2004 Clinical deterioration in community acquired 
infection  associated with lymphocyte 
upsurge in immunocompetent hosts 
No statistical comparison of dengue and 
non-dengue patients 
Deepak 
63 
2006 Differential diagnosis of acute liver failure in 
India 
No statistical comparison of dengue and 
non-dengue patients 
Dietz 
33 
1992 Diagnosis of measles by clinical case 
definition in dengue-endemic areas: 
implications for measles surveillance and 
control 
No statistical comparison of dengue and 
non-dengue patients 
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Dietz 
64 
1990 Epidemic dengue 1 in Brazil, 1986: 
Evaluation of a clinically based dengue 
surveillance system 
No statistical comparison of dengue and 
non-dengue patients 
Gupta 
65 
2000 Gall bladder wall edema in serology proven 
pediatric dengue hemorrhagic fever: A useful 
diagnostic finding which may help in 
prognostication 
No statistical comparison of dengue and 
non-dengue patients 
Kalayanarooj 
66 
1999 Can doctors make an accurate diagnosis of 
dengue infections in an early stage? 
No statistical comparison of dengue and 
non-dengue patients 
Kittigul  
67 
2003 Dengue hemorrhagic fever: knowledge, 
attitude and practice in Ang Thong Province, 
Thailand 
No statistical comparison of dengue and 
non-dengue patients 
Kularatne 
68 
2005 Epidemiology, clinical features, laboratory 
investigations and early diagnosis of dengue 
fever in adults: a descriptive study in Sri 
Lanka 
No statistical comparison of dengue and 
non-dengue patients 
Leelarasamee 
69 
2004 Etiologies of acute undifferentiated febrile 
illness in Thailand 
No statistical comparison of dengue and 
non-dengue patients 
Peyerl-
Hoffman 
70 
2004 Serological investigation of the prevalence of 
anti-dengue IgM and IgG antibodies in 
Attapeu Providence, South Laos 
No statistical comparison of dengue and 
non-dengue patients 
Reynes 
71 
1994 The first epidemic of dengue hemorrhagic 
fever in French Guiana 
No statistical comparison of dengue and 
non-dengue patients 
Rodier 
72 
1996 Epidemic dengue 2 in the city of Djibouti 
1991-1992 
No statistical comparison of dengue and 
non-dengue patients 
Anuradha 
73 
1998 The 1996 outbreak of dengue hemorrhagic 
fever in Delhi, India 
No other febrile illness comparison group 
Chairulfatah 
74 
1995 Clinical manifestations of dengue 
hemorrhagic fever in children in Bandung 
Indonesia 
No other febrile illness comparison group 
Domingues 
75 
2006 Headache features in patients with dengue 
virus infection 
No other febrile illness comparison group 
Espinoza-
Gomez 
76 
2005 Clinical pattern of hospitalized patients 
during a dengue epidemic in Colima, Mexico 
No other febrile illness comparison group 
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Kalayanarooj 
77 
2005 Is dengue severity related to nutritional status No other febrile illness comparison group 
Neeraja 
78 
2006 Serodiagnosis of dengue virus infection in 
patients presenting to a tertiary care hospital 
No other febrile illness comparison group 
Monira 
79 
2004 Clinical and laboratory observations 
associated with the 2000 dengue outbreak in 
Dhaka, Bangladesh 
No other febrile illness comparison group 
Ranjit 
80 
2007 Early differentiation between dengue and 
septic shock by comparison of admission 
hemodynamic, clinical, and laboratory 
variables: A pilot study 
No other febrile illness comparison group 
Shah 
81 
2005 Clinical and laboratory abnormalities due to 
dengue in hospitalized children in Mumbai in 
2004 
No other febrile illness comparison group  
Fadilah 
82 
1999 Quantation of T-lymphocytes subsets helps to 
distinguish dengue hemorrhagic fever from 
classic dengue fever during the acute febrile 
stage 
Quality assessment=48% 
Shah 
83 
2005 Clinical and laboratory profile of dengue, 
leptospirosis, and malaria in children: a study 
from Mumbai 
Quality assessment=30% 
Watt 
36 
2003 Differentiating dengue virus infection from 
scrub typhus in Thai adults with fever 
Quality assessment=40% 
Zavala-
Velazquez 
84 
1996 Unrecognized spotted fever group 
rickettsiosis masquerading as dengue fever in 
Mexico 
Quality assessment=36% 
Ellis 
85 
2006 Causes of dengue fever in adults on the Thai-
Myanmar border 
Limited number of dengue cases 
Ashford 
86 
2003 Outbreak of dengue fever in Palau, Western 
Pacific: risk factors for infection 
Only compared environmental factors  
Pancharoen 
87 
2001 Dengue virus infection during infancy Short report 
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Chapter II Research Design and Methods 
 This chapter provides an in-depth description of the research design and 
analytical methods used to address each of the three previously stated research 
objectives. Although the study design and statistical methods are broadly 
described in the “Methods” sections for each of the subsequent chapters, this 
chapter provides a more detailed description of these methods. First, this chapter 
gives a general description of the location/population of the two clinical study 
sites, including the two study hospitals, and then provides a detailed description 
of the study design and data collection protocol, including descriptions of the 
clinical laboratory variables used in each of the analyses.  
 The chapter concludes with a thorough explanation of all analytical 
methods used for each of the three research objectives. 
IIA. Study sites 
Queen Sirikit National Institute of Child Health (QSNICH) is a tertiary care, 
pediatric hospital sponsored by the Thai Ministry of Public Health. The hospital is 
located in Bangkok, Thailand, the nation’s capital. Bangkok has approximately 7 
million residents, with a population of around 10 million during the daytime hours 
88. QSNICH is a 538-bed teaching hospital, which includes a 30-bed hemorrhagic 
fever ward. Patients seen at the outpatient ward or hemorrhagic fever ward with 
suspected dengue were eligible for the study.  
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 Kamphaeng Phet Province is located in northwestern Thailand with a 
population of approximately 700,000. The city of Kamphaeng Phet is 
approximately 223 miles from Bangkok, with an approximate population of 
44,000 88. Kamphaeng Phet Provincial Hospital (KPPPH), located in the city of 
Kamphaeng Phet, serves the entire province and is the referral center of all 
district hospitals in the province. KPPPH has a more rural catchment area than 
QSNICH. KPPPH is a government-sponsored hospital which serves patients of 
all age groups and has a separate pediatric ward.  
IIB. Enrollment and data collection protocols 
 The clinical study protocol was previously reported by Kalayanarooj and 
colleagues 44. The study enrolled Thai children ages 6 months to 15 years who 
presented to QSNICH or KPPPH with fever onset within 72 hours of presentation 
and oral temperature ≥ 38 degrees Celsius who did not have a specific 
identifiable cause of fever. Patients with hypotension, malnutrition, or history of 
chronic medical illness were excluded. Parental informed consent was obtained 
prior to study enrollment. On the day of enrollment (study day 1), patients were 
admitted to the hospital and a blood sample was obtained by the study nurse. 
Serological assays (IgM/IgG ELISA and hemagglutination inhibition assay) were 
performed on blood samples collected at enrollment and at convalescence. Viral 
isolation and RT-PCR (only 1997 and after) were performed using blood samples 
collected on day of enrollment. Patients with serologic and/or virologic evidence 
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of dengue were considered confirmed dengue cases. Patients were routinely 
observed and daily clinical and laboratory measurements were recorded by a 
study nurse using standardized data collection forms and reviewed by a 
physician for recording errors. On the day of defervescence, finger-stick 
hematocrits were measured every six hours for 18 hours in order to capture 
hemoconcentration. A right lateral decubitus chest x-ray was taken the day 
following defervescence to assess for pleural effusion. After completion of the 
case record, a final diagnosis of DF, DHF, or OFI was assigned by a single 
expert physician (who was not directly involved in patient care) based on review 
of the entire medical record. 
IIB. 1 Clinical data 
 Clinical data was collected daily for each patient during hospitalization 
until discharge (24 hours after defervescence), including: 
Vital signs (temperature, pulse, blood pressure, and respiratory rate) were 
obtained by a ward nurse every 3 to 6 hours. The interval was decreased to 
every 2 hours upon signs of clinical deterioration.   
Weight was measured every morning after breakfast.  
Hematocrits were measured daily. Finger-stick hematocrits were measured at the 
time of defervescence, defined as two temperature readings below 38 ˚C, and 
repeated every six hours for at least 3 measurements. Hematocrits were 
46 
 
46 
 
measured by filling 2 capillary tubes simultaneously and recording the mean of 
the two.  
Right lateral decubitus chest x-rays were taken on patients with stable vital signs 
the day following defervescence and were evaluated by a hospital radiologist. 
The chest x-ray was used to measure the amount of pleural effusion, which is an 
indicator of plasma leakage. The pleural effusion index was calculated as follows: 
PEI=100 x (maximum width of right pleural effusion)/(maximum width of right 
hemithorax).  
IIB. 2 Laboratory data 
 Blood samples for research were obtained each morning the patient was 
in the study up to a maximum of five consecutive samples. Blood samples were 
used for daily complete blood count (hemoglobin and platelets), WBC count, 
differential WBC count, including neutrophils, eosinophils, basophils, 
lymphocytes, monocytes, atypical lymphocytes, bands, other cell types, and liver 
function tests (AST, ALT, and albumin). All serologic and virologic testing was 
performed at the Armed Forces Research Institute of Medical Sciences 
(AFRIMS) in Bangkok, Thailand.  
 Table 2-1 gives an example of when clinical and laboratory data were 
collected for a typical patient in the study. In this example, the subject presented 
to the hospital on the third day of illness and was enrolled in the study (Study day 
1). He/she was followed in the hospital until 24 hours after defervescence, and 
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then had a follow-up outpatient visit 5 days after discharge. Throughout the 
hospitalization phase, clinical data, blood samples, and CBC/WBC/Liver panel 
were obtained daily. A chest x-ray to measure pleural effusion was taken on the 
day after defervescence.  
Each patient had a scheduled follow-up visit approximately 5-8 days after 
defervescence in which clinical and laboratory data were collected. We did not 
use any follow-up data in our analyses as we were looking for early indicators of 
disease and the dynamics of these indicators throughout hospitalization. 
Table 2-2 lists the clinical laboratory variables used, including their 
definition, units, normal range, and how the variable was utilized in each chapter. 
Each variable was utilized differently according to the research question. For 
example, chapter III used longitudinal models to describe how each variable 
changes across time during each patient’s hospitalization. Chapters IV and V 
were cross-sectional analyses of the data. Chapter IV investigated how each 
variable’s greatest deviation (maximum or minimum values) correlated with the 
physician’s final diagnosis and provides classification models that do not require 
indicators of plasma leakage. Chapter V investigated clinical variables at 
presentation to identify patients according to their final diagnosis or severity of 
illness that subsequently ensued. 
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IIC. Data sources 
IIC. 1 Data management 
 Upon study enrollment, each patient received a study identification 
number according to the order in which they were enrolled in the study. Any 
references to individual subjects in these analyses are made using the study 
number. Copies of laboratory test results, x-rays results, and pathology reports 
were included in the study record using the standard reporting formats of the 
testing facilities. One month after enrollment, the patient record was reviewed for 
completeness and data were entered into an electronic database. The original 
files are located and stored at AFRIMS under lock and key and only used for 
study analyses by authorized individuals. Electronic files were exported from 
FoxPro as dBASE (DBF) files and received on CD from Thailand. The files used 
for these analyses were stored on a password-protected shared network drive 
with restricted access. 
IIC. 2 Data processing steps 
The DBF data file was converted to a Stata Intercooled version 9 (Stata 
Corporation, College Station, TX) dataset using StatTransfer version 8 software. 
The DBF file was also converted to an Excel file for use in SPSS AnswerTree 
version 3.1 for Chapter V.  
Data cleaning steps were taken to establish separate analytical datasets 
for each aim and contact was maintained with study personnel in Thailand for 
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any database issues or recording errors found in the data. For example, albumin 
was recorded differently for the first year of the study, in units of g/L, not g/dl. To 
make these data comparable over years, values were converted to g/dl by 
dividing all values where albumin≥10; however, albumin was eventually dropped 
from all analyses. All changes/updates to the database were made to both the 
analytical datasets as well as an original data file, and were annotated in Stata 
DO files. 
IID. Summary of dataset 
Table 2-3 provides a summary of the study sample by the number of 
patients with a final diagnosis of DF, DHF, or OFI in each hospital from 1994-
2007, where KPPPH is from 1994-97 only (note: the descriptive tables of the 
study sample vary for each aim according to different exclusion criteria applied 
for each aim). There were a total of 1384 patients enrolled in the study, of which 
1311 had a final diagnosis of DF, DHF, or OFI (73 patients had an 
unknown/missing final diagnosis or were classified as having a non-viral illness 
and were excluded from all analyses). Among those with a final diagnosis from 
both hospitals, 630 had a dengue illness (394 DF; 236 DHF) and 681 had OFI. 
The majority of patients (86.5%) were enrolled at QSNICH. There were 722 
males and 589 females, with an average age of 7.9 years (95% CI: 7.7, 8.1). The 
average number of days ill at fever day+1 was 6 days (range: 2-12 days).   
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IIE. Detailed analytical methods 
IIE.1 Analytic approach to research objective 1 
The analyses for Chapter III were used to describe the patterns of clinical 
laboratory variables known to be associated with dengue, and how these 
variables change throughout an illness episode for DHF, DF, and OFI, starting 
with the day of presentation (within 72 hours of fever onset) through the day after 
defervescence. The primary analytical methods used for this aim were lowess 
smoothing curves and population-average (marginal) models with a first order 
autoregressive correlation matrix. 
IIE. 1.1 Lowess smoothing curves  
Lowess smoothing curves are often used to assess the bivariate 
associations of two variables in the data and may be used to visually assess 
adherence to the assumption of linearity used in normal least-squares regression 
analysis. Lowess is an abbreviation for locally weighted scatterplot smoothing. 
The technique fits a weighted low-order polynomial for each data point x using a 
subset of the entire dataset that surrounds x, where data points closer to x 
contribute more to the estimate of x (weighted more) than data points further 
away from x 89, 90. Each of the resulting low-order polynomials is then used to 
calculate the lowess regression function. 
 The weighting function used in this technique is the tri-cube weight 
function, where the weight for a given data point is a function of the distance from 
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the data point x being estimated 90. The tri-cubic function is given by 
where  = scaled distance between the weighted data point and the data 
point being estimated. The scaled distance is between 0 and 1 where the scaled 
distance of the point being estimated =0 and the maximum data point in the 
subset of data =1. To calculate distance, a Euclidean distance measure is used 
and is defined as:  , where  
represent predictor variables to obtain a fitted value 90. The bandwidth or subset 
of data used in each polynomial- to estimate each data point - can be adjusted 
and is represented as a proportion of the overall dataset. The bandwidth for all 
lowess analyses in this manuscript was the Stata default bandwidth of 0.8.  
 Lowess curves for these analyses were used to determine the type of 
function the data followed in order to structure an appropriate model. For 
example, in Figure 2-1, platelet count (dependent variable) among patients with 
DHF decreases over time (independent variable) but will eventually reach an 
inflection point and begin to recover; thus, the platelet count does not continue to 
decrease in a linear manner in these patients. When overlapping a linear 
function, quadratic function, and a lowess curve of platelet count and days of 
illness, the lowess curve closely approximates the quadratic curve, more than the 
linear curve; thus, a quadratic model was deemed the best function to fit with this 
model. When similar comparisons were done for other variables among each 
diagnosis, all variables followed a quadratic trend. Thus, quadratic longitudinal 
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models were used to assess the dynamics of clinical laboratory parameters 
throughout the hospitalization of subjects in this study. 
IIE. 1.2 Longitudinal modeling 
 In general, the objective of longitudinal data analysis is to evaluate 
changes in the mean response over time and whether these changes are 
associated with specified covariates 91. A key difference in longitudinal models, in 
which repeated measures are taken on the same individuals, is the violation of 
independence, which is an assumption in many simple linear regression models. 
When interpreting the variance of the mean response in changes over time for 
longitudinal models, the correlation between variances at different time points 
(covariance) must be considered. The covariance between responses at two 
different time points on the same subject can be defined as: 
 
where  and  are the response variables for the  individual at timepoint  
and , respectively, and  or  is the mean response at those timepoints 91. 
The covariance is used in the calculation of the variance of a longitudinal model 
to capture the correlation of response variables. When multiple subjects have  
repeated measures, a variance-covariance matrix can be established and 
defined as: 
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where  is the response variable for  individual across 1, 2,…  
repeated measures, respectively 91. However, this definition assumes the 
variance and covariance is the same across all individuals.  
General assumptions can be made about the variance and covariance of 
a model.  Repeated measures on the same subject may often be positively 
correlated, and these measures are usually assumed to have a higher correlation 
with decreased time separation between measurements 91. In the models 
presented for these analyses, a first-order autoregressive model of the 
covariance was used. This type of covariance pattern has only two parameters 
and assumes that measurements are made at equally spaced intervals over time 
and error terms are dependent on the previous error term only 92. The first-order 
autoregressive correlation is defined as: 
 
where  is the covariance between timepoints  and ,  is the variance, 
and  is the autoregressive correlation parameter between time points  and 
 92. In this type of covariance structure, the correlation decreases exponentially 
across timepoints as seen here: 
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 92 
Reasons for choosing this type of covariance structure were: 1) some subjects 
had only 2 timepoints and a valid covariance structure that depends on multiple 
timepoints for each patient could not be established, 2) there is clinical relevance 
of laboratory parameters following a pattern that is dependent on a previous 
measure, and 3) time intervals were approximately equally spaced at 24 hours, 
since blood samples were collected each morning. 
Population-average models, also referred to as marginal models, were 
used to determine the mean change in clinical laboratory parameters among 
each diagnosis throughout hospitalization while adjusting for covariates of age, 
gender, hospital, and year of study enrollment. After modeling each diagnosis 
separately, interaction terms of diagnosis and day of illness were used to 
evaluate differences in clinical laboratory parameters between the diagnostic 
groups at each timepoint. Population-average models assume fitting of 
 using the identity function and the variance is a fixed scale parameter  that 
depends only on the marginal mean. Assumptions about the correlation have 
minimal effect on the estimates of  so even if the first-order autoregressive 
covariance is incorrect, it will have minimal effects on the estimates of . 
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However, it may have a significant impact on the variance of  and thus the 
significance tests. 
Population-average models were chosen based on the structure of the 
data; some subjects had few data points and applying a random slope and 
intercept model using a quadratic fit would not be valid. Also, as noted above, 
specifying the correct covariance structure is not a necessity for these models. 
Furthermore, as detailed in chapter III, the models that were established tended 
to follow the same trajectory as the individual means at each timepoint.    
IIE. 2 Analytical approach to research objective 2 
This aim provides a cross-sectional evaluation of the most extreme values 
of specific indicators and how they correlated with the physician’s final diagnosis. 
Multivariable binary logistic regression modeling was used to determine 
probability cutpoints that optimized sensitivity and specificity of DHF or severe 
dengue illness in the absence of standard diagnostic measures of plasma 
leakage, such as chest x-rays, ultrasounds, or hemoconcentration. This was 
done by collapsing each patient’s clinical laboratory parameters obtained 
throughout their hospitalization into a maximum or minimum value (see Table 2-
2). Additionally, kappa statistics were used to assess the agreement between the 
final multivariable logistic regression models, the physician’s diagnosis, and the 
WHO classification of DHF versus DF. 
56 
 
56 
 
IIE. 2.1 Univariable and multivariable logistic regression  
Logistic regression is an important technique in the modeling of 
dichotomous dependent variables and is often used in epidemiological studies to 
state an individual’s risk for developing a disease 93. Logistic regression models 
can be defined in terms of probability of a dichotomous outcome as follows: 
 
where  is coded as (0,1) and is expressed in the equation as the probability of 
 93. This probability can also be expressed as the natural log odds of  
(logit): 
 
which is equivalent to: 
 
 
 where the logit is simply a way to linearize the probability of an outcome 93.  
 For the analyses presented in this aim, multivariable logistic regression 
models were established that best distinguished between DF vs. DHF, DHF vs. 
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DF+OFI, any dengue vs. OFI, and severe dengue vs. non-severe dengue+OFI. 
An example model is given:   
 
 
Where  is the estimated probability of outcome (i.e. diagnosis of DHF as 
opposed to DF) and  is the odds of having the outcome of 
interest, for example, a physician’s diagnosis of DHF, with  number of 
covariates in the model 93. Models are expressed as odds ratios where unit 
increases (or decreases) in a certain independent variable of interest represent 
increases (or decreases) in the odds of having one diagnosis compared to 
another, such as DHF as opposed to DF. 
IIE. 2.2 Model building process 
 The process of establishing each multivariable model was a manual 
stepwise procedure in which independent variables were added to the model in 
the order of the univariable analyses that produce the best area under curve 
(AUC) of the receiver operator characteristic (ROC) curve.  
First, univariate logistic regression models were used to evaluate 
indicators that distinguished between the diagnostic groups of interest. For each 
outcome, univariate logistic regression was performed on each of the following 
variables: maximum tourniquet test, hematocrit, % monocytes, % lymphocytes, 
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% neutrophils, AST, and ALT, and minimum platelet count and WBC count (see 
Table 2-2).  Lowess curves from univariable analyses were used assess the 
linear or nonlinear relationship between y and x, and used as evidence to 
determine the categorization for variables that had skewed distributions. If the 
linearity assumption appeared to hold true, then the variable was used as a 
continuous variable. Frequency tables were used to show the distribution of each 
categorized variable with the outcome.  
Second, ROC curves of each univariate logistic regression model were 
produced and the AUC obtained. Significant (  variables from univariable 
analyses with the best AUC values were added in a manual forward selection 
process to establish the best multivariable models. 
Finally, the optimal sensitivity and specificity for each model was 
determined and used to establish a probability cutpoint for each model. The 
optimal sensitivity and specificity was chosen based on a probability cutoff where 
the sum of sensitivity and specificity were maximized, the maximum % correctly 
classified was achieved, and sensitivity remained higher than specificity.    
IIE. 2.3 Validation 
All analyses for this aim were first performed using only the QSNICH data 
as a training dataset. Then, each multivariable model was applied to the KPPPH 
data as a validation of the models to test their performance in a different dataset 
from a different hospital with a different catchment area.  
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IIE. 2.4 Analysis of agreement 
Kappa statistics were used to determine the amount of agreement 
between the final validated multivariable models of DHF vs. DF and DHF vs. All 
others to the physician’s final diagnosis of DHF 94. Additionally, these models 
were compared to the WHO diagnostic criteria for DHF. The physician’s 
diagnosis of DHF was also compared to the WHO diagnostic criteria for DHF.  
Kappa statistics are used to test the percentage of observed agreement to 
agreement expected by chance 94. Using preliminary data, an example of Kappa 
statistic is given: 
Physician 
diagnosis 
WHO DHF WHO DF Total 
+ 125 43 168 
- 16 134 150 
Total 141 177 318 
 
Kappa=( Observed agreement – Expected agreement)/(1- Expected agreement) 
Observed agreement=(125 + 134)/318=.8145 
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Expected agreement =[(141*168) + (177*150)]/3182=.4968 
Kappa=(.8145-.4968)/(1-.4968)=63.14% 
The use of Kappa statistics for this aim will demonstrate that the physicians did 
not strictly adhere to the WHO diagnostic criteria for DHF. This will also help to 
highlight which of the four criteria were in most agreement with physicians and 
which were in least agreement.  
IIE. 3 Analytical approach to research objective 3 
This aim applied the methodology of classification and regression tree 
analysis (CART) to establish classification trees based on data available at the 
day of enrollment only. In CART, the data are partitioned into different nodes 
based on an impurity function where patients within each partitioned node be will 
be as similar as possible in terms of the characteristics analyzed (in this case, 
clinical laboratory parameters) 95, 96, 97. CART is a non-parametric method that 
establishes mutually exclusive subgroups within a sample based on shared 
characteristics that are associated with the outcome of interest 95. CART is used 
with binary outcomes and the final outcome yields prevalence estimates of the 
outcome variable within each of the identified subgroups 96. A simplified example 
of a CART output is presented in Figure 2-2. 
All candidate independent variables were considered, as well as age, and 
the sample was split according to values (cut-points) of the independent variable 
with the largest difference between the impurity in the parent node and a 
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weighted average of the impurity between the two child nodes 96. Each node 
represents the probability of having the dependent measure, for example a 
physician’s final diagnosis of DF or DHF, within each grouping of independent 
variables, which can be categorical or continuous, and is given by a 2x2 table. 
For example, if a cut-off of AST is used to split the outcome variable into the 2x2 
table below, we are left with conditional probabilities of being above or below the 
cut-point given the final diagnosis. 
 DF DHF  
AST<=50 
Left node impurity 
   
AST>50 
Right node impurity 
   
    
 
Which independent variables best ‘split’ the dependent variable is based on the 
impurity function. The impurity function used for this analysis was the Gini 
impurity function (Gini improvement measure), which uses the proportion of 
subjects with the dependent variable in a parent node and a weighted average of 
subjects in the resulting child nodes to calculate an impurity at each possible split 
95, 96, 97. Lemon et al outlined four steps used to calculated Gini improvement 
measure96 : 
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where represents the probability the dependent variable is equal to  in the 
Node  The second step involves calculating the diversity index for each of the 
two resulting child nodes. The third step calculates a weighted diversity index 
using the proportion of subjects from the parent node that are now in the 
resulting child node96: 
3.  
where  and  are the proportion of subjects included from the parent node that 
are in the left  and the right  child nodes, and and 
 are the diversity index parameters for the resulting child nodes. 
The last step calculates the Gini improvement measure by taking the difference 
of the diversity index of the parent node and the weighted diversity index96: 
  
Additionally, each tree can consider a cost-complexity measure, where 
complexity is the number of nodes in a tree. The quality of each tree can be 
penalized if it is too big (pruning). An example of a  ‘pruning’ method is based on 
the Studentized log relative risk (slRR) as described in chapter 4 of Zhang et al 
97. Briefly, for each left and right node (2x2 table as discussed above) a slRR can 
be calculated by taking the log of the relative risk of each left and right node and 
dividing by the standard error of the log relative risk. The value of a slRR for a 
parent node is replaced by the maximum value of the slRR from any of its 
resulting offspring if the offspring slRR was greater than the parent node. Nodes 
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with a slRR less than the cut-off value of 1.96 (equivalent to alpha>0.05) are 
usually pruned. 
 However, for the analyzes presented in Chapter V, no pruning method 
was applied. Instead, stopping rules were used to keep the tree from being fully 
saturated (where the number of nodes in a tree approximates the number of 
subjects). The stopping rules were: 1) no terminal node could contain <5% of the 
original sample size, 2) no more than 5 levels per tree, and 3) a minimum 
improvement in impurity of .0001. 
IIE. 3.1 K-fold validation 
 Validation of each tree was made by using the k-fold validation procedure, 
which establishes differences in the frequency counts of the nodes to estimate 
the selection bias caused by relative risk pruning (splits are made based on the 
impurity function that is closely related to the relative risk) 97. For these analyses, 
the dataset was divided into five subpopulations of equal size, , (i=1,2,3,4,5) 
where  is the sample after removing one of the subpopulations. The  was 
used to establish a split, yielding two 2x2 tables 97: 
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The process was repeated for all of the subpopulations to estimate a selection 
bias for A and D cells by: 
 
 
and  
 
 
This bias was used to correct the frequency counts in the entire dataset and 
establish a relative risk 97. A tree was accepted only if all nodes had a slRR, 
adjusted for selection bias, that was >=1.96 (alpha<=0.05). A final overall 
sensitivity and specificity was calculated for each tree. 
This method has advantages over logistic regression techniques when 
applied to this type of scenario in resource-poor areas: 1) CART is a non-
parametric method and is thus not bound to the assumptions of logistic 
regression, 2) calculating a probability based on a complicated logistic regression 
model would be difficult without the use of computers and, in resource-poor 
areas, this may not be feasible, 3) the CART method mimics a physician’s way of 
thinking by ruling out certain diagnosis based on dichotomizing symptoms and 
does not require calculation of probabilities. Similar methodology has been used 
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in other studies of dengue, however, these studies have their limitations as 
discussed in chapter V 98, 99. 
For this aim, the classification trees distinguish between the different 
categories of dengue disease severity among all patients enrolled with a 
suspected dengue illness. The categories of dengue disease severity used are: 
(1) dengue shock syndrome (DSS, as defined by WHO criteria); (2) DSS or 
PEI>15; (3) DSS or required intravenous fluid; (4) DSS or platelet count 
<=50,000 anytime during illness; (5) DSS or received fluid intervention (oral or 
intravenous) in any 24-hour period that exceeded maintenance volume + 5% 
volume deficit 100, 101. Additional classification trees were used to evaluate 
differences between DHF vs. DF and severe dengue vs. non-severe dengue; 
however, the focus of this aim was on prediction of dengue disease severity and 
limiting trees to only those patients known to have dengue does not suit this 
purpose as confirmatory serology of dengue is not generally available at 
presentation.  
IIF. Analytic software 
The following software was used to perform the analyses presented: Stata 
Intercooled version 9 (StataCorp, College Station, TX) for chapters III and IV and 
SPSS AnswerTree 3.1 (SPSS AnswerTree, version 3.1, SPSS Inc., Chicago, IL) 
for chapter V. As mentioned in section 2C, the data files were received as dbf 
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files and were converted to the appropriate analytic dataset using Stat/Transfer 
(Stat/Transfer version 8 for Windows). 
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Table 2-1 Example of the schedule of measures for a typical patient 
Study day 1 2 3 4 9 
Day of illness 3 4 5 6 11 
Fever day -2 -1 0 1 6 
Clinical data + + + + + 
Blood sample + + + + + 
CBC/WBC/Liver panel + + + + + 
Chest x-ray - - - + - 
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Table 2-2 Clinical laboratory variables used in thesis, including definitions, units, normal ranges, and 
utilization for each research objective 
Variable Definition Units Normal 
rangea,b, c 
Variable Utilization 
Research 
objective 1 
Research 
objective 2 
Research 
objective 3 
Platelet count Platelets (thrombocytes) are non-
nucleated cell fragments that trigger 
substances for the formation of blood 
clotsd 
Cells/mm3 200,000-
500,000 
Continuous 
(square root 
transformation) 
Minimum 
 (per 25,000 
units) 
Continuous 
WBC count White Blood Cells (leukocytes) are 
nucleated cells responsible for producing 
a wide range of immune responsesd 
Cells/mm3 5,000-
10,000 
Continuous 
(natural log 
transformation) 
Minimum 
 (per 500 units) 
Continuous 
Hematocrit The fractional contribution of 
erythrocytes (red blood cells) in the 
blood volume (height of erythrocyte 
column ÷ height of whole blood 
column)d 
% packed blood 
volume 
40-45 Continuous Maximum Continuous 
% Monocytes Leukocyte important in phagocytic 
defensed 
% WBC 
differential 
4-8 Continuous Maximum 
(categorical) 
Continuous 
% Lymphocytes Leukocytes made up of B and T 
lymphocytes and null cells that are 
important for direct and memory immune 
responsesd 
% WBC 
differential 
20-40 Continuous Maximum 
(categorical) 
Continuous 
% Neutrophils Leukocytes important in phagocytosisd % WBC 
differential 
40-60 Continuous Maximum 
(categorical) 
Continuous 
AST Aspartate aminotransferase, liver enzyme 
that catalyzes the transfer of the amino 
group of aspartate to α-keto-glutarate to 
produce oxaloacetate and glutamatee 
SI units (U/L) 15-40 Continuous  
(Box-Cox 
transformation) 
Maximum 
(categorical) 
Continuous 
ALT Alanine aminotransferase, liver enzyme 
that catalyzes the transfer of the amino 
group of alanine to α-keto-glutarate to 
produce pyruvate and glutamatee 
SI units (U/L) 10-35 Continuous  
(Box-Cox 
transformation) 
Maximum 
(categorical) 
Continuous 
Tourniquet Test Measured by inflating blood pressure 
cuff to half systolic and dystolic pressure 
and holding for five minutes, then 
counting the number of petechiae (small 
red spots caused by weak capillary 
vessels) 
# of petechiae/ 
square inch 
N/A N/A Maximum 
(ordinal) 
Ordinal 
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a Reference 102 
b Reference 103 
c Dr. Pra-on Supradish, personal communication from QSNICH  
d Reference 104 
e Reference 105
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Table 2-3 Characteristics of subjects enrolled at the two study hospitals 
and who received a final diagnosis of DHF, DF, or OFI 
Hospital/Diagnosis N (%) Gender Age in years 
mean (range) 
Days ill at 
presentation, 
median Males Females 
QSNICH 1134 (86.5) 614 520 7.7 (0.5, 15.0) 2 
  DHF 
  DF 
  OFI 
182 (16.1) 
330 (29.1) 
622 (54.8) 
105 
177 
332 
77 
153 
290 
8.8 (1.5, 14.9) 
8.5 (2.0, 15.0) 
6.9 (0.5, 14.6) 
  2 
2 
  2 
KPPPH 177 (13.5) 108 69 8.8 (1.4, 14.9) 2 
  DHF 
  DF 
  OFI 
54 (30.5) 
64 (36.2) 
59 (33.3) 
36 
30 
42 
18 
34 
17 
9.1 (2.8, 14.9) 
9.2 (2.7, 14.9) 
8.0 (1.4, 14.3) 
2 
2 
2 
Total 1311  722 589 7.8 (0.5, 15.0) 2 
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Figure 2-1 Lowess smoothing curve overlapped with linear and quadratic 
functions of platelet count and illness day among patients with DHF 
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Figure 2-2 Example of a simplified CART analysis 
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Chapter III: Dynamics of clinical laboratory parameters distinguish among Thai 
pediatric patients with different dengue disease severity 
Abstract 
Background 
Dengue is an emerging infectious disease which is endemic in tropical and 
subtropical areas. A quantitative, longitudinal description of dengue illnesses is 
needed to better understand the dynamics of patients with different grades of 
dengue illness severity. 
Objectives 
To describe the temporal dynamics of clinical laboratory parameters 
throughout the febrile phase among patients with suspected dengue infection. 
Study Design 
Clinical and laboratory data were collected from Thai children aged 6 
months to 14 years who presented to a study hospital within the first 72 hours of 
illness. Final diagnoses- DF, DHF, or other febrile illness (OFI)- were assigned by 
an expert physician. Locally weighted scatterplot smoothing curves and 
population-average models were constructed for laboratory parameters among 
each diagnosis. 
Results 
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Data were available for 1245 children enrolled from 1994-2007 (231 DHF, 
388 DF, and 626 OFI). The median length of observation was five days for 
patients with dengue and four days for patients with OFI. Quadratic functions of 
platelet count, hematocrit, WBC count, % monocytes, % lymphocytes, % 
neutrophils, AST, and ALT were deemed the best fit by assessment of lowess 
curves. Our models showed lower platelet count and higher AST and ALT in 
patients with DHF compared to DF and OFI throughout hospitalization. Lower 
WBC count was observed among patients with dengue in the first four days of 
illness. Lower percent neutrophils and elevated hematocrit was seen among 
those with dengue in the later days of illness.  
Conclusions 
Clinical laboratory variables follow distinct patterns during illness between 
patients with DHF, DF, and OFI. The dynamics of these variables should help 
clinicians identify patients with impending DHF and better utilize limited hospital 
resources.  
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1. Background 
Dengue is a major global health problem, causing an estimated 50-700 
million infections annually and approximately 21,000 deaths 24. Dengue illnesses 
contribute to a significant economic and public health burden in under-developed 
countries and are endemic in many resource-poor tropical and sub-tropical 
regions 28, 29, 31, 32.   
Dengue viruses are transmitted through the bite of infected mosquitoes, 
typically Aedes aegypti or Aedes albopictus.  After a 4-10 day incubation period, 
the initial clinical manifestations of patients with symptomatic dengue infection 
are similar to many other febrile illnesses (OFI). Patients with DF often have a 
self-limited, non-severe, febrile illness. However, patients with DHF develop 
severe symptoms, such as plasma leakage, that manifest in the latter stages of 
illness (critical phase), typically after the initial febrile phase subsides 
(defervescence).  
Despite numerous publications on clinical indicators of dengue illnesses, 
there is limited published information comparing the day-to-day dynamics of 
clinical laboratory parameters in patients with dengue to patients with OFI or 
patients with DF to patients with DHF 39. Early indicators or warning signs to 
identify patients with dengue and impending development of severe symptoms 
would help better utilize limited hospital resources in dengue-endemic regions. 
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2. Objectives 
 The objectives of this study were to describe the temporal dynamics of 
clinical laboratory parameters during the acute illness among patients with DF, 
DHF, and OFI using data obtained from a 12 year prospective pediatric cohort 
study conducted in Thailand. 
3. Study Design 
3.1 Study setting 
 This prospective longitudinal observational study was conducted at two 
hospitals in Thailand: 1) the Queen Sirikit National Institute of Child Health 
(QSNICH) in Bangkok during the years 1994-97, 1999-2002, and 2004-07, and 
2) Kamphaeng Phet Provincial Hospital (KPPPH) during the years 1994-97. The 
study methods have been described elsewhere 44. In brief, children between the 
ages of six months and 15 years, presenting with temperatures  ≥ 38.5˚C for ≤ 72 
hours, and no localizing symptoms were eligible for the study. Exclusion criteria 
included: signs of shock at presentation, chronic disease, or an initial alternate 
non-dengue diagnosis. Children were admitted to the hospital and monitored 
throughout their hospital stay until 24 hours after their fever subsided. Written 
parental informed consent was obtained prior to enrollment. The study protocol 
was approved by the Institutional Review Boards of the Ministry of Public Health, 
Thailand, the U.S. Army, and the University of Massachusetts Medical School.  
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3.2 Clinical laboratory data 
 A blood sample was obtained on the day of enrollment and daily thereafter 
until one day following defervescence or for a maximum of five consecutive blood 
collections. Clinical laboratory studies included complete blood count and manual 
WBC differential. Serological assays (IgM/IgG ELISA and hemagglutination 
inhibition assay), viral isolation, and/or RT-PCR were used to confirm all dengue 
cases. Patients were observed daily and clinical and laboratory measurements 
were recorded using standardized data collection forms.  
 Beginning at defervescence (T<38˚C), finger-stick hematocrits were 
measured every six hours for 18 hours in order to capture hemoconcentration. A 
right lateral decubitus chest x-ray was taken the day following defervescence to 
assess for pleural effusion and a pleural effusion index (PEI) was measured as 
100 x (maximum width of right pleural effusion)/(maximum width of right 
hemithorax). After completion of the case record and careful review of the 
medical record and laboratory results, a final diagnosis of DF, DHF, or OFI was 
assigned by an expert physician who was not directly involved in patient care.  
3.3 Statistical analysis 
 Descriptive characteristics, such as diagnosis, age, gender, length of 
illness at presentation, and study hospital, were evaluated between the three 
diagnostic groups (DHF, DF, and OFI) using t-test for continuous variables with a 
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normal distribution or Wilcoxon rank-sum test for continuous variables with a 
skewed distribution, and Pearson’s χ2 for categorical variables. 
 Population average models (marginal models) were used to assess the 
temporal dynamics of clinical laboratory parameters across days of illness 
throughout the febrile phase until 24 hours after defervescence in subjects with 
DHF, DF, and OFI (Supplementary Figure 3-1). Parameters included in the 
models were platelet count, hematocrit, WBC count, % monocytes, % 
lymphocytes, % neutrophils, AST, and ALT. Some variables were transformed to 
achieve normality: 1) square root transformation for platelet count, 2) natural 
logarithm transformation for WBC count, and 3) Box-Cox transformation for AST 
and ALT (see Appendix A). Each variable was modeled separately for each 
diagnosis and adjusted for age, gender, hospital (QSNICH or KPPPH), and year 
of enrollment. Statistical interactions were used to evaluate differences between 
patients with the diagnoses under study across all illness days. 
4. Results 
4.1 Study sample characteristics 
There were 1384 subjects enrolled in the study; 1311 of these patients 
had a diagnosis of DHF, DF, or OFI (presumed viral, non-dengue illness). For 65 
of these subjects (55 with OFI, 6 with DF, and 4 with DHF), a day of 
defervescence could not be assigned and therefore they were excluded from the 
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analysis. Additionally, one subject was missing information on day of illness and 
was excluded from the analysis.  
A total of 1245 subjects were used in this analysis (231 DHF, 388 DF, and 
626 OFI). Table 3-1 summarizes the characteristics of these subjects. Among 
subjects with dengue, 82% had secondary infections; patients with DHF had a 
higher proportion of secondary infections compared to those with DF (Wilcoxon 
p-value= <.001, 93% of subjects with DHF and 75% of subjects with DF had 
secondary infections). The dominant dengue serotype was DENV1 (42%), 
followed by DENV3 (24%), DENV2 (21%), and DENV4 (13%). However, there 
were no differences between DHF and DF with regard to serotype (Kruskal-
Wallis p-value=.14). Additionally, there were no differences in serotype among 
those with DHF grade I/II compared to DHF grade III/IV (Wilcoxon p-value=.71) 
The median day of illness at enrollment was two days for all three diagnostic 
groups. Defervescence occurred at a median of five days and four days after 
onset of illness in patients with dengue from QSNICH and KPPPH, respectively, 
but occurred on the third day of illness among patients with OFI (Wilcoxon p-
value<.001). Table 3-2 shows the number of patients in each diagnostic group 
according to day of illness. Over 90% of subjects in all three diagnostic groups 
remained in the study until defervescence and over 80% remained until 
defervescence+24 hours. Only 13 patients with dengue (1 with DHF, 12 with DF) 
were not in the study until at least defervescence compared to 43 with OFI (χ2 
p<.001).   
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4.2 Population-average models 
Lowess curves were used to determine the longitudinal functionality of the 
clinical laboratory parameters. Both linear and quadratic functions were used to 
model the data; the quadratic functions showed a closer fit to the lowess curves 
for all of the selected laboratory parameters. Data obtained after seven days of 
illness were not included in the models because very few patients remained 
febrile beyond seven days (Table 3-2).  
Figure 3-1 shows graphs of the models for each variable among all three 
diagnostic groups after adjusting for age, gender, year of enrollment, and hospital 
(QSNICH or KPPPH); adjusted population-average values obtained from the 
models and their 95% confidence intervals are given in Supplementary Table 3-
1. The structure of each population-average model is given in Supplementary 
Figure 3-1. Statistical evidence of significant interactions between diagnosis and 
day of illness with regards to the association with clinical laboratory outcomes is 
given in Table 3-3. Beginning on the second day of illness (median day of 
presentation), patients with DHF had lower platelet counts compared to patients 
with DF and OFI and this difference remained throughout hospitalization. 
Additionally, patients with DF had lower platelet counts throughout hospitalization 
compared to patients with OFI. By the third day of illness, patients with DHF had 
higher maximum daily hematocrit values compared to patients with DF and OFI, 
and patients with DF had higher values compared to patients with OFI. On the 
third, fourth, and fifth days of illness, subjects with DHF had lower % lymphocytes 
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compared to subjects with DF or OFI. Additionally, subjects with dengue had 
lower WBC counts than subjects with OFI during the first five days of illness, and 
subjects with DHF had lower WBC counts compared to subjects with DF on the 
fifth day of illness. However, by the sixth and seventh days of illness, there were 
no differences in WBC counts in subjects with dengue compared to patients with 
OFI. Patients with dengue had elevated AST and ALT levels throughout all days 
of observation compared to patients with OFI, and patients with DHF had higher 
levels compared to patients with DF from days two through six. In the later 
stages of hospitalization, days five through seven, patients with dengue had 
lower percent neutrophils compared to patients with OFI.  
5. Discussion 
Our analysis shows that, on average, patients with dengue illness follow 
divergent patterns in clinical laboratory parameters according to whether they 
eventually manifest as DHF or DF. Some variables, such as platelet count, AST 
and ALT, were different between the two groups as early as the second day of 
illness, which corresponded to the average day of presentation in the study 
cohort, and followed different slopes throughout the febrile and critical 
(defervescence) phases. Other variables, such as hematocrit values, were 
similar at presentation but diverged during the febrile phase. Elevated liver 
enzymes, increased hematocrit, and lower platelet counts have previously been 
proposed as potential indicators of impending plasma leakage 106, 107. WBC 
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counts differed between patients with DHF and DF at presentation; however, 
they were not different between the two groups at the end of the febrile phase or 
during the critical phase of illness. In addition, WBC count, AST and ALT were 
able to distinguish patients with dengue from patients with OFI within the first 72 
hours of illness. These variables could be useful predictors of dengue illness 
while awaiting confirmatory serology. 
Plasma leakage is considered the hallmark of DHF; however, this indicator 
of severe dengue disease is not seen until around the time of defervescence 106. 
Although significant differences in laboratory findings between DHF and OFI 
have been described, many studies have relied on single measurements and 
have not reported the timing of data collection during illness or did not analyze 
changes in laboratory parameters over the entire course of illness 39. A strength 
of our study is the enrollment of subjects within the first three days of illness, and, 
consequently the availability of clinical data collected daily from each subject 
over an extended observation period. By highlighting the average trends in 
clinical laboratory parameters among patients who go on to develop plasma 
leakage, our study should help enhance the clinical management of patients with 
suspected dengue illness. Since these laboratory tests depend on only basic 
clinical laboratory infrastructure, these findings could be widely applied, even in 
resource-limited settings.  
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One criticism of population-average models is they assume that each 
individual follows the same pattern and do not allow for individual variability. 
Some patients used in the analysis did not have more than two or three days of 
observation so reliable estimates of individual variability could not be 
appropriately modeled with these data. However, there is a low amount of 
variability in the dataset, as indicated by the narrow 95% CI of the mean at each 
time point (Supplementary Figure 3-2). Additionally, our models tend to fall within 
the 95% confidence intervals of the actual means during the most common days 
of hospitalization (illness days 2-5). When the models do fall outside of the 95% 
CI of the actual mean, this is explained by the individual level data not being 
transformed to fit a normal distribution nor adjusted for covariates that could 
result in skewed distributions and invalid representation of the true population 
mean at each time point. Individuals with outlying values still tend to follow the 
same slope as that of the population-average model. Accordingly, in actual 
clinical practice, patients could be identified for aggressive clinical management 
based on when serial clinical data collection begins and the slopes of the clinical 
laboratory parameters that each patient follows thereafter.  
One limitation of our study is the lack of validation of the results to other 
study populations, including different dengue-endemic regions and different age 
groups. Some inconsistencies in clinical and laboratory findings across different 
locations and age groups were noted in a systematic review of published studies 
39. However, this study used 12 years of systematically collected data to reflect 
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the clinical course of dengue in a Thai pediatric population where dengue is a 
significant health problem, so our findings are not subject to the same concerns 
as studies that reflect a single outbreak or a limited array of viral 
serotypes/strains. Another limitation is the exclusion of children who first 
presented later in the illness, who might differ from our study population; 
however, the patients in our study did manifest a broad spectrum of dengue 
disease, including substantial degrees of plasma leakage.   
 We provide population-average models using clinical laboratory data 
obtained prospectively from a well-defined cohort of pediatric patients in a 
dengue-endemic region. These models show the average trend in clinical 
laboratory data throughout the febrile and critical phases of illness in patients 
diagnosed with DHF, DF, and OFI.  The average trends in these models could 
potentially be used by clinicians to help identify patients at the greatest risk for 
plasma leakage and better utilize limited hospital resources. This analytical 
approach can be applied to clinical datasets from other dengue-endemic regions 
and age groups to describe the average progression of dengue illness in different 
populations.  
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Table 3-1 Study sample characteristics for research objective 1 
Hospital N (%) Gender Age (years) Median days ill  
Males Females 
Mean 95% CI At presentation 
At defervescence 
(range) 
QSNICH 1074 (86.3) 586 488 7.8  7.6, 8.0 2.0  4.0 (1, 10) 
  DHF 
  DF 
  OFI 
177 
326 
571  
103 
176 
307 
74 
150 
264 
8.8  
8.6  
7.0  
8.4, 9.3 
8.3, 8.9 
6.7, 7.4 
2 .0 
2 .0 
2.0  
5.0 (1, 9) 
5.0 (1, 8) 
3.0 (1, 10) 
 KPPPH 171 (13.7) 105 66 8.9  8.5, 9.3 2.0  4.0 (1, 7) 
  DHF 
  DF 
  OFI 
54 
62 
55  
36 
30 
39 
18 
32 
16 
9.1  
9.3  
8.2  
8.3, 9.9 
8.6, 10.0 
7.4, 9.0 
2.0  
2.0  
2.0  
4.0 (2, 6) 
4.0 (1, 7) 
3.0 (1, 7) 
Total 1245  691 554 8.0  7.7, 8.2 2.0  4.0 (1, 7) 
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Table 3-2 Number of patients in the study with DHF, DF, or OFI at each day 
of illness 
Day of illness* Number of subjects (Number of subjects at defervescence +24 hours) 
DHF DF OFI 
1 58 133 300 
2 136 (1) 248 (4) 492 (59) 
3 229 (5) 379 (20)  521 (136) 
4 225 (25) 363 (51) 361 (111)  
5 199 (83)  309 (112) 220 (70) 
6 112 (76) 173 (120)  146 (60) 
7 33 (25)  43 (31) 84 (50) 
8 5 (2)  8 (6) 31 (23)  
9 3 (1) 1 (0) 8 (5)  
10 2 (2)  -- 1(0) 
11 1 (1) -- -- 
Total patients 
n=defervescence+24 hours (%) ** 
231 
221 (95.7%) 
388 
345 (88.9%) 
626 
522 (83.4%) 
 
* Only five consecutive blood draws were allowed for any given patient 
** Represents the total number of patients remaining in the study up to 24 hours 
after defervescence.
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Table 3-3: P-values from adjusted population-average models indicating differences in association between clinical laboratory 
parameters and diagnosis according to day of illness 
Day 
of 
Illness 
Platelet count WBC count Hct % Monocytes 
 
% Lymphocytes % Neutrophils 
DHF 
vs 
DF 
DHF 
vs 
OFI 
DF 
vs 
OFI 
DHF 
vs 
DF 
DHF 
vs 
OFI 
DF 
vs 
OFI 
DHF 
vs 
DF 
DHF 
vs 
OFI 
DF 
vs 
OFI 
DHF 
vs 
DF 
DHF 
vs 
OFI 
DF 
vs 
OFI 
DHF 
vs 
DF 
DHF 
vs 
OFI 
DF 
vs 
OFI 
DHF 
vs 
DF 
DHF 
vs 
OFI 
DF 
vs 
OFI 
1 .90 .02 .001 .12 <.001 <.001 <.001 <.001 .18 .03 .95 .002 .25 .25 .88 .85 .64 .74 
2 <.001 <.001 <.001 .17 <.001 <.001 .27 .003 .03 .04 .10 .08 .02 .19 .15 .004 .04 .19 
3 <.001 <.001 <.001 .98 <.001 <.001 <.001 <.001 <.001 .02 .003 .48 <.001 <.001 .02 <.001 .11 <.001 
4 <.001 <.001 <.001 .04 <.001 <.001 <.001 <.001 <.001 .20 .004 .06 <.001 <.001 .02 <.001 .26 <.001 
5 <.001 <.001 <.001 <.001 <.001 <.001 <.001 <.001 <.001 .64 .07 .12 <.001 .002 .15 .01 <.001 <.001 
6 <.001 <.001 <.001 <.001 .03 <.001 <.001 <.001 <.001 .98 .93 .85 .45 .48 .99 .52 <.001 <.001 
7 <.001 <.001 <.001 <.001 <.001 <.001 <.001 <.001 .01 .85 .39 .45 .90 .36 .39 .02 <.001 <.001 
 
 
 
 
 
 
 
 
 
 
Table 3-3 (Continued) 
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Day 
of 
Illness 
AST ALT 
DHF 
vs 
DF 
DHF 
vs 
OFI 
DF 
vs 
OFI 
DHF 
vs 
DF 
DHF 
vs 
OFI 
DF 
vs 
OFI 
1 .08 <.001 <.001 .04 <.001 .001 
2 <.001 <.001 <.001 <.001 <.001 <.001 
3 <.001 <.001 <.001 <.001 <.001 <.001 
4 <.001 <.001 <.001 <.001 <.001 <.001 
5 <.001 <.001 <.001 <.001 <.001 <.001 
6 <.001 <.001 <.001 <.001 <.001 <.001 
7 .01 <.001 <.001 .04 <.001 <.001 
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Figure 3-1 Adjusted population-average models for each clinical laboratory parameter among patients with dengue 
hemorrhagic fever (DHF), dengue fever (DF), or other febrile illnesses (OFI) 
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Supplemental Table 3-1: Population-average mean values with 95% CI for each clinical laboratory parameter among the diagnostic 
groups at each day of illness. 
Day of Illness Platelets WBC Hct % Monocytes % Lymphocytes % Neutrophils 
Illness Day 1 
  DHF 
  DF 
  OFI 
 
244653 (226237, 263789) 
243686 (232122, 255532) 
265438 (256338, 274698) 
 
6503 (5903, 7165) 
7073 (6656, 7517) 
9879 (9428, 10351) 
 
36.8 (36.0, 37.6) 
38.3 (37.8, 38.7) 
38.8 (38.5, 39.1) 
 
3.9 (3.2, 4.6) 
5.0 (4.5, 5.6) 
4.0 (3.6, 4.4) 
 
14.4 (11.2, 17.6) 
11.7 (9.3, 14.0) 
10.7 (8.8, 12.7) 
 
82.3 (78.4, 86.1) 
81.7 (79.1, 84.3) 
82.4 (80.3, 84.4) 
Illness Day 2 
  DHF 
  DF 
  OFI 
 
174911 (164845, 185276) 
208406 (201101, 215841) 
252267 (245818, 258801) 
 
4317 (4060, 4591) 
4510 (4332, 4696) 
7547 (7279, 7826) 
 
39.1 (38.5, 40.0) 
38.8 (38.4, 39.1) 
38.5 (38.3, 38.7) 
 
3.5 (3.1, 3.9) 
4.3 (4.0, 4.6) 
4.0 (3.8, 4.2) 
 
24.4 (22.5, 26.3) 
27.2 (25.8, 28.6) 
25.0 (23.7, 26.2) 
 
68.6 (66.3, 71.0) 
64.4 (62.8, 66.0) 
66.7 (65.3, 68.1) 
Illness Day 3 
  DHF 
  DF 
  OFI 
 
124697 (117217, 132409) 
179336 (173053, 185732) 
242972 (236529, 249502) 
 
3451 (3271, 3642) 
3419 (3294, 3548) 
6138 (5917, 6368) 
 
40.5 (40.1, 41.0) 
39.0 (38.7, 39.3) 
38.2 (37.9, 38.4) 
 
3.3 (2.9, 3.6) 
3.8 (3.5, 4.1) 
4.0 (3.8, 4.2) 
 
32.4 (30.9, 34.1) 
38.5 (37.2, 39.7) 
35.6 (34.3, 36.9) 
 
56.1 (54.1, 58.1) 
50.3 (48.9, 51.7) 
54.8 (53.4, 56.2) 
Illness Day 4 
  DHF 
  DF 
  OFI 
 
89595 (83244, 96181) 
155665 (149726, 161719) 
237351 (230996, 244343) 
 
3323 (3148, 3507) 
3080 (2966, 3199) 
5314 (5110, 5527) 
 
41.3 (40.9, 41.8) 
39.0 (38.7, 39.3) 
37.8 (37.6, 38.0) 
 
3.2 (2.8, 3.5) 
3.5 (3.2, 3.8) 
3.9 (3.7, 4.2) 
 
38.7 (37.1, 40.3) 
45.5 (44.2, 46.8) 
42.8 (41.4, 44.2) 
 
44.8 (42.7, 46.8) 
39.3 (37.8, 40.8) 
46.6 (45.1, 48.2) 
Illness Day 5 
  DHF 
  DF 
  OFI 
 
65960 (60440, 71721) 
136680 (130950, 142533) 
235279 (227328, 243368) 
 
3823 (3647, 4070) 
3299 (3172, 3430) 
4898 (4684, 5123) 
 
41.4 (40.9, 41.9) 
38.8 (38.5, 39.1) 
37.4 (37.2, 37.7) 
 
3.2 (2.9, 3.5) 
3.3 (3.0, 3.6) 
3.8 (3.5, 4.1) 
 
43.0 (41.4, 44.6) 
48.3 (46.9, 49.6) 
46.4 (44.7, 48.1) 
 
34.5 (32.5, 36.6) 
31.5 (30.0, 33.0) 
42.2 (40.3, 44.0) 
Illness Day 6 
  DHF 
  DF 
  OFI 
 
50908 (44630, 57599) 
121773 (114752, 129002) 
236711 (225430, 248268) 
 
5380 (5004, 5784) 
4200 (3987, 4423) 
4806 (4521, 5110) 
 
40.8 (40.1, 41.4) 
38.3 (37.9, 38.7) 
37.1 (36.7, 37.4) 
 
3.4 (3.0, 3.9) 
3.4 (2.9, 3.8) 
3.6 (3.2, 4.1) 
 
45.4 (43.1, 47.8) 
46.8 (44.9, 48.8) 
46.5 (44.0, 49.0) 
 
25.5 (22.6, 28.3) 
26.8 (24.6, 29.0) 
41.4 (38.7, 44.2) 
Illness Day 7 
  DHF 
  DF 
  OFI 
 
42324 (33109, 52669) 
110432 (99778, 121627) 
241678 (223942, 260092) 
 
9047 (8013, 10213) 
6355 (5836, 6920) 
5020 (4575, 5509) 
 
39.4 (38.4, 40.3) 
37.6 (37.0, 38.2) 
36.7 (36.1, 37.2) 
 
3.8 (2.9, 4.7) 
3.6 (2.8, 4.4) 
3.4 (2.6, 4.2) 
 
46.0 (41.8, 50.2) 
41.1 (37.7, 44.5) 
43.0 (38.9, 47.1) 
 
17.5 (12.5, 22.5) 
25.2 (21.4, 29.1) 
44.4 (40.0, 48.9) 
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Supplementary Table 3-1 (Continued) 
 AST ALT 
Illness Day 1 
  DHF 
  DF 
  OFI 
 
41.8 (37.8, 46.5) 
37.6 (35.5, 39.9) 
31.6 (30.5, 32.8) 
 
21.5 (19.3, 24.1) 
18.7 (17.5, 20.0) 
16.2 (15.5, 16.9) 
Illness Day 2 
  DHF 
  DF 
  OFI 
 
57.4 (53.0, 62.4) 
44.3 (42.3, 46.5) 
31.7 (30.9, 32.6) 
 
26.6 (24.3, 29.2) 
20.8 (19.7, 22.0) 
16.3 (15.8, 16.8) 
Illness Day 3 
  DHF 
  DF 
  OFI 
 
74.5 (68.7, 81.1) 
50.9 (48.6, 53.4) 
32.0 (31.1, 32.8) 
 
31.8 (29.1, 35.0) 
23.1 (21.9, 24.4) 
16.5 (15.9, 17.0) 
Illness Day 4 
  DHF 
  DF 
  OFI 
 
89.0 (81.6, 97.5) 
56.7 (54.0, 59.6) 
32.3 (31.4, 33.3) 
 
36.7 (33.3, 40.6) 
25.6 (24.1, 27.1) 
16.7 (16.1, 17.3) 
Illness Day 5 
  DHF 
  DF 
  OFI 
 
95.8 (87.5, 105.3) 
61.0 (57.9, 64.3) 
32.7 (31.7, 33.8) 
 
40.4 (36.5, 44.9) 
28.2 (26.5, 30.0) 
16.9 (16.2, 17.6) 
Illness Day 6 
  DHF 
  DF 
  OFI 
 
91.9 (82.7, 102.6) 
63.2 (59.4, 67.3) 
33.3 (31.9, 34.8) 
 
42.2 (37.6, 47.5) 
31.0 (28.8, 33.4) 
17.1 (16.3, 18.0) 
Illness Day 7 
  DHF 
  DF 
  OFI 
 
79.1 (68.4, 92.5) 
62.9 (57.5, 69.1) 
34.0 (31.9, 36.3) 
 
41.6 (35.6, 49.2) 
33.9 (30.5, 37.8) 
17.4 (16.1, 18.8) 
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Supplementary Figure 3-1: Representative notation of population-average models used in this study 
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Supplementary Figure 3-2: Comparisons between population-average models and 95% CI of the 
mean at each day of illness across eight clinical laboratory parameters for each diagnostic group 
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Appendix 3.A 
Box-Cox transformation of AST: 
 
(AST^-0.4262729-1)/-0.4262729 
 
Box-Cox transformation of ALT: 
 
(ALT^-0.4095955-1)/0.4095955 
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Chapter IV: Classification of dengue illness based on readily available laboratory 
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Footnotes page 
ABBREVATIONS 
 ALT- alanine transaminase; AST- aspartate transaminase; AUC- area 
under the curve; CI- Confidence Interval; Corr. Class- Correctly Classified; DF- 
dengue fever; DHF- dengue hemorrhagic fever; DSS- dengue shock syndrome; 
DENV- dengue virus; Hct- hematocrit; KPPPH- Kamphaeng Phet Provincial 
Hospital; ln, natural logarithm; max- maximum; min- minimum; OFI- other febrile 
illness; pts- patients; PEI- pleural effusion index; PCR- polymerase chain 
reaction; , predicted probability; Prob. Cutoff- Probability Cutoff; QSNICH- 
Queen Sirikit National Institute of Child Health; ROC- receiver operator 
characteristic; WBC- white blood cell; WHO- World Health Organization. 
Running head: Classification of dengue illness 
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Abstract 
 Reporting of dengue illness is largely based on clinical criteria, however, 
controversy surrounds WHO guidelines for the diagnosis of dengue hemorrhagic 
fever (DHF). The aim of this study was to examine dengue illness classification 
using only clinical laboratory data, without relying on X-ray, ultrasound findings, 
or calculation of percent hemoconcentration. We analyzed data from a 
prospective study of children who presented with acute febrile illness to two 
hospitals in Thailand. Multivariable logistic regression models were used to 
determine probability cutoffs that best distinguished: 1) DHF vs. dengue fever 
(DF), 2) DHF vs. DF + other febrile illness (OFI), 3) Dengue vs. OFI, 4) Severe 
dengue vs. non-severe dengue + OFI. Data from the second hospital were used 
as a validation set. A total of 1227 patients were included in the analysis (228 
DHF, 386 DF, and 613 OFI). The sensitivity of the models ranged from 89.2% 
(dengue vs. OFI) to 79.6% (DHF vs. DF). The models demonstrated high 
sensitivity in the validation dataset. These models could be used to calculate a 
probability of DHF or severe dengue to classify patients based on readily 
available clinical laboratory data and will need to be validated in other dengue 
endemic regions. 
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 Dengue is an emerging infectious disease throughout the world and is 
endemic in tropical and subtropical areas. Recent estimates are that 3.6 billion 
people (55% of the global population) are at risk of dengue infection and that 70-
500 million dengue virus (DENV) infections occur annually, 2.1 million of which 
are severe dengue illnesses with ~21,000 deaths 24. DENV is spread by 
mosquito vectors, usually Aedes aegypti or Aedes albopictus. Dengue illnesses 
are usually classified as two distinct entities: dengue fever (DF) and dengue 
hemorrhagic fever (DHF), with the most severe cases of DHF classified as 
dengue shock syndrome (DSS). Patients diagnosed with DF typically have a mild 
febrile illness with two or more of the following: headache, myalgia, arthralgia, 
rash, hemorrhagic manifestations, and leukopenia 108. DHF is defined by four 
diagnostic criteria established by the WHO: fever, thrombocytopenia (platelet 
count <100,000 cells/mm3), bleeding tendency (positive tourniquet test or 
spontaneous bleeding), and plasma leakage (evidence of pleural effusion, 
ascites or >20% hemoconcentration) 11. Some patients with DF may exhibit 
severe illness, but do not meet all four WHO DHF criteria.  Likewise, some 
patients meeting diagnostic criteria for DHF have relatively mild illness, with 
minimal evidence of plasma leakage and bleeding diathesis not requiring medical 
intervention. 
 Previous studies have shown limited agreement between a physician’s 
diagnosis of severe dengue illness and strict adherence to the WHO definition of 
DHF, and have placed emphasis on a simpler definition of severe dengue illness 
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16, 17, 57, 109. Dengue endemic regions often have limited hospital resources and 
may not have the capability to perform chest x-rays or ultrasounds to detect 
pleural effusion or ascites, making it more difficult to fulfill the WHO criteria for 
the diagnosis of DHF. Changes in hematocrit may be influenced by early fluid 
resuscitation. In addition, baseline, convalescent, and/or reference hematocrit 
values are needed to demonstrate hemoconcentration; these values are often 
missing. Given these scenarios, patients with a severe dengue infection may be 
classified as DF, if WHO criteria are consistently applied, which may 
underestimate the global severity of dengue illness. Additionally, resource-poor 
areas lack essential laboratory support and may be unable to differentiate a 
DENV infection from other febrile illness (OFI). Previous studies suggest that  
other or additional indicators not in the WHO definition can distinguish patients 
with DHF from DF or patients with dengue from patients with OFI 39. However, 
among the studies with multivariable models, all of the final models produced had 
limited generalizability and none of these models were statistically validated.   
 The aim of this study was to assess the value of laboratory measures 
physicians use to classify dengue illnesses. Using more readily available clinical 
laboratory measures, we developed, evaluated, and validated different models of 
dengue illness classification based on a large, prospectively collected dataset, 
and compared our models to the WHO classification system and an experienced 
physician’s diagnosis. We also assessed whether laboratory parameters alone 
could appropriately classify severe vs. milder dengue illnesses. 
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Material and methods 
Study setting 
 A longitudinal observational study was conducted at two hospitals in 
Thailand: 1) the Queen Sirikit National Institute of Child Health (QSNICH) in 
Bangkok during the years 1994-97, 1999-2002, and 2004-07, and 2) Kamphaeng 
Phet Provincial Hospital (KPPPH) during the years 1994-97. The study methods 
have been described elsewhere 44. In brief, children between the ages of six 
months and 15 years, presenting with temperature ≥ 38.5˚C for ≤ 72 hours, and 
no localizing symptoms were eligible for the study. Exclusion criteria included: 
signs of shock at presentation, chronic disease, or an initial alternate non-dengue 
diagnosis. Children were admitted to the hospital and monitored throughout their 
hospital stay until 24 hours after their fever subsided. Written parental informed 
consent was obtained prior to enrollment. The study protocol was approved by 
the Institutional Review Boards of the Ministry of Public Health, Thailand, the 
U.S. Army, and the University of Massachusetts Medical School.  
 A blood sample was obtained on the day of enrollment and daily thereafter 
until one day following defervescence or for a maximum of five consecutive blood 
collections. Clinical laboratory studies included complete blood count and manual 
WBC differential, serum aspartate transaminase (AST) and serum alanine 
transaminase (ALT) levels. Serological assays (IgM/IgG ELISA and 
hemagglutination inhibition assay), viral isolation, and/or RT-PCR were used to 
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confirm all dengue cases. Patients were observed daily and clinical and 
laboratory measurements were recorded using standardized data collection 
forms.  
 On the day of defervescence, finger-stick hematocrits were measured 
every six hours for 18 hours in order to capture hemoconcentration. A right lateral 
decubitus chest x-ray was taken the day following defervescence and a pleural 
effusion index (PEI) was measured as 100 x (maximum width of right pleural 
effusion)/(maximum width of right hemithorax). After completion of the case 
record and careful review of the medical record and laboratory results, a final 
diagnosis of DF, DHF, or OFI was assigned by an expert physician, who was not 
directly involved in patient care.  
Severe dengue definition 
 An additional category was constructed to classify patients with severe 
dengue vs. non-severe dengue. Patients with dengue were classified as having 
severe dengue if they met any of the following criteria: 1) final diagnosis of DHF 
grade 3 or 4 (i.e., DHF with shock); 2) significant pleural effusion (PEI>15); 3) 
required total fluid intervention (oral or intravenous) in any 24-hour period that 
exceeded maintenance volume + 5% volume deficit 100, 101; or 4) required any 
intravenous fluid (IVF) throughout hospitalization (IVF was administered only 
under stringent circumstances, such as poor intake of oral fluids or signs of 
shock).  
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Statistical analysis 
 Descriptive characteristics, such as diagnosis, age, gender, length of 
illness at presentation, and which one of the two hospitals patients were admitted 
to were evaluated using t-tests for continuous variables and Pearson’s χ2 test for 
categorical variables. 
 Logistic regression models were constructed using data from QSNICH 
and validated using data from KPPPH. For each outcome (DF vs. DHF, DHF vs. 
all others, any dengue vs. OFI, and severe dengue vs. all others), univariate 
logistic regression was performed on the training dataset (QSNICH) for each of 
the following variables: maximum values for tourniquet test (number of petechiae 
per square inch), hematocrit, AST, ALT, % neutrophils, % lymphocytes, and % 
monocytes, and minimum platelet count and WBC count. Lowess curves were 
used to assess the distribution of the independent variables and determine the 
categorization for those with skewed distributions. If the linearity assumption held 
true, then the variable was used as a continuous variable. 
 Multivariable models were constructed for each outcome in a manual 
stepwise procedure based on the univariate indicators with the best area under 
the receiver operator characteristic (ROC) curve. For variables that were highly 
correlated, only the variable with the higher area under the curve (AUC) from the 
univariate analysis was used in the multivariable modeling. Variables that did not 
remain significant at the alpha=0.05 level were removed from the model and the 
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variable with the next highest area under the ROC was added into the model. 
The optimal sensitivity and specificity for each final multivariable model was 
chosen based on a probability cutoff where the sum of sensitivity and specificity 
were maximized, the maximum % correctly classified was achieved, and 
sensitivity remained higher than specificity.  
 Sensitivity and specificity for each model was also established in the test 
dataset using the same coefficients and probability cutoff as from the training 
dataset.   
 The % agreement between the physician’s diagnosis of DHF or the 
probability of DHF obtained from the models and the WHO definition of DHF was 
evaluated using Kappa statistics. The optimal probability cutoff from the model 
was used to determine the proportion of patients that would be defined as DHF 
where each patient above the cutoff was considered DHF and each patient below 
the cutoff was considered not to have DHF.   
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Results 
Characteristics of the Study Populations 
 There were 1384 patients enrolled in the study; 1311 of these patients had 
a diagnosis of DHF, DF, or OFI (presumed viral, non-dengue illness). For 65 of 
these patients (55 with OFI, 6 with DF, and 4 with DHF), a day of defervescence 
could not be assigned and they were excluded from the analysis. Some patients 
with OFI were discharged from the study prior to defervescence due to a 
negative PCR. An additional 19 patients failed to have information available on 
all clinical laboratory variables used in the analysis and were excluded.  
 There were 1227 patients included in the analysis (228 with DHF, 386 with 
DF, and 613 with OFI). Patients with DHF were classified by grade as follows: 
grade 1 (n=59), grade 2 (n=129), grade 3 (n=39), and grade 4 (n=1). There were 
1058 patients who completed the study at QSNICH and 169 patients from 
KPPPH (Table 4-1). The number of patients included in each model is shown in 
Figure 4-1. 
 We compared the characteristics of subjects enrolled at QSNICH and 
those treated KPPPH (Table 4-1). A higher proportion of patients with DHF were 
enrolled at KPPPH compared to QSNICH (30.8% vs. 16.6%, P<0.001). Patients 
presenting to KPPPH were also older than those presenting to QSNICH (8.9 
[95% CI: 8.4, 9.3] vs. 7.7 [95% CI: 7.5, 7.9], P<0.001). However, at QSNICH, 
patients with DHF presented later than patients with DF or OFI (2.3 vs. 2.1 and 
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1.7, respectively, P<0.001) and patients with DF presented later than patients 
with OFI (2.1 vs. 1.7, respectively, P<0.001). Additionally, at QSNICH, patients 
with DHF and patients with DF were older than patients with OFI (P<0.001). At 
KPPPH, a lower percentage of males was seen among patients with DF 
compared to patients with DHF or OFI (χ2 P=0.03 and χ2 P=0.02, respectively).  
Univariate analysis  
 After  univariate logistic regression modeling using the QSNICH data, 
clinical laboratory variables distinguishing each of the different diagnostic 
categories included minimum platelet count, maximum daily hematocrit (Hct), 
AST>100, maximum ALT, and a positive tourniquet test (>20 petechiae) (Table4-
2). Unit decreases in minimum platelet count and increases in maximum Hct, 
AST, ALT, and having a positive tourniquet test were associated with having a 
more severe outcome. The AUC for these variables ranged from 0.92 to 0.54. 
Additional variables of declining age and decreases in minimum WBC count 
distinguished between all categories except DHF vs. DF and were associated 
with having a more severe outcome in each model. The maximum % 
lymphocytes and % neutrophils distinguished patients with DHF versus DF and 
those with dengue versus OFI.  
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Multivariable analysis  
 Table 4-3 shows the results of multivariable analysis using QSNICH data. 
Maximum AST and ALT were found to be highly correlated (Pearson 
correlation=0.86); therefore, we utilized only maximum AST levels in the 
modeling. Incremental decreases in minimum platelet count (one unit= 25,000 
cells/mm3) and a maximum AST>100 were found to be associated with a more 
severe outcome in all the final multivariable models. Additionally, increases in the 
maximum daily Hct were associated with having a diagnosis of DHF when 
compared to DF or DF+OFI. Increases in maximum % neutrophils, age, and 
incremental decreases in minimum WBC count (one unit=500 cells/mm3) were 
associated with a diagnosis of DHF versus DF. All variables except maximum % 
lymphocytes and % neutrophils showed an association with having severe 
dengue illness compared to non-severe dengue or OFI. In addition to 
distinguishing patients with severe dengue, a tourniquet test of petechiae>=20 
was also included in the model for distinguishing patients with serologically 
confirmed dengue from those with OFI. Younger patients experienced a  higher 
odds of DHF or severe dengue after adjusting for all other variables in the model.   
 The probability cut-off for each multivariable model was defined as the 
probability that gave the highest % of patients correctly classified where the sum 
of sensitivity and specificity was maximized and sensitivity remained higher than 
specificity. Figure 4-2 illustrates the trade-off between sensitivity and specificity 
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for each probability cut-off for all of the multivariable models and shows the 
optimal cutpoint.  
Validation of multivariable models 
 The frequency distribution of each diagnosis (DHF, DF, OFI) according to 
the optimal probability cut-off for each model is given in Figure 4-3, showing the 
distribution of diagnoses in both the training (QSNICH)  and test (KPPPH) 
datasets. The sensitivity/specificity analysis, including AUC, positive and 
negative predictive values, and % correctly classified, and validations with the 
test data set are indicated in Table 4-4. When applying each model to the test 
data set, the sensitivity decreased by 2.7% (DHF vs. DF) to 8.9% (DHF vs. All 
Others). The specificity increased for each validation except Severe dengue vs. 
All Others, where specificity decreased and sensitivity increased. The % correctly 
classified decreased by 0.7% (DHF vs. DF) to 4.3% (Severe dengue vs. All 
Others). The final model distinguishing between patients with dengue and 
patients with OFI performed the best, giving the highest AUC, specificity, and % 
correctly classified in both the training and test datasets. Figure 4-4 shows the 
four validated multivariable models. Coefficients for the calculation of probability 
for each model were obtained by taking the natural logarithm of the odds ratio for 
each variable shown in Table 4-3.  
 Outside of a research setting, the entire spectrum of a patient’s illness 
may not be available. Therefore, each model was applied to the test dataset 
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using data only at defervescence and at 24 hours after defervescence, the period 
of greatest risk for plasma leakage and when patients are most likely to require 
hospitalization. When using data from the test dataset obtained in these later 
stages of illness, the sensitivity for most models decreased. However, using data 
obtained only at 24 hours after defervescence, it remained moderately high for 
DHF vs. DF, increasing from 77% to 86%, and DHF vs. All others at 71%. 
Classification from models compared to WHO and Physician diagnosis of 
DHF 
 Table 4-5 shows the % agreement and Kappa statistics between the 
model’s classification of DHF, the physician’s diagnosis of DHF, and the WHO 
diagnosis of DHF. When applying the optimal probability cutoffs, the % 
agreement between the model and the WHO classification of DHF compared to 
DF was 80.0% (к=0.58, P<0.001). The % agreement between the model and the 
WHO definition of DHF improved to 86.2% when compared to all others 
(DF+OFI, к=0.60, P<0.001). In both cases, the model had a higher % agreement 
with a WHO diagnosis of DHF than the physician’s diagnosis of DHF.  
 The model of DHF vs. DF classified 42.0% (258/614) of patients with 
dengue as having DHF. The physician diagnosed 37.1% (228/614) of patients 
with dengue as DHF and strict adherence to the WHO definition would have 
diagnosed 33.1% (203/614) patients with dengue as DHF. The model of DHF vs. 
all others classified 51.6% (317/614) of patients with dengue as DHF. The model 
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of severe dengue vs. all others classified 49.2% (302/614) of patients with 
dengue as having a severe dengue illness, including 203 patients diagnosed by 
the physician as DF. Only 6.5% (40/614) of patients with dengue were diagnosed 
by the physician as DHF grade 3 or 4. 
 Discussion 
 In this study, we developed models using clinical laboratory indicators to 
find associations with an expert physician’s final diagnosis and WHO criteria of 
DHF and DF. Although these models rely on laboratory results, these tests are 
part of standard clinical practice, and the models do not rely on more costly chest 
x-rays or other measures of capillary leakage. In addition, we established a 
category of severe dengue illness using indicators known to be associated with 
DSS. We found a large percentage of patients with dengue would be classified 
as having a severe dengue illness given their clinical laboratory values 
throughout their hospitalization. To our knowledge, our study involves the largest 
set of systematically collected data to address these questions.  
 An important aspect of this study is the use of a validation dataset. 
Previous studies have shown that strict adherence to WHO criteria does not 
identify all severe dengue disease 16, 17, 57, 109. Some studies have used simpler 
definitions that may be suitable for identifying severe disease and are less 
confusing for physicians 13, 109, 110, 111, 112, 113; however, these different definitions 
have not been previously validated. The validation dataset in our study involved a 
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different hospital, with a distinct and more rural catchment area (approximately 
350 km northwest of Bangkok). Although patients at KPPPH were older, and 
more patients were diagnosed with DHF, our models were still a robust fit for 
these data with little change in the AUC when compared to the training dataset. 
KPPPH is also in a region where Japanese encephalitis (JE) virus is known to 
co-circulate and there is routine vaccination against JE 114, 115. This diversity adds 
to the validation of the models presented here.  
 There is controversy surrounding the classification of DHF using the WHO 
definition. The previous WHO definition of DHF requires strict adherence to four 
criteria, which includes ambiguous definitions of bleeding tendency and 
hemoconcentration 11. By comparing our models to an expert physician’s 
diagnosis of DHF and the WHO definition of DHF, the ambiguity of components 
of the WHO definition of DHF is abrogated by finding other, objective, indicators 
that do not depend on convalescent visits or use of expensive tests in resource 
limited areas. Although the physician in our study used chest x-rays to determine 
the final diagnosis, our models show high sensitivity in distinguishing DHF from 
DF and DHF from all others without including chest x-ray or hemoconcentration 
findings. Our models did not show an improved % agreement over the 
physician’s diagnosis or the WHO definition of DHF. However, this is not 
surprising when considering that the physician used PEI as an indicator for 
plasma leakage and the majority of patients diagnosed with DHF had evidence of 
pleural effusion. Nevertheless, our validated model of DHF vs. DF did show a 
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high % agreement with both the physician’s diagnosis of DHF and the WHO 
definition (79.5% and 80.0%, respectively). 
  We showed high sensitivity and specificity in classifying patients with 
severe dengue defined by shock or need for fluid resuscitation. Some indicators 
used in the WHO definition of DHF are affected by early hydration, and detection 
of hemoconcentration and plasma leakage can be difficult 110. We defined a less-
subjective category of “severe dengue” which considered the amount of fluid 
resuscitation needed, and produced a model with high sensitivity and specificity 
without using a chest x-ray or hemoconcentration. Although early hydration can 
still affect the values of hematocrit used in our models, we have removed the 
requirement for baseline or convalescent hematocrits that may not always be 
available outside of a research setting.  Furthermore, we applied our models to 
the validation dataset using data obtained at 24 hours after defervescence only 
and still achieved high sensitivity and specificity for DHF vs. DF and DHF vs. All 
others. This suggests that our models will be applicable outside of a research 
setting and perhaps generalizable to patients who present later in illness; 
however, further studies are needed to test the generalizability  of these models 
in these study populations and in different geographic settings with different 
illness prevalence  estimates. .   
 Bleeding tendency is often indicated by a positive tourniquet test, but the 
test method is not always harmonized among treatment centers (SJT- 
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unpublished data) and confusion arises as to which cutoff should be used to 
indicate a positive test 110. We found that a cutoff >=20 petechiae yielded a 
higher AUC when compared to a cutoff of >=10 petechiae (data not shown). 
However, across all multivariable models, a positive tourniquet test showed an 
association only in patients with dengue compared to patients with OFI. This 
supports use of this indicator to identify patients with dengue, whereas the 
tourniquet test has performed less well for distinguishing DHF from DF 15, 44, 113, 
116.  
 Minimum platelet count and maximum Hct were associated with DHF and 
are part of the WHO definition. Although platelet count and Hct are included in 
the model, not all patients diagnosed by physicians with DHF had a platelet count 
below 100,000 and most patients with DHF had plasma leakage detected by 
pleural effusion rather than by hemoconcentration. Our models have no 
thresholds for particular variables but instead use a combination of clinical 
laboratory variables to calculate a probability which can be used to classify 
patients.  
 The main limitation to our study is the exclusion of children who first 
presented during later stages of their illness. This study design limits the number 
of patients who developed severe dengue illness. Our study was also limited to 
Thailand’s pediatric population. However, this reflects what is seen in Southeast 
Asia, where the majority of dengue cases are in the pediatric population.  
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 Our study identified clinical indicators that could be used to calculate a 
patient’s probability of DHF or severe dengue illness. From our models, patients 
with DF or mild dengue illness and OFI have a uniformly low probability of DHF 
or severe dengue. The probability calculated from our models could be used to 
classify patients when other indicators, such as a chest x-ray or convalescent 
sera, are unavailable. These models are not meant to guide clinical management 
but can be used for retrospective classification of dengue illness in the absence 
of standard indicators of plasma leakage. Such classification is not only important 
for research purposes but may enable greater accuracy of epidemiologic 
reporting of dengue disease severity in affected resource poor endemic regions.   
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Table 4-1 Study population characteristics 
Hospital N (%) Gender Age (years) Days ill at presentation 
Male Female Mean 95% CI Mean  95% CI 
QSNICH 1058 (86.2) 579 479 7.7 * 7.5, 7.9 2.0  1.9, 2.0 
  DHF 
  DF 
  OFI 
176 (16.6)a 
324 (30.6)a 
558 (52.7)a 
102 
175 
302 
74 
149 
256 
8.8  
8.6  
6.9  
8.3, 9.3 
8.2, 8.9 
6.6, 7.1 
2.3  
2.1  
1.7  
2.2, 2.4 
2.0, 2.2 
1.7, 1.8 
 
KPPPH 169 (13.8) 102 67 8.9*  8.4, 9.3 2.0  1.8, 2.0 
  DHF 
  DF 
  OFI 
52 (30.8)b 
62 (36.7)b 
55 (32.5)b 
35 
29 
38 
17 
33 
17 
9.1  
9.3  
8.3  
8.3, 9.9 
8.5, 10.0 
7.5, 9.1 
2.0  
2.2  
1.9  
1.8, 2.2 
 
2.0, 2.4 
1.8, 2.1 
Total 1227  681 546 7.9  7.7, 8.1 1.9  1.9, 2.0 
Abbreviations: CI, Confidence Interval; DF, dengue fever; DHF, dengue hemorrhagic fever; OFI, other febrile illness; KPPPH, Kamphaeng Phet 
Provincial Hospital. QSNICH, Queen Sirikit National Institute of Child Health 
* P<.001 for age between the QSNICH and KPPPH cohorts 
a Percentage of diagnosis in QSNICH cohort 
b Percentage of diagnosis in KPPPH cohort 
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Table 4-2 Univariate analysis of maximum and minimum values of clinical laboratory variables using the training QSNICH 
dataset 
 DHF vs. DF DHF vs. All Others Dengue vs. OFI Severe Dengue vs. All Others 
Odds 
ratio 
95% 
confidence 
interval 
AUC Odds 
ratio 
95% 
confidence 
interval 
AUC Odds 
ratio 
95% 
confidence 
interval 
AUC Odds 
ratio 
95% 
confidence 
interval 
AUC 
Age (years) 1.03      0.97, 1.09 0.52 1.15 1.09, 1.21 ** 0.62 1.21 1.16, 1.27 ** 0.66 1.13 1.07, 1.20 ** 0.60 
Gendera 1.17 0.81, 1.70 0.52 1.17 0.84, 1.62 0.52 1.05 0.83, 1.34 0.51 1.22 0.86, 1.72  0.52 
Min. Plateletsb 0.46 0.39, 0.54 ** 0.84 0.42 0.37, 0.48 ** 0.92 0.54 0.50, 0.58 ** 0.90 0.49 0.43, 0.55 ** 0.90 
Min. WBC 
countc 
1.01 0.94, 1.09 0.52 0.75 0.70, 0.80 ** 0.74 0.56 0.52, 0.60 ** 0.90 0.72 0.66, 0.78 ** 0.76 
Max. Hct. (%) 1.29 1.21, 1.37 ** 0.73 1.39 1.32, 1.47 ** 0.79 1.24 1.19, 1.29 ** 0.69 1.39 1.32, 1.47 ** 0.78 
Max. % 
Monocytes 
   <=5d 
  >5/<=10 
  >10 
 
 
 
0.85 
0.67 
 
 
 
0.57, 1.28 
0.39,1.14 
 
 
 
 
0.54 
 
 
 
0.83 
0.87 
 
 
 
0.58, 1.19 
0.54, 1.41 
 
 
 
 
0.52 
 
 
 
0.97 
1.37 
 
 
 
0.70, 1.18 
0.95, 1.96 
 
 
 
 
0.53 
 
 
 
0.84 
1.25 
 
 
 
0.57, 1.24 
0.78, 2.02 
 
 
 
 
0.54 
Max. % 
Lymphocytes 
   <=40d 
   >40/<=50 
   >50/<=60 
   >60 
 
 
 
0.58 
0.42 
0.52 
 
 
 
0.34, 1.01 
0.24, 0.73 * 
0.30, 0.88 * 
 
 
 
 
 
0.58 
 
 
 
1.18 
1.08 
1.14 
 
 
 
0.76, 1.86 
0.67, 1.73 
0.74, 1.77 
 
 
 
 
 
0.52 
 
 
 
2.15 
2.99 
2.39 
 
 
 
1.52, 3.04 ** 
2.08, 4.29 ** 
1.70, 3.34 ** 
 
 
 
 
 
0.61 
 
 
 
1.88 
1.37 
1.32 
 
 
 
1.16, 3.03 * 
0.81, 2.31  
0.80, 2.15 
 
 
 
 
 
0.56 
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Max. % 
Neutrophils 
   <=60d 
   >60/<=75 
   >75 
 
 
 
2.04 
1.61 
 
 
 
1.23, 3.38 * 
1.001, 2.58 
 
 
 
 
0.57 
 
 
 
1.46 
0.92 
 
 
 
0.93, 2.31 
0.60, 1.42 
 
 
 
 
0.55 
 
 
 
0.70 
0.45 
 
 
 
0.49, 0.99 * 
0.33, 0.62 ** 
 
 
 
 
0.58 
 
 
 
1.21 
0.92 
 
 
 
0.75, 1.97 
0.59, 1.44 
 
 
 
 
0.53 
Max. ASTe 
  <=100d 
  >100 
 
 
4.61 
 
 
3.12, 6.83 ** 
 
 
0.68 
 
 
14.10 
 
 
9.72, 20.45 ** 
 
 
0.77 
 
 
39.36 
 
 
20.54, 75.41** 
 
 
0.70 
 
 
10.71 
 
 
7.3, 15.64 ** 
 
 
0.75 
Max. ALTe 
  <=50d 
  >50/<=100 
  >100 
 
 
3.02 
3.28 
 
 
1.87, 4.87 ** 
1.99, 5.43 ** 
 
 
 
0.63 
 
 
6.97 
9.05 
 
 
4.49, 10.83 ** 
5.61, 14.59 ** 
 
 
 
0.70 
 
 
8.71 
21.68 
 
 
5.09, 14.88 ** 
9.35, 50.27 ** 
 
 
 
0.65 
 
 
4.98 
12.47 
 
 
3.11, 7.98 ** 
7.66, 20.28 ** 
 
 
 
0.71 
Max. Tourniquet 
Testf 
  <=20d 
   >20 
 
 
 
 
1.59        
 
 
 
 
1.01, 2.50 * 
 
 
 
 
0.54 
 
 
 
 
6.02 
 
 
 
 
4.03, 9.00 ** 
 
 
 
 
0.70 
 
 
 
 
10.22    
 
 
 
 
7.70, 13.57 ** 
 
 
 
 
0.76 
 
 
 
 
6.27        
 
 
 
 
4.06, 9.70 ** 
 
 
 
 
0.70 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; DF, dengue fever; DHF, dengue hemorrhagic fever; Hct, hematocrit; max, maximum; min, minimum; OFI, other 
febrile illness; QSNICH, Queen Sirikit National Institute of Child Health; WBC, white blood cell 
*P<0.05  
**P<0.001 
a Reference group is females  
b One unit = 25,000 cells/mm3 
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c One unit = 500 cells/mm3  
d Reference group 
e Units/dL 
f Number of petechiae per square inch 
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Table 4-3 Multivariable models among the training QSNICH dataset 
 DHF vs. DF DHF vs. All Others Dengue vs. OFI Severe Dengue vs. All Others 
(non-severe dengue + OFI) 
Odds 
ratio 
95% 
confidence 
interval 
Odds 
ratio 
95% 
confidence 
interval 
Odds 
ratio 
95% 
confidence 
interval 
Odds 
ratio 
95% 
confidence 
interval 
Age (years) 0.90 0.83, 0.99 *     0.88 0.81, 0.96 ** 
Min. Plateletsa 0.53 0.45, 0.62 ** 0.51 0.44, 0.59 ** 0.68 0.63, 0.74 ** 0.61 0.53, 0.69 ** 
Min.WBC countb 1.19 1.05, 1.34 *   0.68 0.63, 0.74 ** 0.88 0.80, 0.98 ** 
Max. Hct. (%) 1.19 1.10, 1.29 ** 1.17 1.09, 1.25 **   1.23 1.14, 1.32 ** 
Max.% Neutrophils 
   <=60c 
   >60/<=75 
   >75 
 
 
 
2.10 
1.89 
 
 
 
1.10, 3.99 * 
1.03, 3.49 * 
   
 
 
0.56 
0.55 
 
 
 
0.31, 0.99 * 
0.33, 0.93 * 
 
 
 
 
 
 
 
 
Max. ASTd 
  <=100c 
  >100 
 
 
2.32 
 
 
1.43, 3.78 ** 
 
 
3.40 
 
 
2.14, 5.40 ** 
 
 
8.99 
 
 
4.07, 19.85 ** 
 
 
2.31 
 
 
1.45, 3.68 ** 
Max. Tourniquet Teste 
  <=20a 
  >20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.80 
 
 
 
2.51, 5.75 ** 
 
 
 
 
 
 
 
 
Abbreviations: AST, aspartate aminotransferase; DF, dengue fever; DHF, dengue hemorrhagic fever; Hct, hematocrit; max, maximum; min, minimum; OFI, other febrile illness; QSNICH, Queen 
Sirikit National Institute of Child Health; WBC, white blood cell 
*P<0.05 
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**P<0.001 
a One unit = 25,000 cells/mm3 
b One unit = 500 cells/mm3 
c Reference group  
d Units/dL 
e Number of petechiae per square inch 
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Table 4-4 Validation of training QSNICH multivariable models to the KPPPH test dataset using the optimal probability cutoff 
 DHF vs. DF 
 
DHF vs. All Others Dengue vs. OFI Severe Dengue vs. All 
Others 
QSNICH KPPPH QSNICH KPPPH QSNICH KPPPH QSNICH KPPPH 
AUC 0.87 0.86 0.94 0.91 0.96 0.93 0.92 0.86 
Sensitivity 79.6 76.9 85.8 76.9 89.2 81.6 83.0 83.3 
Specificity 79.3 80.6 85.4 85.5 88.4 90.9 82.3 76.7 
(+) predictive value 68.0 76.9 53.9 70.2 87.1 94.9 44.3 49.2 
(-) predictive value 87.8 80.6 96.8 89.3 90.1 70.4 96.6 94.4 
% Corr. Class 79.6 78.9 85.4 82.8 88.7 84.6 82.4 78.1 
Abbreviations: AUC, area under the curve; Corr. Class, Correctly Classified; DF, dengue fever; DHF, dengue hemorrhagic fever; KPPPH, Kamphaeng Phet Provincial Hospital; OFI, other febrile 
illness; QSNICH, Queen Sirikit National Institute of Child Health  
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Table 4-5 Comparison of % agreement and Kappa statistics between the final models, WHO DHF criteria, and the physician's 
final diagnosis 
 Model vs. WHO Model vs. Physician Physician vs. WHO 
% Agreement Kappa P-value % Agreement Kappa P-value % Agreement Kappa P-value 
DHF vs. All Others 
     Prob. cutoff = 0.19 
 
86.2 
 
0.60 
 
<0.001 
 
85.5 
 
0.59 
 
<0.001 
 
92.4 
 
0.74 
 
<0.001 
DHF vs. DF 
     Prob. cutoff = 0. 35 
 
80.0 
 
0.58 
 
<0.001 
 
79.5 
 
0.57 
 
<0.001 
 
84.6 
 
0.66 
 
<0.001 
Abbreviations: DF, dengue fever; DHF, dengue hemorrhagic fever; Prob. Cutoff, Probability cutoff; WHO, World Health Organization 
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Figure 4-1 Flow chart of study 
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Figure 4-2 Sensitivity and specificity of multivariable logistic regression 
models from the training dataset 
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Figure 4-3 Distribution of calculated probabilities among each diagnosis for 
each model 
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Figure 4-4 Validated multivariable probability models for classifying 
patients with dengue 
(A) Equation 1: DHF vs. DF 
 
(B) Equation 2: DHF vs. All others 
 
(C) Equation 3: Dengue vs. OFI 
 
(D) Equation 4: Severe dengue vs. All others 
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ABBREVIATIONS 
 DENV- dengue virus; DF- dengue fever; DHF- dengue hemorrhagic fever; 
DSS- dengue shock syndrome; OFI- other febrile illness; QSNICH- Queen Sirikit 
National Institute of Child Health; KPPPH- Kamphaeng Phet Provincial Hospital; 
PEI- pleural effusion index; AST- aspartate transaminase; ALT- alanine 
transaminase; Hct- hematocrit; WBC- white blood cell; ROC- receiver operator 
characteristic; AUC- area under the curve; PCR- polymerase chain reaction; min- 
minimum; max- maximum; pts- patients. 
FIGURE LEGENDS 
 Figure 4-1. Flow chart of study. Boxes show the total number of patients 
enrolled in the study, reasons for exclusion from the analysis, and the number of 
patients from the training dataset (QSNICH) and the test dataset (KPPPH) used 
in each model. Abbreviations: DF, dengue fever; DHF, dengue hemorrhagic 
fever; KPPPH, Kamphaeng Phet Provincial Hospital; OFI, other febrile illness; 
QSNICH, Queen Sirikit National Institute of Child Health 
 Figure 4-2. Sensitivity and specificity of multivariable logistic regression 
models from the training dataset. Sensitivity is indicated by the solid blue line; 
specificity is indicated by the solid red line; the optimal probability cutoff is 
indicated by a solid vertical line. (A) DHF vs. DF with an optimal probability 
cutoff=0.35; (B) DHF vs. All others with an optimal probability cutoff=0.19; (C) 
Dengue vs. OFI with an optimal probability cutoff=0.45; (D) Severe dengue vs. All 
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others with an optimal probability cutoff=0.17. Abbreviations: DF, dengue fever; 
DHF, dengue hemorrhagic fever; OFI, other febrile illness. 
 Figure 4-3. Distribution of calculated probabilities among each diagnosis 
for each model. Blue=DHF; Red=DF; Gold=OFI. In each section, the top panel 
represents the distribution of probabilities in the training dataset (QSNICH) and 
the bottom panel represents the distribution of probabilities in the test dataset 
(KPPPH). (A) DHF vs. DF where the optimal probability cutoff=0.35; (B) DHF vs. 
All others where the optimal probability cutoff=0.19; (C) Dengue vs. OFI where 
the optimal probability cutoff=0.45; (D) Severe dengue vs. All others where the 
optimal probability cutoff=0.25. Abbreviations: DF, dengue fever; DHF, dengue 
hemorrhagic fever; KPPPH, Kamphaeng Phet Provincial Hospital; OFI, other 
febrile illness; QSNICH, Queen Sirikit National Institute of Child Health. 
 Figure 4-4. Validated multivariable probability models for classifying 
patients with dengue. (A) DHF vs. DF; (B) DHF vs. All others; (C) Dengue vs. 
OFI; (D) Severe dengue vs. All others. 
*Note: Categorical variables (% neutrophils, % monocytes, positive tourniquet 
test, AST, and gender) are 0/1. 
Abbreviations: AST, aspartate aminotransferase; DF, dengue fever; DHF, 
dengue hemorrhagic fever; Hct, hematocrit; ln, natural logarithm; Neuts, % 
neutrophils; WBC, white blood cell. 
130 
 
130 
 
Chapter V: Classification of dengue disease severity among pediatric Thai patients 
using early clinical laboratory indicators 
 
James A. Potts1, Alan L. Rothman1, Anon Srikiatkhachorn1, Robert V. Gibbons2, 
Stephen Thomas2, Pra-on Supradish3, Stephenie C. Lemon4, Daniel H. Libraty1, 
Sharone Green1*, Siripen Kalayanarooj3 
 
1 University of Massachusetts Medical School, Worcester, Massachusetts, 
Department of Immunology and Virology 
2 Department of Virology, Armed Forces Research Institute of Medical Sciences, 
Bangkok, Thailand 
3 Queen Sirikit National Institute of Child Health, Bangkok, Thailand 
4 University of Massachusetts Medical School, Worcester, Massachusetts, 
Department of Preventative and Behavioral Medicine 
 
* Corresponding Author 
  
131 
 
131 
 
Abstract 
 Background: Dengue virus is endemic in tropical and sub-tropical 
resource-poor countries. Dengue illness can range from a nonspecific febrile 
illness to  severe disease, Dengue Shock Syndrome (DSS), in which patients 
develop circulatory failure. Earlier diagnosis of severe dengue illnesses would 
have a substantial impact on the allocation of health resources in endemic 
countries. 
 Methods and findings: We compared clinical laboratory findings 
collected within 72 hours of fever onset from children presenting to one of two 
hospitals in Thailand. Classification and regression tree analysis was used to 
develop diagnostic algorithms using different categories of dengue disease 
severity to distinguish between patients at elevated risk for developing a severe 
dengue illness and those at low risk.  
 A diagnostic algorithm using WBC count, percent monocytes, platelet 
count, and hematocrit achieved 97% sensitivity to identify patients who went on 
to develop DSS while correctly excluding 48% of non-severe cases. Addition of 
an indicator of severe plasma leakage to the WHO definition led to 99% 
sensitivity using WBC count, percent neutrophils, AST, platelet count, and age.  
 Conclusions: This study identified two easily applicable diagnostic 
algorithms using early clinical indicators obtained within the first 72 hours of 
illness onset. The algorithms have high sensitivity to distinguish patients at 
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elevated risk for developing severe dengue illness from patients at low risk, 
which included patients with mild dengue and other non-dengue febrile illnesses. 
Although these algorithms need to be validated in other populations, this study 
highlights the potential usefulness of specific clinical indicators early during the 
course of  illness. 
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Author summary 
Patients with severe dengue illness typically develop complications in the 
later stages of illness, making early clinical management of all patients with 
suspected dengue infection difficult. An early prediction tool to identify which 
patients will have a severe dengue illness will improve the utilization of limited 
hospital resources in dengue endemic regions. We performed classification and 
regression tree (CART) analysis to establish predictive algorithms of severe 
dengue illness. Using a Thai hospital pediatric cohort of patients presenting 
within the first 72 hours of a suspected dengue illness, we developed diagnostic 
decision algorithms using simple clinical laboratory data obtained on the day of 
clinical presentation. These algorithms correctly classified almost all patients who 
developed a severe dengue illness while excluding upwards of 50% of patients 
with mild dengue or other febrile illnesses. Our algorithms utilized white blood cell 
counts, percent white blood cell differentials, platelet counts, elevated aspartate 
aminotransferase, hematocrit, and patient’s age. If these algorithms can be 
validated in other regions and age groups, they will help in the clinical 
management of patients with suspected dengue illness who present within the 
first three days of fever onset. 
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Background 
 Dengue fever (DF) and dengue hemorrhagic fever (DHF), the more severe 
form of dengue illness, are re-emerging viral diseases 10. Dengue is endemic in 
resource-poor countries in tropical and subtropical areas. Dengue viruses are 
transmitted through the bite of an infected mosquito 7. Illnesses caused by 
dengue viruses can range from a nonspecific febrile illness, as in most DF cases, 
to more severe illness with bleeding, thrombocytopenia, and plasma leakage, in 
cases of DHF 11. DHF with circulatory failure defines DHF grades 3 and 4, also 
termed dengue shock syndrome (DSS) 11.  However, strict adherence to WHO 
criteria for diagnosis of DHF has been difficult and some researchers have 
established different categories of severe dengue illnesses 13, 16, 110, 111.  
 Dengue has a substantial economic impact in developing countries 28, 30. 
Individuals and families are impacted by lost wages, cost of seeking care, cost of 
treatment, missed school, and extended effects of recovery 28, 29, 30, 31, 32. 
Prevention and control strategies have been poorly implemented or unsustained 
and thus largely ineffective 20, 117.  
 Currently, there is no licensed vaccine or anti-viral against dengue. The 
treatment for patients with suspected dengue is supportive care consisting of 
rehydration and anti-pyretics 11. Patients with suspected dengue are often 
hospitalized for close monitoring. Plasma leakage occurs around the time of 
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defervescence. Prior to this critical phase, it has proven difficult to differentiate 
mild vs. severe dengue illness. Ideally, only severe cases of DF and DHF should 
be hospitalized.  However, there are no diagnostic/prognostic tools available to 
distinguish severe dengue from non-severe dengue or other febrile illness (OFI) 
during the early stages of illness. Such tools could improve clinical practice by 
decreasing the number of un-necessary hospitalizations, improving utilization of 
limited hospital resources to treat more severely ill patients, improving outcomes 
of severely ill patients by administering needed care earlier, and improving the 
capability of physicians in developing or rural areas to make a more accurate 
early diagnosis. 
 We conducted a prospective study of Thai children with acute febrile 
illness, consistent with dengue, enrolled from an early stage of illness onset 44. 
We applied classification and regression tree (CART) analysis to this dataset to 
distinguish patients with severe dengue illness from those with mild dengue 
illness and OFI. CART analysis is a non-parametric analytic tool that has many 
advantages over logistic regression models 96, 118. CART was used to establish a 
diagnostic decision tree using clinical laboratory variables and patient 
characteristics collected at presentation.  
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Methods 
 Study Setting. A longitudinal observational study was conducted at two 
hospitals in Thailand: 1) the Queen Sirikit National Institute of Child Health 
(QSNICH) in Bangkok during 1994-97, 1999-2002, and 2004-07, and 2) the 
Kamphaeng Phet Provincial Hospital (KPPPH) during 1994-97. The study 
methods have been described in detail elsewhere 44. In brief, children between 
the ages of six months and 15 years presenting with temperature ≥ 38˚C for no 
more than 72 hours and no localizing symptoms were eligible for enrollment with 
parental consent. Exclusion criteria included: signs of shock at presentation, 
chronic illness, or an initial alternate non-dengue diagnosis. Subjects were 
admitted to the hospital and monitored until 24 hours after defervescence. The 
study protocol was approved by the Institutional Review Boards of all 
participating institutions. 
 A blood sample was obtained on the day of enrollment and daily thereafter 
until discharge or for a maximum of five consecutive blood collections. 
Serological assays (IgM/IgG ELISA and hemagglutination inhibition assay), virus 
isolation, and/or RT-PCR were used to confirm all dengue cases. Patients were 
observed and daily clinical and laboratory measurements were recorded using 
standardized data collection forms.  
 After defervescence (2 consecutive temperatures below 38 ˚C), serial 
finger-stick hematocrits were measured to capture hemoconcentration. A right 
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lateral decubitus chest x-ray was taken the day following defervescence and a 
pleural effusion index (PEI) was measured as 100 x (maximum width of right 
pleural effusion)/(maximum width of right hemithorax). After completion of the 
case record, an expert physician, who was not directly involved in patient care, 
assigned a final diagnosis of DF, DHF, or OFI based upon chart review following 
WHO guidelines 11. 
 Categories of Dengue Illness Severity. Since not all DHF cases are 
severe, and not all DF cases are mild, we applied several different categories of 
dengue disease severity using data from each patient’s entire hospital course : 1) 
dengue shock syndrome (DSS, as defined by WHO criteria); 2) DSS or PEI>15; 
3) DSS or required intravenous fluid; 4) DSS or platelet count <=50,000 anytime 
during illness; 5) DSS or received fluid intervention (oral or intravenous) in any 
24-hour period that exceeded maintenance volume + 5% volume deficit 100, 101.   
 Clinical Laboratory Variables and Patient Characteristics. The input 
variables used for establishing each tree were platelet count, hematocrit, WBC 
count, percent monocytes, percent lymphocytes, percent neutrophils, AST, ALT, 
tourniquet test (+/-), age, and gender, all of which were obtained on the day of 
presentation. 
 Statistical Analysis. Descriptive characteristics of the study sample were 
compared using t-tests and Pearson’s χ2. CART analysis was performed using 
SPSS Answer Tree 3.0 software (see Supplementary Methods) 119. Age, gender, 
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and clinical laboratory data on the day of presentation were used to establish 
diagnostic decision trees to distinguish patients with severe dengue illness from 
those with non-severe illness or OFI. Stopping rules were: 1) no terminal node 
could contain <5% of the original sample size, 2) no more than 5 levels per tree, 
and 3) a minimum improvement in impurity of .0001.   
 Additional analyses were performed to examine differences in diagnostic 
trees according to the day of presentation among the low risk, non-severe group. 
The final trees selected were those that had minimum misclassification of severe 
dengue illness in low risk nodes (high sensitivity) and maximum correct 
classification of non-severe dengue and OFI in low risk nodes (high specificity). 
In each terminal node, patients were classified as low risk or elevated risk of 
severe dengue illness where optimal sensitivity could be achieved. For all 
analyses, sensitivity was weighted more heavily than specificity by using 
misclassification cost ratio of 1:10 severe dengue vs. non-severe. Each tree was 
validated using the k-fold cross validation method 95, 97. We used k=5 in our 
analysis.  
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Results 
 Study Sample. In total, 1384 patients were enrolled in the study. Of these, 
1311 had a final diagnosis of DHF, DF, or OFI. Of the remaining 73 patients, 32 
had an undetermined diagnosis due to lack of convalescent blood sample for 
serology, and 41 had a presumed non-viral infection. An additional 81 patients 
were missing one or more variables of interest on the day of presentation and 
were excluded from the analysis.         
 Table 5-1 describes the 1230 patients included in the analysis. Among 
these, 208 had a final physician diagnosis of DHF (53 grade 1, 118 grade 2, 36 
grade 3, 1 grade 4), 374 had DF, and 648 had OFI. Secondary infections 
accounted for 81.9% of all dengue infections (74.6% of DF cases and 95.2% of 
DHF cases). The most prevalent serotype of dengue infections was DENV1 
(40.7%). Table 5-2 indicates the number of patients with severe dengue based 
on different definitions. 
 Classification Tree for Dengue Shock Syndrome. Trees were generated 
for each of the five categories of severe dengue illness. As summarized in Table 
5-2, and shown in Figure 5-1 (Tree 1), the tree that provided the best 
discrimination on the day of presentation categorized severe dengue as DSS. 
The initial splitting variable in the tree is WBC count; other variables in the tree 
include percent monocytes, platelet count, and hematocrit. The tree resulted in 
five terminal nodes, of which three are considered low risk and two are 
considered elevated risk. The three low risk nodes are 1) WBC>8500, 2) 
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WBC<=8500 and percent monocytes >9.0, and 3) WBC<=8500, percent 
monocytes<=9.0, platelet count >160200, and hematocrit>40%. The two nodes 
considered elevated risk of severe dengue were 1) WBC<=8500, percent 
monocytes <=9.0, and platelet count <=160200 (64.9% of patients with severe 
dengue) and 2) WBC<=8500, percent monocytes<=9.0, platelet count >160200, 
and Hct<=40 (32.4% of patients with severe dengue). 
 A total of 576 (48.3%) patients with non-severe dengue were classified 
correctly in the low risk group at the cost of misclassifying one patient who later 
manifested DHF grade 3. The initial splitting variable correctly classified 384 
(32%) of the patients with non-severe dengue.  The patients that were correctly 
classified as low risk included 63.7% of all OFI, 32.1% of all DF, 41.5% of all 
DHF grade 1, and 17.8% of all DHF grade 2. Patients with non-severe dengue 
illness were more likely than patients with OFI to be classified as elevated risk of 
severe dengue (70.1% of non-severe dengue versus 36.3% of OFI). 
 Among the 617 (51.7%) patients with non-severe illness that were 
classified as elevated risk, the median day of presentation was 72 hours after 
illness onset and the average length of hospital stay was 6.8 days; patients with 
non-severe dengue that were correctly classified had a median day of 
presentation of 48 hours after illness onset and an average length of hospital 
stay of 7.3 days. To assess differences according to the day of presentation, the 
tree was applied using data from patients with non-severe illness at 72 hours 
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among patients who were still febrile. In this group of low risk patients, the 
percent correctly classified as low risk decreased slightly from 48% to 44% (data 
not shown). 
 Classification Tree using DSS or PEI>15. Figure 5-2 shows a diagnostic 
decision tree in which severe disease was defined as DHF grade 3 or 4 or 
PEI>15 (Tree 2). This disease categorization added nine patients with DHF 
grade 1 and 37 patients with DHF grade 2. No patients diagnosed with OFI or DF 
had a PEI>15. For this tree, the initial splitting variable was WBC count; other 
variables in the tree include AST, percent neutrophils, platelet count, and age. 
There are eight terminal nodes, of which five are considered low risk and three 
are considered elevated risk. The five low risk nodes are 1) WBC>13700, 2) 
WBC<=13700, AST 36-50, and platelet count >282000, 3) WBC<=13700, AST 
36-50, platelet count <=282000, and age<=6.75, 4) WBC<=13700, AST<=35, 
and percent neutrophils<=68%, and 5) WBC<=13700, AST<=35, percent 
neutrophils>68%, and platelet count>291000. The three elevated risk nodes are 
1) WBC<=13700, AST>50 (72.3% of patients with severe dengue), 2) 
WBC<=13700, AST 36-50, platelet count <=282000, and age>6.75 (16.9% of 
patients with severe dengue), and 3) WBC<=13700, AST<=35, percent 
neutrophils>68%, and platelet count<=291000 (9.6% of patients with severe 
dengue).   
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 This tree correctly classified 505 (44%) patients with non-severe dengue 
at the cost of misclassifying one patient with severe dengue. The misclassified 
patient was diagnosed with DHF grade 2 and had PEI of 25.8. All patients with 
DHF grade 3 or grade 4 were correctly classified in this tree as elevated risk of 
severe dengue. Among the 505 patients correctly classified as low risk of severe 
dengue, 380 were OFI (58.6% of OFI), 105 were DF (28.1% of DF), and 20 were 
DHF grade 1 or 2 (16.0% of non-severe DHF). Patients with non-severe dengue 
illness were more likely than patients with OFI to be classified as elevated risk.  
When the tree was applied using data from patients with non-severe illness at 72 
hours, the percent of non-severe cases correctly classified as low risk increased 
from 44% to 50%.  
 Classification Tree using Other Categories of Dengue Disease Severity. 
We assessed the generalizability of our trees using other categories of dengue 
disease severity (Table 5-2). For example, when applying the tree that was 
generated using DSS as the only criterion for dengue disease severity (Tree 1) to 
different categories of severity, the percentage of patients with a severe dengue 
illness that were misclassified as low risk ranged from 12.5% to 17.6% and the 
percentage of patients with non-severe illness that were correctly classified 
ranged from 48.6% to 52.1%. All additional trees (Trees 3-5) had moderate 
specificity but limited sensitivity (Table 5-2), with a misclassification of severe 
dengue as low risk ranging from 34.9% to 42.6% and a correct classification of 
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non-severe illness ranging from 72.1% to 81.5%. Each tree shared the same 
initial splitting variable of WBC count (data not shown).  
Discussion 
 Early diagnosis of severe dengue illness not only has the potential to 
reduce morbidity and mortality, but could also reduce the economic impact of 
dengue illness by decreasing the duration of hospitalization and the number of 
patients who will develop shock. We identified two diagnostic algorithms using 
early clinical laboratory indicators and patient characteristics that could 
distinguish patients with severe dengue from those with non-severe dengue or 
other febrile illnesses within the first 72 hours of illness.  
 When applying these trees to other (broader) categories of disease 
severity, a high sensitivity was still achieved. Previous studies have shown that 
modified definitions of dengue disease severity have better agreement with a 
treating physician’s assessment when compared to strict adherence to WHO 
criteria 13, 14, 15, 16. For any classification of dengue disease severity utilized, a 
high proportion of patients with non-severe dengue or other febrile illness were 
correctly classified as low risk of severe dengue (Table 5-2). These data suggest 
that patients classified as ‘elevated risk’ of severe dengue based on these 
algorithms should be treated and managed more aggressively; in comparison, 
our data suggest that patients classified as ‘low risk’ of severe dengue could be 
safely managed on an outpatient basis. 
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 The single patient with severe dengue that was misclassified in Tree 1 
presented within the first 24 hours of illness, had an initial WBC count of 13700, 
and was diagnosed with DHF grade 3. Five other patients with severe dengue in 
Tree 1 also presented within the first 24 hours and yet were correctly classified 
as elevated risk. When we further investigated the effect of day of presentation 
by using day 3 data from all non-severe cases, we found that day of presentation 
had little effect on the sensitivity of Trees 1 and 2 (within the first 72 hours); Tree 
1 still correctly classified 44% of the non-severe cases as low risk of severe 
dengue infection and, in Tree 2, the percent correctly classified as low risk 
increased from 44% to 50%. 
 Many of the variables used in our decision algorithms have been shown to 
distinguish between patients with dengue and patients with OFI in other settings 
39. Trees 1 and 2 have an initial splitting variable of WBC count, which reinforces 
the reported utility of this variable in distinguishing severe dengue illness within 
the first days of illness 39, 120, 121, 122, 123. Both trees included nodes using platelet 
count as the splitting variable. Thrombocytopenia is a hallmark of severe dengue 
disease, although it frequently occurs in DF as well 11. Platelet counts are able to 
distinguish between patients with dengue and OFI 39, 122. However, when 
producing a tree using a minimum platelet count of <=50,000 as part of the 
categorization of severity (Severity category 4), the tree misclassified 42.5% of 
patients with severe dengue (Table 5-2). These data suggest that 
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thrombocytopenia is not a specific marker for severe disease in the early febrile 
phase of dengue illness. 
 One criticism of CART analysis is that the cutoff values may not be 
clinically meaningful. However, when we re-defined the cutoff values for Trees 1 
and 2 the results maintained high sensitivity. For example, in Tree 1 when we 
rounded platelet count to 160,000, the results remained the same. In Tree 2, 
when we rounded the cutoffs of platelet count to 290,000 and 280,000, percent 
neutrophils to 70%, and age to 7, the tree correctly classified 45.9% of the non-
severe cases while still achieving 94.0% sensitivity for severe cases. 
Interestingly, many of the cutoff lab values in our decision trees fall within the 
‘normal’ range; this suggests that established ‘normal’ ranges for routine 
laboratory tests have low sensitivity to detect clinically relevant changes. 
 Tanner and colleagues published an analysis establishing dengue 
decision trees; however, their analysis was based on only three WHO-defined 
DHF cases and it was unclear if these three cases met other objective criteria for 
severity 99. In contrast, our study has 37 cases of more severe WHO-defined 
DSS and 171 cases of DHF grade 1 or 2. We also applied other criteria that 
could classify patients with dengue as having severe illness. Their study included 
a platelet count of <50,000 as part of the definition of severe dengue, and the 
resulting tree was limited in its sensitivity (82.6%) 99. Although the tree had a high 
specificity, sensitivity is a more important clinical consideration in the detection of 
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severe disease. A more recent decision tree study by Lee and colleagues found 
a history of clinical bleeding, serum urea, and serum protein to distinguish 
between patients with DF and patients with DHF; however, both studies have 
limited clinical utility as a predictive algorithm for patients with severe dengue 
because virologic confirmation of dengue infection is not known at presentation 
98, 99.  Our study identifies those with severe dengue illness among all suspected 
dengue cases. 
 Our study is subject to some limitations. First, our study included only 
pediatric patients from two hospitals in Thailand. However, because the majority 
of dengue cases in Thailand and other regions of Southeast Asia are children, 
our findings are clinically relevant 8, 11, 21. Further validation using datasets in 
other dengue endemic regions is needed to establish the clinical utility of our 
algorithms in other populations. Additionally, because our study enrolled patients 
only during the initial 72 hours of illness, we cannot make any conclusions 
regarding the sensitivity and specificity of these classification trees at later time 
points in illness. 
 We provide two decision tree algorithms using 12 years of systematically 
collected clinical data from a well-defined cohort of pediatric patients in a 
dengue-endemic region. Our algorithms have minimal misclassification of WHO-
defined DSS cases among all patients with suspected dengue infection who 
present within the first 72 hours of illness. These algorithms also have minimal 
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misclassification of other severe dengue illnesses using different categorizations 
of severity. A robust, validated decision algorithm can be easily implemented in 
resource limited settings to identify patients who are at risk for developing a more 
severe dengue illness and limit the number of unneeded hospitalizations. 
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Table 5-1 Study sample characteristics, in the total sample and by final diagnosis 
 Age 
(mean, 95% CI, 
years) 
Gender 
(m:f ratio) 
Days ill at 
presentation 
mean (median) 
Length of observational period 
 (24 hours after defervescence) 
mean(median)* 
DHF  
  Grade 1 (n=53) 
  Grade 2 (n=118) 
  Grade 3/4 (n=37) ** 
 
 
8.4 (7.4, 9.4) 
9.1 (8.5, 9.6) 
8.5 (7.6, 9.4)  
 
2.3 
1.3 
0.9 
 
2.0 (2) 
2.3 (2) 
2.4 (2) 
 
6.2 (6) 
6.4 (6) 
7.3 (7)*** 
DF (n=374) 8.6 (8.4, 8.9) 1.1 2.1 (2) 6.3 (6) 
OFI (n=648) 7.1 (6.8, 7.3) 1.2 1.8 (2) 5.3 (5) 
* Includes only those patients who remained in the study until the end of the observational period (50 DHF grade1; 110 DHF grade 2; all DHF grade 
3 and 4; 327 DF; 495 OFI) 
** Only 1 patient had DHF grade 4; this subject was combined with DHF grade 3 for analysis 
*** DHF grade 3 or 4 had longer observational periods when compared to patients with DHF grade 1 and 2, DF, or OFI (p<.001). 
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Table 5-2 CART analysis using different categories of severe dengue illness* 
Tree Outcome variable 
for tree 
Outcome variable for 
evaluation of tree 
% Misclassified severe 
dengue 
(# classified as low 
risk/total severe) 
 
% Correctly classified 
non-severe 
(# classified as low 
risk/total non-severe) 
1 Severity Category 
1 
Severity Category 1 2.7% 
(1/37) 
48.3% 
(576/1193) 
Severity Category 2 16.9%  
(14/83) 
49.1% 
(563/1147) 
Severity Category 3 16.8% 
(25/149) 
51.1% 
(552/1081) 
Severity Category 4 12.5% 
(20/160) 
52.1% 
(557/1070) 
Severity Category 5 17.6% 
(12/68) 
48.6% 
(565/1162) 
2 Severity Category 
2 
Severity Category 1 0.0% 
(0/37) 
42.2% 
(504/1193) 
Severity Category 2 1.2% 
(1/83) 
44.0% 
(505/1147) 
Severity Category 3 9.4% 
(14/149) 
45.5% 
(492/1081) 
Severity Category 4 5.0% 
(8/160) 
46.5% 
(498/1070) 
Severity Category 5 8.8% 
(6/68) 
43.0% 
(500/1162) 
3 Severity Category 
3 
Severity Category 3 34.9% 
(52/149) 
72.1% 
(779/1081) 
4 Severity Category 
4 
Severity Category 4 42.5% 
(68/160) 
81.5% 
(872/1070) 
5 Severity Category 
5 
Severity Category 5 42.6% 
(29/68) 
77.3.0% 
(898/1162) 
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* Severity Category 1: DSS (DHF grade 3 or 4) 
  Severity Category 2: DSS or PEI>15 
  Severity Category 3: DSS or required intravenous fluid resuscitation during hospitalization 
  Severity Category 4: DSS or had min platelet count <=50,000 during hospitalization 
  Severity Category 5: DSS or received fluid intervention (oral or intravenous) >5% volume deficit above maintenance
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Figure 5-1 Decision tree using DSS as 'severe dengue' 
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Figure 5-2 Decision tree using DSS or dengue+PEI>15 as 'severe dengue' 
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Supplementary Methods 
Classification and Regression Tree Analysis 
 CART is a non-parametric statistical technique that is used to partition 
data into mutually exclusive and exhaustive subgroups (nodes) where patients 
within each partitioned node are as homogenous as possible in terms of the 
outcome measure of interest (diagnosis) 95. The data is partitioned according to 
the independent variable that provides the greatest difference in an impurity 
function with respect to the outcome measure. At each point in the process, the 
root (parent nodes) split into two child nodes. The Gini impurity function was 
used for this analysis, which uses the proportion of the dependent variable in the 
parent nodes and a weighted average of patients in the resulting child nodes to 
calculate impurity at each split 95, 96, 97. The data continue to be split until at least 
one stopping rule is met. The final nodes, terminal nodes, are mutually exclusive 
and exhaustive. 
 For validation of trees, the dataset was divided into five subsets where 
each subset acts as a validation dataset while the remaining subsets are used as 
a training dataset. This process is repeated five times until each subset has 
acted as the validation dataset. All CART analyses were performed using SPSS 
Answer Tree 3.0 software 119. 
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Figure legends 
Figure 5-1: CART algorithm #1 for identifying patients who subsequently 
developed severe dengue (defined as WHO criteria for dengue shock syndrome, 
DSS) using clinical laboratory data obtained within the first three days of illness. 
Each node is shown with the selected splitting variable, the number of patients 
with severe/non-severe or OFI, and the proportion of each from the parent node. 
Terminal nodes are marked as ‘elevated risk’ of severe dengue illness, outlined 
in red, and ‘low risk’ of severe dengue, outlined in blue. 
Figure 5-2: CART algorithm #2 for identifying patients who subsequently 
developed severe dengue (defined as WHO criteria for dengue shock syndrome, 
DSS, or dengue with significant pleural effusion) using clinical laboratory data 
obtained within the first three days of illness. Pleural effusion index (PEI) >15 
was used as the criterion for significant pleural effusion. Each node is shown with 
the selected splitting variable, the number of patients with severe/non-severe or 
OFI, and the proportion of each from the parent node. Terminal nodes are 
marked as ‘elevated risk’ of severe dengue illness, outlined in red, and ‘low risk’ 
of severe dengue, outlined in blue. 
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Chapter VI Conclusions 
 The objective of this dissertation was to advance the knowledge and 
improve the clinical understanding of dengue illness. Using the available data, we 
applied various statistical methods to elucidate the clinical course of dengue 
illness and how the different disease manifestations compare with each other 
and other febrile illnesses.  
Dynamics of clinical laboratory parameters distinguish among Thai 
pediatric patients with different dengue disease severity  
 The research objective of this study (Chapter III) was to describe the 
temporal dynamics of clinical laboratory parameters throughout the febrile phase 
of patients with suspected dengue illness. Using population average models, we 
established mathematical functions of these parameters for each diagnostic 
group (DHF, DF, OFI). We identified differences in the population-average 
means as well as differences in the slopes among the various diagnostic groups. 
These indicators could be used to evaluate trends in several clinical laboratory 
parameters in patients with suspected dengue illness and identify those subjects 
whose parameters follow the trends of patients who eventually develop DHF. 
These patients could be managed more aggressively in order to reduce the 
likelihood of shock resulting from severe plasma leakage. 
 These findings contribute to the existing literature (presented in Chapter I) 
by applying longitudinal techniques to evaluate changes over the course of 
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illness in patients with dengue. Many of the recent studies did not evaluate 
changes over time, or did not apply appropriate statistical methodology, to do so. 
However, these findings should be validated in other populations and age 
groups.   
The development of plasma leakage is considered to be the hallmark 
feature of DHF. There are several ways to effectively measure plasma leakage 
which have been previously validated 106, 124. However, patients with DHF don’t 
develop plasma leakage until later in the course of illness, typically around the 
time of defervescence. Until defervescence, patients with DHF have similar 
clinical symptoms as patients with DF or OFI and therefore can be hard to 
distinguish these from other groups. This analysis has allowed us to assess 
which variables may be useful in identifying patients with DHF. Furthermore, the 
analysis shows when in the course of illness these variables might be most 
useful to distinguish subjects with a particular diagnosis (DHF, DF, or OFI).  
Classification of dengue illness based on readily available laboratory data  
The goal of this research objective (Chapter IV) was to establish and 
validate logistic regression models that can be used to classify subjects with 
dengue without the need for expensive or unobtainable measurements of plasma 
leakage (e.g., chest X-ray or hemoconcentration). The study design utilized two 
different hospitals, which allowed us to establish our models using data from one 
hospital and then validate this model using data from the other hospital.  
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For patients with dengue to be classified as DHF, they must meet all four 
WHO criteria for DHF: 1) fever, 2) hemorrhagic manifestations (positive 
tourniquet test, epistaxis, hematemesis and/or melena), 3) thrombocytopenia 
(100,000/mm3 or less), and 4) evidence of plasma leakage (pleural effusion, 
ascites, or hemoconcentration>20% 11. There is, however, controversy 
surrounding this classification system. In typical clinical care in resource-poor 
dengue-endemic countries, patients may not meet the criteria for plasma leakage 
or thrombocytopenia simply because of a failure to perform the relevant 
laboratory and radiographic tests. Strict adherence to the classification criteria 
may therefore lead to underreporting of DHF, leaving a false impression of the 
burden of disease. Lastly, dengue disease may not be dichotomous but rather 
cover a spectrum of disease severity in which some patients with DF are 
severely ill and some patients with DHF have mild illness.  
The purpose of the models presented in chapter IV was to provide 
classification criteria for patients with dengue illness in resource-poor areas 
where routine measures of plasma leakage are not always available. For 
example, Clark, et al estimated the total direct cost to the family of a child with a 
symptomatic dengue episode in Thailand in 2005 to be 1,026 Baht (US$24) 29. 
This estimate did not include the cost of travel to and from the hospital; many 
patients in rural areas of Thailand may have to travel long distances to obtain an 
appropriate level of treatment. The cost of a chest x-ray in a government-
sponsored pediatric hospital in Thailand is approximately 150 Baht and the cost 
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of a chest ultrasound is approximately 1500 Baht (Dr. Pra-on Supradish, 
personal communication). Although Thailand has government sponsored 
healthcare, many families choose private care 29. For these reasons, subjects 
may not be willing to pay for a chest x-ray if it is unnecessary nor be willing to 
return for a convalescent hematocrit.  
 The main findings of this research objective are presented in the logistic 
regression models shown in Fig 4.4. When these models were validated, they 
maintained a high sensitivity and percentage of subjects correctly classified as 
DHF, DF, or OFI when compared to a physician’s diagnosis using chest x-ray or 
hemoconcentration to make a diagnosis (Table 4-4). Additionally, the simplicity of 
these models allow for the easy classification of patients with suspected or 
confirmed dengue illness in the absence of a measure of plasma leakage. These 
models can be used to classify patients as DHF based on readily available 
laboratory data during illness and still achieve close to the same sensitivity and 
specificity as a physician using chest X-ray findings and other WHO criteria to 
make a diagnosis of DHF. Our classification models can be helpful for 
researchers/epidemiologists trying to monitor dengue outbreaks and conduct 
dengue disease surveillance in resource poor areas.   
 Additionally, these logistic regression models do not require particular 
variables to be dichotomized (i.e. platelets<100,000) but instead allow for a 
combination of variables to calculate a patient’s probability of having dengue. For 
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example, a subject previously classified as having DF due to a platelet count of 
101,000 can be classified as DHF using the model because other variables 
beside platelet count contribute to the calculation of this probability. 
 An important future direction for this research would be to test these 
logistic regression models in different populations. Patients presenting later in the 
course of illness may not have received clinical care during the febrile phase of 
their illness, which could result in more abnormal clinical laboratory values than 
seen among subjects in this study. This could result in different probability 
cutpoints for these patients. Additionally, it would be of interest to obtain inter-
rater reliability among physicians diagnosing the same patients and make direct 
comparisons to our classification models.  
Prediction of dengue disease severity among pediatric Thai patients using 
early clinical laboratory indicators  
 The purpose of this analysis (Chapter V) was to establish a predictive 
diagnostic tool that clinicians can use to identify subjects who present with a 
suspected dengue infection who will eventually develop severe dengue disease. 
First, we defined five categories of dengue disease severity: 1) dengue shock 
syndrome (DSS, as defined by WHO criteria); 2) DSS or PEI>15; 3) DSS or 
required intravenous fluid; 4) DSS or platelet count <=50,000 anytime during 
illness; 5) DSS or received fluid intervention (oral or intravenous) in any 24-hour 
period that exceeded maintenance volume + 5% volume deficit 100, 101. We then 
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established diagnostic trees for each category. Lastly, we applied each tree to all 
of the categories and calculated the sensitivity and specificity. 
 We found that subjects diagnosed as DHF grade 3 or 4 could be identified 
with high sensitivity based on four clinical laboratory values collected on the day 
of enrollment (Fig 5.1). Only one subject with DSS was misclassified as “low risk” 
in this tree. Additionally, when we defined severe dengue as either DSS or 
dengue with PEI>15, a decision tree using five clinical laboratory values identified 
all but one subject classified as having severe dengue (Fig 5.2). When these two 
algorithms were applied to different categories of dengue disease severity, the 
sensitivity in identifying those subjects classified as severe remained high. 
 These two algorithms yield promising results in allowing clinicians to easily 
identify and better manage patients with impending severe dengue disease. 
Potentially, clinicians could triage patients identified as “high risk” and begin 
aggressive fluid replacement therapy. Patients identified as “low risk” could be 
managed on an outpatient basis. 
 CART analysis provides easily interpretable results and has many 
advantages over more complicated analytical approaches with complex output. 
Additional analytical techniques were applied to this data set for comparison to 
the CART analyses presented in chapter V: 
1) Various logistic regression models, using the same diagnostic outcomes, 
were established and optimal probability cut-points were selected for each 
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model. The probability cutpoints were selected to achieve the same 
sensitivity as the CART analysis to compare the performance of logistic 
regression models to CART analysis. For example, Tree 1 misclassified 
one subject with DSS, so the probability cutpoint selected for the logistic 
regression model was where one subject with DSS was misclassified. For 
this logistic regression model, the percent of subjects correctly classified 
was 34.4% compared to 48.3% from the CART analysis shown in Figure 
5-1. In this example, a higher percentage of correctly classified subjects 
was achieved in the CART analysis compared to the logistic regression 
model while maintaining the same sensitivity in both approaches.  
2) Boosted-CART (boostrap aggregation CART) analysis was performed 
using Stata 125. Boosted-CART analysis is a modification of CART that 
uses a weighted-average that is applied to subjects who are misclassified; 
it is often applied to CART analyses that yield only 2 nodes 119, 126. When 
this technique was applied to our data (Figure 6-1), the results were 
similar to the CART analyses presented in chapter V in which WBC count 
explained the majority of variation in the model (44.6%). 
3) Chi-squared automatic interaction detector (CHAID) is a type of 
homogenous classification analysis, similar to CART, that produces trees 
which can have more than two categories at each branch (not binary). 
This type of analytical tool, used by Tanner et al 99, uses an F test for 
continuous target variables and chi-squared test if the target variable is 
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categorical 119. This technique was applied to our dataset; however, the 
resulting tree (Figure 6-2) was not as robust as the CART analyses shown 
in chapter V. A modification of CHAID called exhaustive CHAID combines 
categories of statistically different nodes found in CHAID and computes 
adjusted p-values to find a stronger association with the target variable 
which yields a better split 119. Exhaustive CHAID was not used with our 
dataset and further exploration of this analytical technique may be of 
interest.  
Study Strengths and limitations 
Limitations: 
The major limitation affecting all three studies is that the data set was 
limited to a pediatric cohort from Thailand. This means that the results may not 
be generalizable to other age groups (e.g., adults) or to other dengue endemic 
populations. However, for research objective 2 (Chapter IV), we stratified the 
data set by hospital to create separate training and validation datasets. There 
were differences between the cohorts from the two; KPPPH had a higher 
proportion of DHF than QSNICH, study participants from KPPPH were older, 
KPPPH is a more rural area, and there is co-circulation of Japanese encephalitis 
(JE) in Kamphaeng Phet but not in Bangkok. However, this validation method 
(training and test datasets) could not be applied to the analyses in Chapter V due 
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to the small numbers of patients with severe dengue. Instead, the K-fold 
validation procedure was used for these analyses and is described in Chapter V.  
 Another limitation is that the physician’s final diagnoses were assigned by 
a single expert clinician. Therefore, the statistical models may not show 
equivalent sensitivity and specificity when compared to diagnoses assigned by 
other physicians. It is likely that there would not be complete concordance in 
diagnoses assigned by different physicians, even with an established guideline 
provided by the WHO, as there was imperfect agreement between our expert 
physician’s diagnosis of DHF and the WHO criteria for DHF (Chapter IV).  
Although the overwhelming majority of subjects diagnosed as DHF by the 
physician also met the WHO criteria for DHF, there was not complete agreement. 
This is also evident in the literature where researchers have established their 
own criteria for diagnosing a patient with dengue that they felt was severe but 
failed to meet all four WHO criteria for DHF 13, 16, 110, 111.   
The criteria for enrollment in this study excluded patients who were 
severely ill at presentation. This was done to capture patients in the earlier 
phases of illness in order to establish descriptive and predictive models of 
dengue disease. However, this also limited the number of patients in our study 
with severe outcomes. Future studies should validate our findings in patients who 
present later in the course of illness with severe disease. 
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Different DENV serotypes can cause a slightly different spectrum of 
disease 4, 6. Furthermore, the prominent serotype differs each year 5. Changes in 
the health care system in Thailand, such as the 30 baht universal health 
coverage program implemented in 2001, affected our enrollment so that more 
patients were enrolled in the early years of the study than in subsequent years 
127. The 30 baht healthcare system expands government-funded healthcare to 
uninsured individuals and cost each patient no more than 30 baht ($0.84 US) per 
outpatient or inpatient visit 127. However, models were adjusted for year of 
enrollment where necessary (Chapters III and IV).   
Strengths: 
 This study used 12 years of systematically collected data from a diverse 
pediatric cohort in a dengue endemic region. Subjects were followed from the 
first three days of illness until 24 hours after their fever subsided allowing for a 
longitudinal description of dengue illness with little missing data (>85% of 
subjects had no missing data). Based on the systematic review of the literature 
presented in chapter I, very few studies have evaluated clinical laboratory 
parameters over time. Our unique study design allowed us to utilize appropriate 
statistical methodology to analyze trends and establish classification and 
predictive algorithms using clinical laboratory parameters among patients with a 
suspected dengue illness. 
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Additionally, the study design utilized patients hospitalized at two pediatric 
medical centers. This enabled us to test the generalizability of models 
established in chapter IV and address limitations in the existing literature. The 
characteristics of the subjects were different between the two hospitals, thus 
allowing for a more robust validation of our models. To our knowledge, no other 
studies have utilized a validation approach to test their models 39.   
Another strength of our study is the involvement of international experts in 
the field of dengue research. The physician providing the final diagnoses of 
subjects, Dr. Suchitra Nimmannitya, is an internationally-known dengue expert 
and made substantial contributions to the establishment of the original WHO 
guidelines for dengue illness. This limits the variability of diagnosis between 
hospitals and across study years. 
Final conclusions 
The studies presented make substantial contributions to the existing 
literature regarding the description, classification, and prognostication of dengue 
illness from the perspective of the clinical laboratory. Additionally, these studies 
utilized analytical approaches that can be used by others and offer new ideas for 
further exploration of clinical laboratory data among patients with suspected 
dengue illness. These studies provide promising results of predictive algorithms 
and classification tools that might be used in resource-poor dengue endemic 
regions to improve hospital resource utilization in the management of dengue 
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outbreaks. The priorities for future research should focus on overcoming some of 
the limitations in these analyses; for example, validation in other populations and 
age groups, and additional testing with different diagnosing physicians. 
In addition to advancing the research presented and to overcome some of  
its limitations, a focus of future research should be placed on prevention and 
awareness of dengue.  Lack of sustained vector control is one of the reasons for 
the resurgence of dengue, as well as other viruses carried by the Aedes aegypti 
mosquito such as yellow fever and chikungunya 128. The very successful efforts 
to eliminate yellow fever, led by William Gorgas during the building of the 
Panama Canal, focused on eliminating breeding sites of Aedes aegypti 
mosquitoes 129. The efforts led by Fred Soper eliminated yellow fever and 
dengue transmission from most of Central and South America in the 1950s and 
1960s 129. However, these efforts were not sustained because of competing 
resources as there was no longer a perceived need 18. This ultimately helped 
lead to the resurgence of Aedes aegypti populations in the Americas in the 
1970s, and, eventually, the hyperendemicity of dengue serotypes in the 1980s, 
causing outbreaks of severe disease into the 21st century. Also, control of 
dengue and yellow fever was merged with malaria control, and the government 
response to the resurgence in dengue outbreaks was to use ultra low volume 
insecticide sprays, which have proved to be ineffective against the Aedes aegypti 
mosquito 130. A successful vector-response program would be one that can be 
sustained, mimics previous successes, and has active community involvement 
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coordinated through public health officials. Community-wide elimination of Aedes 
mosquito breeding sites is vital; however, community responses are typically 
highest only during or after an outbreak 19.  
Other causes for the resurgence in dengue illnesses are rapid 
urbanization and globalization. Gubler found a positive correlation between 
global population growth and the incidence of DF/DHF, particularly in urban 
areas (see Figure 6-3) 128, 131. Rapid and unplanned urbanization has led to a 
lack of water resources in densely populated areas. This has caused individuals 
to store rainwater in uncovered barrels, thus providing a habitat for Aedes 
mosquitoes to lay eggs. Urbanization has also led to inadequate sewer and 
waste management systems, which has been shown to increase Aedes aegypti 
populations 20. 
 Globalization has caused a disease that was once confined to tropical 
areas and travelers to be widespread throughout the world. Modern 
transportation allows individuals who may be infected with dengue virus to travel 
from country to country in a matter of hours, well within the incubation period of 
the virus. Travelers from non-endemic areas who visit endemic areas and then 
return home can initiate autochthonous dengue transmission, which can cause 
large outbreaks in highly susceptible populations 26, 132. This also increases the 
risk of establishing hyperendemicity and its association with severe dengue 
illness.  
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 Another cause for the resurgence in dengue illnesses is climate instability. 
Increases in temperature lead to storage of water in open containers, especially 
in tropical resource-poor areas, increasing the number of potential Aedes aegypti 
breeding sites. One study conducted in Veracruz, Mexico used autoregressive 
models to assess the association between the El Nino Southern Oscillation cycle 
and the number of reported dengue cases from 1995-2002 133. They found that 
increases in sea-surface temperature, minimum weekly temperature, and rainfall 
were associated with increases in the reported number of dengue cases.    
The Centers for Disease Control and Prevention (CDC) have recently 
updated the National Notifiable Infectious Disease List to include dengue fever 
134. With the resurgence and global spread of dengue and given the concerns 
over the WHO criteria for DHF, proposed revisions to the WHO criteria have 
recently been published 135. The new WHO guidelines for classification of dengue 
illnesses have only two categories, “dengue” and “severe dengue,” and thus 
have a reduced emphasis on the DHF vs. DF classification 135. However, data 
supporting the new classification scheme have not been peer-reviewed or 
validated against the existing literature. The updated WHO guidelines state that 
the clinical key to effective dengue disease management is early recognition and 
understanding of the clinical phases of the disease, which is crucial for 
identification of dengue outbreaks 135. This study contributes to finding useful 
solutions to early recognition of dengue, improves the clinical knowledge of how 
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dengue illnesses progress throughout the febrile and critical phases, and 
provides recommendations for future research. 
170 
 
170 
 
Figure 6-1 Boosted CART analysis comparing dengue and OFI 
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Figure 6-2 Chi-squared automatic interaction detector (CHAID) tree defining DSS as 'severe dengue' 
 
  
Total
Non-severe dengue+OFI 1193 100.0%
Severe dengue 37 100.0%
AST<=47
Non-severe dengue+OFI 850 71.2%
Severe dengue 12 32.4%
Platelets<=153600
Non-severe dengue+OFI 99 8.2%
Severe dengue 5
13.5%
Platelets>153600
Non-severe dengue+OFI 751 63.0%
Severe dengue 7 18.9%
AST >47 & <=81
Non-severe dengue+OFI 237 19.9%
Severe dengue 9 24.3%
AST>81
Non-severe dengue+OFI 106 8.9%
Severe dengue 16 43.2%
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Figure 6-3 Average annual number of DF/DHF cases reported to the WHO 
and of countries reporting dengue 
(courtesy of Farrar, et al 131) 
 
173 
 
173 
 
Bibliography 
1. Nelson KE, Williams CM, 2207. Infectious disease epidemiology: Theory  
and practice. Boston: Jones and Bartlett. 
2. Henchal EA, Putnak JR, 1990. The dengue viruses. Clin Microbiol Rev 3:  
376-96. 
3. Rothman AL, 2003. Immunology and immunopathogenesis of dengue  
disease. Advances in Virus Research 60: 397-419. 
4. Thomas L, Verlaeten O, Cabie A, Kaidomar S, Moravie V, Martial J,  
Najioullah F, Plumelle Y, Fonteau C, Dussart P, Cesaire R, 2008.  
Influence of the dengue serotype, previous dengue infection, and  
plasma viral load on clinical presentation and outcome during a  
dengue-2 and dengue-4 co-epidemic. Am J Trop Med Hyg 78: 990- 
8. 
5. Nisalak A, Endy TP, Nimmannitya S, Kalayanarooj S, Thisayakorn U,  
Scott RM, Burke DS, Hoke CH, Innis BL, Vaughn DW, 2003.  
Serotype-specific dengue virus circulation and dengue disease in  
Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg 68:  
191-202. 
6. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S,  
Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis  
FA, Nisalak A, 2000. Dengue viremia titer, antibody response  
pattern, and virus serotype correlate with disease severity. J Infect  
174 
 
174 
 
Dis 181: 2-9. 
7. Halstead SB, 1988. Pathogenesis of dengue: challenges to molecular  
biology. Science 239: 476-81. 
8. Gubler DJ, 1998. Dengue and dengue hemorrhagic fever. Clinical  
Microbiology Reviews 11: 480-96. 
9. Morens DM, 2009. Dengue Fever and dengue hemorrhagic Fever.  
Pediatric Infectious Disease Journal 28: 635-6. 
10. Morens DM, Fauci AS, 2008. Dengue and hemorrhagic fever: a potential  
threat to public health in the United States. JAMA 299: 214-6. 
11. World Health Organization, 1997. Dengue haemorrhagic fever: diagnosis,  
treatment, prevention, and control. Geneva. 
12. Nimmannitya S, 1987. Clinical spectrum and management of dengue  
haemorrhagic fever. Southeast Asian J Trop Med Public Health 18:  
392-7. 
13. Harris E, Videa E, Perez L, Sandoval E, Tellez Y, Perez ML, Cuadra R,  
Rocha J, Idiaquez W, Alonso RE, Delgado MA, Campo LA,  
Acevedo F, Gonzalez A, Amador JJ, Balmaseda A, 2000. Clinical,  
epidemiologic, and virologic features of dengue in the 1998  
epidemic in Nicaragua. American Journal of Tropical Medicine and  
Hygiene 63: 5-11. 
14. Murgue B, Deparis X, Chungue E, Cassar O, Roche C, 1999. Dengue: an  
evaluation of dengue severity in French Polynesia based on an  
175 
 
175 
 
analysis of 403 laboratory-confirmed cases. Tropical Medicine and  
International Health 4: 765-73. 
15. Phuong CX, Nhan NT, Kneen R, Thuy PT, van Thien C, Nga NT, Thuy TT,  
Solomon T, Stepniewska K, Wills B, 2004. Clinical diagnosis and  
assessment of severity of confirmed dengue infections in  
Vietnamese children: is the world health organization classification  
system helpful? American Journal of Tropical Medicine and  
Hygiene 70: 172-9. 
16. Setiati TE, Mairuhu AT, Koraka P, Supriatna M, Mac Gillavry MR,  
Brandjes DP, Osterhaus AD, van der Meer JW, van Gorp EC,  
Soemantri A, 2007. Dengue disease severity in Indonesian  
children: an evaluation of the World Health Organization  
classification system. BMC Infect Dis 7: 22. 
17. Srikiatkhachorn A, Gibbons RV, Green S, Libraty DH, Mammen MP,  
Thomas SJ, Endy TP, Vaughn DW, Nisalak A, Ennis FA, Rothman  
AL, Nimmannitaya S, Kalayanarooj S, 2010. Dengue hemorrhagic  
fever: the sensitivity and specificity of the world health organization  
definition for identification of severe cases of dengue in Thailand,  
1994-2005. Clin Infect Dis 50(8): 1135-43. 
18. Gubler D, 2005. The emergence of epidemic dengue fever and dengue  
hemorrhagic fever in the Americas: a case of failed public health  
policy. Rev Panam Salud Publica 17: 221-4. 
176 
 
176 
 
19. Koenraadt CJ, Tuiten W, Sithiprasasna R, Kijchalao U, Jones JW, Scott  
TW, 2006. Dengue knowledge and practices and their impact on  
Aedes aegypti populations in Kamphaeng Phet, Thailand. Am J  
Trop Med Hyg 74: 692-700. 
20. Gubler DJ, Clark GG, 1995. Dengue/dengue hemorrhagic fever: the  
emergence of a global health problem. Emerging Infectious  
Diseases 1: 55-7. 
21. Halstead SB, 1992. The XXth century dengue pandemic: need for  
surveillance and research. World Health Statistics Quarterly.  
Rapport Trimestriel de Statistiques Sanitaires Mondiales 45: 292-8. 
22. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L, 1990.  
Dengue hemorrhagic fever in Cuba, 1981: a retrospective  
seroepidemiologic study. Am J Trop Med Hyg 42: 179-84. 
23. Carrington CV, Foster JE, Pybus OG, Bennett SN, Holmes EC, 2005.  
Invasion and maintenance of dengue virus type 2 and type 4 in the  
Americas. J Virol 79: 14680-7. 
24. Beatty M, 2009. Global burden of dengue: Pediatric Dengue Vaccine  
Initiative. http://www.pdvi.org/about_dengue/GBD.asp (unpublished  
data). 
25. Freedman DO, Weld LH, Kozarsky PE, Fisk T, Robins R, von Sonnenburg  
F, Keystone JS, Pandey P, Cetron MS, 2006. Spectrum of disease  
and relation to place of exposure among ill returned travelers. N  
177 
 
177 
 
Engl J Med 354: 119-30. 
26. Effler PV, Pang L, Kitsutani P, Vorndam V, Nakata M, Ayers T, Elm J,  
Tom T, Reiter P, Rigau-Perez JG, Hayes JM, Mills K, Napier M,  
Clark GG, Gubler DJ, 2005. Dengue fever, Hawaii, 2001-2002.  
Emerg Infect Dis 11: 742-9. 
27. Center for Disease Control and Prevention, 2007. Dengue hemorrhagic  
fever--U.S.-Mexico border, 2005. MMWR Morb Mortal Wkly Rep  
56: 785-9. 
28. Anderson KB, Chunsuttiwat S, Nisalak A, Mammen MP, Libraty DH,  
Rothman AL, Green S, Vaughn DW, Ennis FA, Endy TP, 2007.  
Burden of symptomatic dengue infection in children at primary  
school in Thailand: a prospective study. Lancet 369: 1452-9. 
29. Clark DV, Mammen MP, Jr., Nisalak A, Puthimethee V, Endy TP, 2005.  
Economic impact of dengue fever/dengue hemorrhagic fever in  
Thailand at the family and population levels. American Journal of  
Tropical Medicine and Hygiene 72: 786-91. 
30. Suaya J, Shepard D, Armien B, Caram M, Castillo L, Chantha N, Garrido  
F, Kongsin S, Lum L, Montoya R, Sah B, Siqueira J, Sughayyar R,  
Tyo K, 2007. Multi-country study of costs of dengue among  
ambulatory and hospitalized patients. The American Journal of  
Tropical Medicine and Hygiene 77: 55. 
31. Suaya JA, Shepard DS, Siqueira JB, Martelli CT, Lum LC, Tan LH,  
178 
 
178 
 
Kongsin S, Jiamton S, Garrido F, Montoya R, Armien B, Huy R,  
Castillo L, Caram M, Sah BK, Sughayyar R, Tyo KR, Halstead SB,  
2009. Cost of Dengue cases in eight countries in the Americas and  
Asia: a prospective study. American Journal of Tropical Medicine  
and Hygiene 80: 846-55. 
32. Meltzer MI, Rigau-Perez JG, Clark GG, Reiter P, Gubler DJ, 1998. Using  
disability-adjusted life years to assess the economic impact of  
dengue in Puerto Rico: 1984-1994. American Journal of Tropical  
Medicine and Hygiene 59: 265-71. 
33. Dietz VJ, Nieburg P, Gubler DJ, Gomez I, 1992. Diagnosis of measles by  
clinical case definition in dengue-endemic areas: implications for  
measles surveillance and control. Bull World Health Organ 70: 745- 
50. 
34. Flannery B, Pereira MM, Velloso LdF, Carvalho CC, De Codes LG, Orrico  
GS, Dourado CM, Riley LW, Reis MG, Ko AI, 2001. Referral pattern  
of leptospirosis cases during a large urban epidemic of dengue. Am  
J Trop Med Hyg 65: 657-63. 
35. Karande S, Gandhi D, Kulkarni M, Bharadwaj R, Pol S, Thakare J, De A,  
2005. Concurrent outbreak of leptospirosis and dengue in Mumbai,  
India, 2002. J Trop Pediatr 51: 174-81. 
36. Watt G, Jongsakul K, Chouriyagune C, Paris R, 2003. Differentiating  
dengue virus infection from scrub typhus in Thai adults with fever.  
179 
 
179 
 
Am J Trop Med Hyg 68: 536-8. 
37. Wilder-Smith A, Earnest A, Paton NI, 2004. Use of simple laboratory  
features to distinguish the early stage of severe acute respiratory  
syndrome from dengue fever. Clin Infect Dis 39: 1818-23. 
38. Schwartz E, Mileguir F, Grossman Z, Mendelson E, 2000. Evaluation of  
ELISA-based sero-diagnosis of dengue fever in travelers. Journal  
of Clinical Virology 19: 169-73. 
39. Potts JA, Rothman AL, 2008. Clinical and laboratory features that  
distinguish dengue from other febrile illnesses in endemic  
populations. Tropical Medicine and International Health 13: 1328- 
40. 
40. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC,  
Vandenbroucke JP, 2007. The Strengthening the Reporting of  
Observational Studies in Epidemiology (STROBE) statement:  
guidelines for reporting observational studies. Annals of Internal  
Medicine 147: 573-7. 
41. Ali N, Nadeem A, Anwar M, Tariq WU, Chotani RA, 2006. Dengue fever in  
malaria endemic areas. J Coll Physicians Surg Pak 16: 340-2. 
42. Zahur ur R, Maqbool A, Azhar M, Mehmood A, 2001. Clinical spectrum of  
thrombocytopenia in adult population of Karachi. JCPSP, Journal of  
the College of Physicians and Surgeons Pakistan. College of  
Physicians and Surgeons Pakistan, Karachi, Pakistan 11: 603-605. 
180 
 
180 
 
43. Low JG, Ooi EE, Tolfvenstam T, Leo YS, Hibberd ML, Ng LC, Lai YL, Yap  
GS, Li CS, Vasudevan SG, Ong A, 2006. Early Dengue infection  
and outcome study (EDEN) - study design and preliminary findings.  
Ann Acad Med Singapore 35: 783-9. 
44. Kalayanarooj S, Vaughn DW, Nimmannitya S, Green S, Suntayakorn S,  
Kunentrasai N, Viramitrachai W, Ratanachu-eke S, Kiatpolpoj S,  
Innis BL, Rothman AL, Nisalak A, Ennis FA, 1997. Early clinical and  
laboratory indicators of acute dengue illness. Journal of Infectious  
Diseases 176: 313-21. 
45. Phuong HL, de Vries PJ, Nga TT, Giao PT, Hung le Q, Binh TQ, Nam NV,  
Nagelkerke N, Kager PA, 2006. Dengue as a cause of acute  
undifferentiated fever in Vietnam. BMC Infect Dis 6: 123. 
46. Suwandono A, Kosasih H, Nurhayati, Kusriastuti R, Harun S, Ma'roef C,  
Wuryadi S, Herianto B, Yuwono D, Porter KR, Beckett CG, Blair PJ,  
2006. Four dengue virus serotypes found circulating during an  
outbreak of dengue fever and dengue haemorrhagic fever in  
Jakarta, Indonesia, during 2004. Trans R Soc Trop Med Hyg 100:  
855-62. 
47. Chadwick D, Arch B, Wilder-Smith A, Paton N, 2006. Distinguishing  
dengue fever from other infections on the basis of simple clinical  
and laboratory features: application of logistic regression analysis. J  
Clin Virol 35: 147-53. 
181 
 
181 
 
48. Deparis X, Murgue B, Roche C, Cassar O, Chungue E, 1998. Changing  
clinical and biological manifestations of dengue during the dengue- 
2 epidemic in French Polynesia in 1996/97--description and  
analysis in a prospective study. Trop Med Int Health 3: 859-65. 
49. Sawasdivorn S, Vibulvattanakit S, Sasavatpakdee M, Iamsirithavorn S,  
2001. Efficacy of clinical diagnosis of dengue fever in paediatric  
age groups as determined by WHO case definition 1997 in  
Thailand. Dengue Bulletin. World Health Organization Regional  
Office for South East Asia, New Delhi, India 25: 56-64. 
50. Bruce MG, Sanders EJ, Leake JA, Zaidel O, Bragg SL, Aye T, Shutt KA,  
Deseda CC, Rigau-Perez JG, Tappero JW, Perkins BA, Spiegel  
RA, Ashford DA, 2005. Leptospirosis among patients presenting  
with dengue-like illness in Puerto Rico. Acta Trop 96: 36-46. 
51. Buchy P, Vo VL, Bui KT, Trinh TX, Glaziou P, Le TT, Le VL, Bui TC, 2005.  
Secondary dengue virus type 4 infections in Vietnam. Southeast  
Asian J Trop Med Public Health 36: 178-85. 
52. Hammond SN, Balmaseda A, Perez L, Tellez Y, Saborio SI, Mercado JC,  
Videa E, Rodriguez Y, Perez MA, Cuadra R, Solano S, Rocha J,  
Idiaquez W, Gonzalez A, Harris E, 2005. Differences in dengue  
severity in infants, children, and adults in a 3-year hospital-based  
study in Nicaragua. Am J Trop Med Hyg 73: 1063-70. 
53. McBride WJ, Mullner H, LaBrooy JT, Wronski I, 1998. The 1993 dengue 2  
182 
 
182 
 
epidemic in Charters Towers, North Queensland: clinical features  
and public health impact. Epidemiol Infect 121: 151-6. 
54. Nunes-Araujo FR, Ferreira MS, Nishioka SD, 2003. Dengue fever in  
Brazilian adults and children: assessment of clinical findings and  
their validity for diagnosis. Ann Trop Med Parasitol 97: 415-9. 
55. Cardier JE, Marino E, Romano E, Taylor P, Liprandi F, Bosch N, Rothman  
AL, 2005. Proinflammatory factors present in sera from patients  
with acute dengue infection induce activation and apoptosis of  
human microvascular endothelial cells: possible role of TNF-alpha  
in endothelial cell damage in dengue. Cytokine 30: 359-65. 
56. La Russa VF, Innis BL, 1995. Mechanisms of dengue virus-induced bone  
marrow suppression. Baillieres Clinical Haematology 8: 249-70. 
57. Bandyopadhyay S, Lum LC, Kroeger A, 2006. Classifying dengue: a  
review of the difficulties in using the WHO case classification for  
dengue haemorrhagic fever. Tropical Medicine and International  
Health 11: 1238-55. 
58. Ageep AK, Malik AA, Elkarsani MS, 2006. Clinical presentations and  
laboratory findings in suspected cases of dengue virus. Saudi Med  
J 27: 1711-3. 
59. Akram DS, Igarashi A, Takasu T, 1998. Dengue virus infection among  
children with undifferentiated fever in Karachi. Indian J Pediatr 65:  
735-40. 
183 
 
183 
 
60. Baruah J, Shiv A, Kumar GA, 2006. Incidence of dengue in a tertiary care  
centre - Kasturba Hospital, Manipal. Indian Journal of Pathology &  
Microbiology. Indian Association of Pathologists & Microbiologists,  
Chandigarh, India 49: 462-463. 
61. Baruah HC, Mohapatra PK, Kire M, Pegu DK, Mahanta J, 1996.  
Haemorrhagic manifestations associated with dengue virus  
infection in Nagaland. Journal of Communicable Diseases 28: 301- 
303. 
62. Cheng VC, Wu AK, Hung IF, Tang BS, Lee RA, Lau SK, Woo PC, Yuen  
KY, 2004. Clinical deterioration in community acquired infections  
associated with lymphocyte upsurge in immunocompetent hosts.  
Scand J Infect Dis 36: 743-51. 
63. Deepak NA, Patel ND, 2006. Differential diagnosis of acute liver failure in  
India. Ann Hepatol 5: 150-6. 
64. Dietz VJ, Gubler DJ, Rigau-Perez JG, Pinheiro F, Schatzmayr HG, Bailey  
R, Gunn RA, 1990. Epidemic dengue 1 in Brazil, 1986: evaluation  
of a clinically based dengue surveillance system. Am J Epidemiol  
131: 693-701. 
65. Gupta S, Singh SK, Taneja V, Goulatia RK, Bhagat A, Puliyel JM, 2000.  
Gall bladder wall edema in serology proven pediatric dengue  
hemorrhagic fever: a useful diagnostic finding which may help in  
prognostication. Journal of Tropical Pediatrics 46: 179-181. 
184 
 
184 
 
66. Kalayanarooj S, Nimmannitya S, Suntayakorn S, Vaughn DW, Nisalak A,  
Green S, Chansiriwongs V, Rothman A, Ennis FA, 1999. Can  
doctors make an accurate diagnosis of dengue infections at an  
early stage? Dengue Bulletin. World Health Organization Regional  
Office for South East Asia, New Delhi, India 23: 1-9. 
67. Kittigul L, Suankeow K, Sujirarat D, Yoksan S, 2003. Dengue hemorrhagic  
fever: knowledge, attitude and practice in Ang Thong Province,  
Thailand. Southeast Asian J Trop Med Public Health 34: 385-92. 
68. Kularatne SA, Gawarammana IB, Kumarasiri PR, 2005. Epidemiology,  
clinical features, laboratory investigations and early diagnosis of  
dengue fever in adults: a descriptive study in Sri Lanka. Southeast  
Asian J Trop Med Public Health 36: 686-92. 
69. Leelarasamee A, Chupaprawan C, Chenchittikul M, Udompanthurat S,  
2004. Etiologies of acute undifferentiated febrile illness in Thailand.  
J Med Assoc Thai 87: 464-72. 
70. Peyerl-Hoffmann G, Schwobel B, Jordan S, Vamisaveth V, Phetsouvanh  
R, Christophel EM, Phompida S, Sonnenburg FV, Jelinek T, 2004.  
Serological investigation of the prevalence of anti-dengue IgM and  
IgG antibodies in Attapeu Province, South Laos. Clinical  
Microbiology and Infection. Blackwell Publishing, Oxford, UK 10:  
181-184. 
71. Reynes JM, Laurent A, Deubel V, Telliam E, Moreau JP, 1994. The first  
185 
 
185 
 
epidemic of dengue hemorrhagic fever in French Guiana. American  
Journal of Tropical Medicine and Hygiene 51: 545-553. 
72. Rodier GR, Gubler DJ, Cope SE, Cropp CB, Soliman AK, Polycarpe D,  
Abdourhaman MA, Parra JP, Maslin J, Arthur RR, 1996. Epidemic  
dengue 2 in the city of Djibouti 1991-1992. Trans R Soc Trop Med  
Hyg 90: 237-40. 
73. Anuradha S, Singh NP, Rizvi SN, Agarwal SK, Gur R, Mathur MD, 1998.  
The 1996 outbreak of dengue hemorrhagic fever in Delhi, India.  
Southeast Asian J Trop Med Public Health 29: 503-6. 
74. Chairulfatah A, Setiabudi D, Ridad A, Colebunders R, 1995. Clinical  
manifestations of dengue haemorrhagic fever in children in  
Bandung, Indonesia. Ann Soc Belg Med Trop 75: 291-5. 
75. Domingues RB, Kuster GW, Onuki de Castro FL, Souza VA, Levi JE,  
Pannuti CS, 2006. Headache features in patients with dengue virus  
infection. Cephalalgia 26: 879-82. 
76. Espinoza-Gomez F, Diaz-Duenas P, Torres-Lepe C, Cedillo-Nakay RA,  
Newton-Sanchez OA, 2005. Clinical pattern of hospitalized patients  
during a dengue epidemic in Colima, Mexico. Dengue Bulletin.  
World Health Organization Regional Office for South East Asia,  
New Delhi, India 29: 8-17. 
77. Kalayanarooj S, Nimmannitya S, 2005. Is dengue severity related to  
nutritional status? Southeast Asian J Trop Med Public Health 36:  
186 
 
186 
 
378-84. 
78. Neeraja M, Lakshmi V, Teja VD, Umabala P, Subbalakshmi MV, 2006.  
Serodiagnosis of dengue virus infection in patients presenting to a  
tertiary care hospital. Indian J Med Microbiol 24: 280-2. 
79. Monira P, Shahina T, Ali MM, Mamun KZ, Islam MN, 2004. Clinical and  
laboratory observations associated with the 2000 dengue outbreak  
in Dhaka, Bangladesh. Dengue Bulletin. World Health Organization  
Regional Office for South East Asia, New Delhi, India 28: 96-106. 
80. Ranjit S, Kissoon N, Gandhi D, Dayal A, Rajeshwari N, Kamath SR, 2007.  
Early differentiation between dengue and septic shock by  
comparison of admission hemodynamic, clinical, and laboratory  
variables: a pilot study. Pediatr Emerg Care 23: 368-75. 
81. Shah I, Katira B, 2007. Clinical and laboratory profile of dengue,  
leptospirosis and malaria in children: a study from Mumbai. Arch  
Dis Child 92: 561. 
82. Fadilah SA, Sahrir S, Raymond AA, Cheong SK, Aziz JA, Sivagengei K,  
1999. Quantitation of T lymphocyte subsets helps to distinguish  
dengue hemorrhagic fever from classic dengue fever during the  
acute febrile stage. Southeast Asian J Trop Med Public Health 30:  
710-7. 
83. Ira S, Bhushan K, 2005. Clinical and laboratory abnormalities due to  
dengue in hospitalized children in Mumbai in 2004. Dengue  
187 
 
187 
 
Bulletin. World Health Organization Regional Office for South East  
Asia, New Delhi, India 29: 90-96. 
84. Zavala-Velazquez JE, Yu XJ, Walker DH, 1996. Unrecognized spotted  
fever group rickettsiosis masquerading as dengue fever in Mexico.  
Am J Trop Med Hyg 55: 157-9. 
85. Ellis RD, Fukuda MM, McDaniel P, Welch K, Nisalak A, Murray CK, Gray  
MR, Uthaimongkol N, Buathong N, Sriwichai S, Phasuk R,  
Yingyuen K, Mathavarat C, Miller RS, 2006. Causes of fever in  
adults on the Thai-Myanmar border. Am J Trop Med Hyg 74: 108- 
13. 
86. Ashford DA, Savage HM, Hajjeh RA, McReady J, Bartholomew DM,  
Spiegel RA, Vorndam V, Clark GG, Gubler DG, 2003. Outbreak of  
dengue fever in Palau, Western Pacific: risk factors for infection.  
Am J Trop Med Hyg 69: 135-40. 
87. Pancharoen C, Thisyakorn U, 2001. Dengue virus infection during infancy.  
Transactions of the Royal Society of Tropical Medicine and  
Hygiene. Royal Society of Tropical Medicine and Hygiene, London,  
UK 95: 307-308. 
88. National Statistical Office, 2009. Thailand: Thomas Brinkhoff. 
89. Cleveland W, 1979. Robust locally weighted regression and smoothing  
scatterplots. Journal of the American Statistical Association 74:  
829-836. 
188 
 
188 
 
90. Cleveland WS, Devlin S.J., 1988. Locally weighted regression: an  
approach to regression analysis by local fitting. Journal of the  
American Statistical Association 83: 596-610. 
91. Fitzmaurice GM, Laird NM, Ware JH, 2004. Applied longitudinal analysis.  
Hoboken, NJ: John Wiley and Sons, Inc. 
92. Hedeker D, Gibbons RD, 2006. Longitudinal data analysis. Hoboken, NJ:  
Wiley-Interscience. 
93. Kleinbaum D, Kupper L, Muller K, Nizam A, 1998. Applied regression  
analysis and other multivariable methods. Pacific Grove: Duxbury  
Press. 
94. Landis JR, Koch GG, 1977. The measurement of observer agreement for  
categorical data. Biometrics 33: 159-74. 
95. Breiman L, Friedman JH, Olshen RA, Stone CJ, 1984. Classification and  
regression trees. Belmont: Wadsworth, Inc. 
96. Lemon SC, Roy J, Clark MA, Friedmann PD, Rakowski W, 2003.  
Classification and regression tree analysis in public health:  
methodological review and comparison with logistic regression.  
Annals of Behavioral Medicine 26: 172-81. 
97. Zhang H, Singer B, 1999. Statistics for Biology and Health: Recursive  
partitioning in the health sciences. New York: Springer. 
98. Lee VJ, Lye DC, Sun Y, Leo YS, 2009. Decision tree algorithm in deciding  
hospitalization for adult patients with dengue haemorrhagic fever in  
189 
 
189 
 
Singapore. Tropical Medicine and International Health. 
99. Tanner L, Schreiber M, Low JG, Ong A, Tolfvenstam T, Lai YL, Ng LC,  
Leo YS, Thi Puong L, Vasudevan SG, Simmons CP, Hibberd ML,  
Ooi EE, 2008. Decision tree algorithms predict the diagnosis and  
outcome of dengue Fever in the early phase of illness. PLoS Negl  
Trop Dis 2: e196. 
100. Holliday MA, Segar WE, 1957. The maintenance need for water in  
parenteral fluid therapy. Pediatrics 19: 823-32. 
101. Johns Hopkins Hospital, 2009. The Harriet Lane Handbook: a manual for  
pediatric house officers: The Harriet Lane Service, Children's  
Medical and Surgical Center of The Johns Hopkins Hospital. 
102. Hyde RM, 2000. Immunology. Baltimore, MD: Lippincott Williams and  
Wilkins. 
103. Tietz NW, 1983. Clinical guide to laboratory tests. Company WBS, ed.  
Philadelphia. 
104. Germann WJ and Stanfield SC, 2002. Principles of Human Physiology.  
San Francisco: Benjamin Cummings. 
105. Berg JM, Tymoczko JL, Stryer L, 2002. Biochemistry. New York: WH  
Freeman and Company. 
106. Srikiatkhachorn A, 2009. Plasma leakage in dengue haemorrhagic fever.  
Thromb Haemost 102: 1042-9. 
107. Srikiatkhachorn A, Green S, Markers of dengue disease severity. Curr Top  
190 
 
190 
 
Microbiol Immunol 338: 67-82. 
108. Nimmannitya S, Thisyakorn U, Hemsrichart V, 1987. Dengue  
haemorrhagic fever with unusual manifestations. Southeast Asian J  
Trop Med Public Health 18: 398-406. 
109. Balmaseda A, Hammond SN, Perez MA, Cuadra R, Solano S, Rocha J,  
Idiaquez W, Harris E, 2005. Short report: assessment of the World  
Health Organization scheme for classification of dengue severity in  
Nicaragua. American Journal of Tropical Medicine and Hygiene 73:  
1059-62. 
110. Rigau-Perez JG, 2006. Severe dengue: the need for new case definitions.  
Lancet Infect Dis 6: 297-302. 
111. Rigau-Perez JG, Bonilla GL, 1999. An evaluation of modified case  
definitions for the detection of dengue hemorrhagic fever. Puerto  
Rico Association of Epidemiologists. Puerto Rico Health Sciences  
Journal 18: 347-52. 
112. Thangaratham PS, Tyagi BK, 2007. Indian perspective on the need for  
new case definitions of severe dengue. Lancet Infect Dis 7: 81-2. 
113. Wills B, Tran VN, Nguyen TH, Truong TT, Tran TN, Nguyen MD, Tran VD,  
Nguyen VV, Dinh TT, Farrar J, 2009. Hemostatic changes in  
Vietnamese children with mild dengue correlate with the severity of  
vascular leakage rather than bleeding. American Journal of Tropical  
Medicine and Hygiene 81: 638-44. 
191 
 
191 
 
114. A-Nuegoonpipat N, Panthuyosri N, Anantapreecha S, Chanama S, Sa- 
Ngasang A, Sawanpanyalert P, Kurane I, 2008. Cross-reactive IgM  
responses in patients with dengue or Japanese encephalitis.  
Journal of Clinical Virology 42: 75-7. 
115. Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V,  
Suntayakorn S, Puttisri P, Hoke CH, 1989. An enzyme-linked  
immunosorbent assay to characterize dengue infections where  
dengue and Japanese encephalitis co-circulate. American Journal  
of Tropical Medicine and Hygiene 40: 418-27. 
116. Cao XT, Ngo TN, Wills B, Kneen R, Nguyen TT, Ta TT, Tran TT, Doan  
TK, Solomon T, Simpson JA, White NJ, Farrar JJ, 2002. Evaluation  
of the World Health Organization standard tourniquet test and a  
modified tourniquet test in the diagnosis of dengue infection in Viet  
Nam. Tropical Medicine and International Health 7: 125-32. 
117. Koenraadt CJ, Aldstadt J, Kijchalao U, Sithiprasasna R, Getis A, Jones  
JW, Scott TW, 2008. Spatial and temporal patterns in pupal and  
adult production of the dengue vector Aedes aegypti in Kamphaeng  
Phet, Thailand. American Journal of Tropical Medicine and Hygiene  
79: 230-8. 
118. Lewis R, 2000. An introduction to Classification and Regression Tree  
(CART) analysis. Annual Meeting of the Society for Academic  
Emergency Medicine. San Francisco, CA. 
192 
 
192 
 
119. SPSS, 2001. AnswerTree 3.0 User's Guide. Chicago, IL: SPSS, Inc. 
120. Abbasi A, Butt N, Sheikh QH, Bhutto AR, Munir SM, Ahmed SM, 2009.  
Clinical features, diagnostic techniques and management of dual  
dengue and malaria infection. J Coll Physicians Surg Pak 19: 25-9. 
121. Butt N, Abbassi A, Munir SM, Ahmad SM, Sheikh QH, 2008.  
Haematological and biochemical indicators for the early diagnosis  
of dengue viral infection. J Coll Physicians Surg Pak 18: 282-5. 
122. Libraty DH, Myint KS, Murray CK, Gibbons RV, Mammen MP, Endy TP, Li  
W, Vaughn DW, Nisalak A, Kalayanarooj S, Hospenthal DR, Green  
S, Rothman AL, Ennis FA, 2007. A comparative study of  
leptospirosis and dengue in thai children. PLoS Negl Trop Dis 1:  
e111. 
123. Oishi K, Saito M, Mapua CA, Natividad FF, 2007. Dengue illness: clinical  
features and pathogenesis. J Infect Chemother 13: 125-33. 
124. Srikiatkhachorn A, Krautrachue A, Ratanaprakarn W, Wongtapradit L,  
Nithipanya N, Kalayanarooj S, Nisalak A, Thomas SJ, Gibbons RV,  
Mammen MP, Jr., Libraty DH, Ennis FA, Rothman AL, Green S,  
2007. Natural history of plasma leakage in dengue hemorrhagic  
fever: a serial ultrasonographic study. Pediatr Infect Dis J 26: 283- 
90; discussion 291-2. 
125. Schonlau M, 2005. Boosted regression (boosting): An introductory tutorial  
and a Stata plugin. The Stata Journal 5: 330-354. 
193 
 
193 
 
126. Sutton CD, 2005. Classification and regression trees, bagging, and  
boosting. Handbook of Statistics 24: 11-329. 
127. Damrongplasit K, Melnick GA, 2009. Early results from Thailand's 30 Baht  
Health Reform: something to smile about. Health Aff (Millwood) 28:  
w457-66. 
128. Gubler DJ, 2002. The global emergence/resurgence of arboviral diseases  
as public health problems. Arch Med Res 33: 330-42. 
129. Morrison AC, Zielinski-Gutierrez E, Scott TW, Rosenberg R, 2008.  
Defining challenges and proposing solutions for control of the virus  
vector Aedes aegypti. PLoS Med 5: e68. 
130. Newton EA, Reiter P, 1992. A model of the transmission of dengue fever  
with an evaluation of the impact of ultra-low volume (ULV)  
insecticide applications on dengue epidemics. Am J Trop Med Hyg  
47: 709-20. 
131. Farrar J, Focks D, Gubler D, Barrera R, Guzman MG, Simmons C,  
Kalayanarooj S, Lum L, McCall PJ, Lloyd L, Horstick O, Dayal- 
Drager R, Nathan MB, Kroeger A, 2007. Towards a global dengue  
research agenda. Trop Med Int Health 12: 695-9. 
132. Hayes JM, Rigau-Perez JG, Reiter P, Effler PV, Pang L, Vorndam V,  
Hinten SR, Mark KE, Myers MF, Street K, Bergau L, Meyer C,  
Amador M, Napier M, Clark GG, Biggerstaff BJ, Gubler DJ, 2006.  
Risk factors for infection during a dengue-1 outbreak in Maui,  
194 
 
194 
 
Hawaii, 2001. Trans R Soc Trop Med Hyg 100: 559-66. 
133. Hurtado-Diaz M, Riojas-Rodriguez H, Rothenberg SJ, Gomez-Dantes H,  
Cifuentes E, 2007. Short communication: impact of climate  
variability on the incidence of dengue in Mexico. Trop Med Int  
Health 12: 1327-37. 
134. Center for Disease Control and Prevention, 2010. Notice to readers:  
Changes to the National Notifiable Infectious Disease List and data  
presentation---Jan 2010. Morbidity and Mortality Weekly Report 59:  
11. 
135. World Health Organization, 2009. Dengue: Guidelines for diagnosis,  
treatment, prevention, and control. Geneva: World Health  
Organization/Special Programme for Research and Training in  
Tropical Diseases. 
 
 
 
